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IL   interleukin 
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MHC   major histocompatability complex 
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PGE2   prostaglandin E2 
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PM   particulate matter 
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PUFA   polyunsaturated fatty acid 
ROFA   residual oil fly ash 
RT   room temperature 
SI    stimulation index 
sc   subcutaneously  
SD   standard deviation 
SIP   amorphous silica particles 
SO2   sulfur dioxide 
TCR   T cell receptor 
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Th   T helper 
TNF   tumor necrosis factor 
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The prevalence of respiratory allergy has increased during the last few decades. Air 
pollution is one of the factors that may contribute to this process by stimulating immune 
responses to common allergens. Particulate matter (PM), a heterogeneous air pollutant, is 
involved in both acute and long-term respiratory effects. One of its main components, 
diesel exhaust particles (DEP), is known to have immunomodulating properties. The 
introduction to this thesis gives an overview of the present knowledge with respect to the 
role of air pollution in respiratory allergy.  
 
Basics of the adaptive immune response  
 
The immune system consists of two closely connected defense layers, the innate and the 
adaptive (also called specific) immune system. The first is evolutionary older and consists 
of barriers such as skin and mucosal surfaces and of broad pattern recognition leading to 
phagocytosis, complement activation, and extracellular killing. The specific immune 
system consists of B and T lymphocytes, which bear receptors that specifically bind to 
unique structures (antigens). The adaptive immune response has different effector 
mechanisms at its disposal, and forms a memory system to enable a faster and greater 
response at a subsequent exposure (Roitt 1988, Janeway and Travers 1994). T and B cells 
need 2 signals for activation (Bretscher 1992). Signal 1 is provided by antigen recognition, 
while signal 2 consists of non-specific costimulation. Signal 1 in the absence of signal 2 
leads to inactivation by means of induction of unresponsiveness or apoptosis.  
 
T cell activation  
 
Two T cell subsets can be distinguished based on the expression of the accessory 
molecules cluster of differentiation (CD) CD4 and CD8. T helper (Th) cells express CD4 
and use this molecule as a coreceptor in association with their antigen-specific T cell 
receptor (TCR) to recognize antigen. TCRs are generated by means of gene-segment 
recombination, leading to TCR polymorphism. The antigen is bound to major 
histocompatability complex class II (MHCII) present on antigen presenting cells (APC) 
and B cells and consists of enzymatically cleaved peptide fragments (8-10 amino acids) of 
protein antigen. A first signal for activation of the Th cell with the correct specificity is 
provided by the recognition of this MHCII-peptide complex via the TCR-CD3 complex. 
Recognition of a specific epitope by an effector Th cell induces the expression of CD40-
ligand and CD28 on the T cell surface (Noelle et al., 1992). Binding of this CD28 molecule 
to either B7-1 (CD80) or B7-2 (CD86) present on the APC generates signal 2 for T cell 
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activation (Clark and Ledbetter 1994). The activated Th cell on its turn can provide signal 
2 for T cytotoxic (Tc) cells and B cells, and produces immunomodulating cytokines such as 
interleukin (IL)-2.  
Cytotoxic T cells express CD8 in combination with their TCR, which recognizes antigen 
presented in context of MHC class-I molecules. The latter are expressed on all nucleated 
cells, and in general display peptide fragments of proteins present within the cell 
cytoplasm. However, dendritic cells (DC) are also able to present exogenous antigen on 
MHCI (Machy et al., 2000). In case of presented non-self peptides and in the presence of 
signal 2, Tc cells can become effector cells that produce cytokines and lyse target cells. 
Signal 2 can be provided either by costimulation from the APC or by a Th cell specific for 
the same antigen.  
 
B cell activation 
 
B cells possess membrane-inserted immunoglobulins (Ig) by which they specifically 
recognize native protein, binding of which provides signal 1. Requirement for signal 2 
depends on the nature of the antigen. The majority of antigens are so called thymus-
dependent antigens, and B cells need costimulation from activated Th cells to respond to 
them (Clark and Ledbetter 1994). After binding, internalization and proteolytical cleavage, 
their epitopes are presented on MHCII molecules on the B cell surface. Ligation of CD40-
ligand on the activated T cell with its receptor CD40 on the B cell delivers signal 2 leading 
to the activation of the B cell (Noelle et al., 1992). Activated B cells that express 
costimulatory molecule B7-1 or B7-2 (CD80/CD86) are able to function as APC, and are 
receptive for cytokines augmenting proliferation and differentiation. Some of the daughter 
cells become long-lived memory cells, while most of them become antibody-producing 
plasma cells, initially secreting IgM. In the course of a response, B cells are able to switch 
to the production of other isotypes like IgG and IgE by means of gene-segment 
rearrangement of the constant part of the Ig molecule. The different isotypes activate 
distinct effector mechanisms after binding to antigen. In case of respiratory allergy the 
antibody switch to IgE is a crucial event, as is described in paragraph “IgE-mediated 
respiratory allergy”.   
 
T helper cell subsets  
 
Th cells in mouse (Mosmann et al., 1986, Mosmann and Coffman 1989) and man 
(Wierenga et al., 1990, Romagnani 1991) can be divided in the functional subsets Th1 and 
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Th2 cells, according to the pattern of cytokines they produce. Both arise from Th0 cells and 
direct effector mechanisms against intra- and extracellular antigens, respectively. While 
Th0 cells stimulate both type 1 and type 2 responses by producing a mixture of cytokines 
such as IL-2, IL-4 and interferon (IFN)γ, Th1 cεlls produce IFNγ and IL-2, and Th2 cells 
produce IL-4, IL-5, IL-6, IL-10 and IL-13 (Fig. 1) (Openshaw et al., 1995). Type 1 
responses are cellular responses characterized by activation of Tc cells and macrophages 
and production of IFNγ and IgG2a in mouse. The Th2 subset, on the other hand, provides 
support for humoral responses, characterized by IgG1 and IgE production, sensitization of 
mast cells, and eosinophil maturation (Kapsenberg et al., 1991). Tc cells can likewise be 
divided into Tc1 and Tc2.  
 MHC
   II
IL-12
IFNγ
+
+
Th1
Th2
TCR
Th0
Cell
APC
IL-4
IL-4
IL-5
IL-6
IL-10
IL-13
IFNγ
IL-2
 
Figure 1: After presentation of antigen       on a MHCII molecule of an antigen presenting cell 
(APC), the Th0 cell differentiates into either a Th1 or a Th2 cell, stimulated by respectively IFNγ or 
IL-4.  
 
In addition to Th1 and Th2 cells, also Th3 cells, producing high amounts of transforming 
growth factor (TGF)β, have been defined (Mosmann and Sad, 1996). Initially, Th1 and Th2 
cells were regarded as complete opposites, inhibiting each other’s actions (Maggi et al., 
1992), and their balance determining which effector mechanism was activated (Romagnani 
et al., 1997). However, in practice the complete distinction between Th1 and Th2 appears 
not always appropriate. Immune responses often comprise a mixture of Th1 (type 1) and 
Th2 (type 2) effector mechanisms, and Th1 and Th2 responses can be predominant at 
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different stages of the immune response (Mosmann and Sad 1996). Moreover, single Th 
cells are able to display great diversity in their cytokine profile (Kelso et al., 1999), and 
instead of counteracting, Th1 and Th2 cells may even reinforce each other’s actions 
(Randolph et al., 1999, Hansen et al., 1999). Therefore a model in which there are no 
discrete subsets but rather a continuum of different combinations of cytokine secretion may 
be more appropriate.  
 
IgE-mediated respiratory allergy 
 
Sensitization and challenge  
 
Allergy can be defined as an inappropriate response to an innocuous foreign substance 
(Janeway and Travers 1994). The inherited tendency to develop high IgE responses to an 
antigen is called atopy. Several genes have been suggested to be involved in this tendency 
and to increase the risk and severity of allergy (Howard et al., 2000). The definition of 
atopy is not clear, since several indicators such as total IgE, specific IgE, positive skin 
prick test and clinical manifestations have been used. Respiratory allergy to common 
protein antigens like pollen is, in contrast to low molecular weight allergens (Scheerens et 
al., 1999), a Th2-driven, IgE-mediated, immediate reaction. However, in asthmatics 
possibly also Th1 cells play a role (Krug et al., 1996, Krug and Frew 1997).   
The allergic response can be divided in two temporally distinct phases, the 
sensitization and the challenge (Fig. 2). During sensitization, the antigen is presented to 
specific T cells, which differentiate into different subsets and memory cells. In IgE-
mediated allergy the formation of a Th2 subset is pivotal for the production of specific IgE 
which binds to the FcεRI receptor on mast cells and basophils, thereby “sensitizing” them. 
During a second contact with the antigen, which is called the challenge, the antigen 
crosslinks the surface-bound IgE of the basophil/mastcell. This causes the cell to 
degranulate and release several mediators, such as histamines, leukotrienes, prostaglandins 
and cytokines, producing symptoms characteristic for respiratory allergy like rhinitis, 
conjunctivitis and airway hyperresponsiveness. While some conclude IgE is indispensable 
for hyperresponsiveness (Hamelmann et al., 1997) and for eosinophil infiltration (Coyle et 
al., 1996), others claim that alternative, IgE-independent pathways exist (Mehlop et al., 
1997). In addition to the key role of Th2 cells in the initiation of disease by inducing IgE 
production, their cytokines also play an important role in the effector phase. IL-4 (Corry et 
al., 1996) and IL-5 (Foster et al., 1996) appear to be crucial in processes like respectively 
hyperreactivity and eosinophilia, although differences between mice strains and 
sensitization protocols are observed (Hogan et al., 1998). 
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Figure 2: The allergic response can be divided into two temporally distinct phases: the sensitization 
phase (left) and the challenge phase (right).  eo = eosinophil, MBP = major basic protein. Antigen is 
depicted as      
 
 
Tumor necrosis factor (TNF) α (Kips et al., 1993) and IFNγ (Hessel et al., 1997) may also 
contribute to hyperresponsiveness. Other Th2 cytokines, such as GM-CSF, IL-3 and IL-5 
act on eosinophils by chemoattracting them, supporting their effector function, and 
prolonging their survival (Weller et al., 1996). Eosinophils are clearly participants in 
promoting the pathogenesis of allergy by releasing mediators such as leukotriene C4, 
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oxygen radicals and cationic proteins such as major basic protein (MBP). These may cause 
inflammation and destruction of other cells like the epithelium. This may lead to a higher 
susceptibility of underlying smooth muscle for contractile mediators (Corry et al., 1996) or 
exposure of sensory nerve endings (Motojima et al., 1989), both contributing to airway 
hyperresponsiveness.  
 
Determining T helper subset balance in the lung  
 
The crucial factor causing a Th2 subset to be formed is unknown, but several factors are 
involved during the innate and the adaptive immune response (Kirman and Le Gros 1998). 
The innate immune system is the first line of defense an antigen encounters when entering 
the body. But it probably serves a more important function than just bridging time until the 
more sophisticated adaptive immune response develops (Medzhitov and Janeway Jr., 
1997), for it has the ability to discriminate between potential pathogens and innocuous 
antigens (Fearon and Locksley 1996, Matzinger 1994). Innate compounds that select 
proteins for endocytosis by APC, like mannose or scavenger receptors on DC and 
macrophages or complement factor CD3 on antigen, determine which antigens activate Th 
cells. Furthermore, cellular and soluble components of the innate immune system provide 
instruction that enables the adaptive immune system to develop appropriate strategies for 
elimination. For example, activation of macrophages through cell surface pattern 
recognition receptors causes the production of cytokines like IL-12, which is involved in 
regulation of Th1/Th2 balance (Fearon and Locksley 1996). IL-12 induces IFNγ production 
by T cells, which suppresses Th2 development. In atopic subjects, the frequency of Th cells 
that are unresponsive to IL-12 is high (Hilkens et al., 1996). However, alveolar 
macrophages of asthmatics display enhanced IL-12 production (Magnan et al., 1998), and 
IL-12 deficient mice do not show generalized enhancement of type 2 cytokines or 
antibodies (Rempel et al., 2000). IL-4 also plays an important role by stimulating Th2 
responses and simultaneously inhibiting Th1 development (Trinchieri 1995). In the early 
phase of the response the cellular source of IL-4 are possibly natural killer (NK) 1.1+ T 
cells (Vikari and Zlotnik, 1996), while in a later phase of the Th2 response mast cells 
(Bradding et al., 1992) or basophils (Aoki et al., 1995) are the main source in addition to 
Th2 cells themselves. Except for the latter these are all cells belonging to the innate 
immune system. Another possibility is a role for IL-6, produced by APC or one of the 
many other cell types able to produce IL-6 like macrophages, in T cell differentiation. IL-6 
directly stimulates T cells to generate small amounts of IL-4, sufficient to induce autocrine 
upregulation of IL-4 and its receptor (Rincon et al., 1997).  
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In this microenvironment with different cells and soluble mediators, the APC takes 
up antigen in order to present it to T cells. The most efficient APC is the dendritic cell 
(DC), which resides mainly in peripheral non-lymphoid tissue where many antigens are 
encountered, such as the airways. In the lung, resting DCs preferentially stimulate Th2 
responses, while Th1 immunity relies completely on the provision of appropriate 
microenvironmental stimuli such as TNFα (Stumbles et al., 1998). In general, however, the 
most important stimuli appear to be IFNγ and PGE2, inducing respectively maturation of 
DC that produce high levels of IL-12 (stimulating Th1 responses) and maturation of DC 
that produce PGE2 (stimulating Th2 responses) (Kapsenberg et al., 1999). After antigen 
uptake by means of macropinocytosis or via mannose or Fc receptors, the DC migrates to 
the draining lymph node to present antigen to T cells. During migration the DC loses its 
capacity to take up antigen, but it upregulates the expression of MHCII and various 
adhesion and costimulatory molecules, and increases its unique ability to stimulate naive T 
cells. Of the latter, B7-1 (CD80) and B7-2 (CD86) interact with CD28 on the T cell, and 
have been proposed to be involved in the course (Morikawa and Nagashima 2000, Larche 
et al., 1998) of Th1 and Th2 reactions respectively. The definite role of B7-1 and B7-2 in 
the development of Th1 and Th2-mediated responses respectively (Kuchroo et al. (1995)) 
remains unclear.  
While present in the airways, however, the antigen-presenting functions of the DC 
are suppressed, mainly by signals from adjacent cell populations like (subpopulations of) 
alveolar macrophages. Alveolar macrophages suppress T-cell-dependent immunity by 
means of cytokines which inhibit proliferation of T cells and APC-activity of DC (Holt et 
al., 1993, Holt 1996, Poulter et al., 1994, Strickland et al., 1996, Thepen et al., 1992). 
Suppressing activity of alveolar macrophages may be partly blocked in asthmatics by the 
presence of high levels of GM-CSF (Bilyk and Holt 1993, Holt et al., 1996). Moreover, 
airway macrophages from asthmatic subjects show higher APC activity (Larche et al., 
1998).  
Nature and number of doses of the antigen also play a role in Th differentiation. 
Intrinsic characteristics of the allergen may stimulate either Th1 or Th2 differentiation, as 
may for example be concluded from the fact that modification of allergen structure can 
cause a change in Th cell differentiation (Gieni et al., 1993). Also dose is important in 
determining Th differentiation, as moderate and/or high doses in general induce Th2 
differentiation, whereas low or very high doses stimulate Th1 (Rogers and Croft 2000).  
Finally age also influences Th balances. The intrauterine environment is biased 
toward a Th2-response, and all newborns are biased toward Th2 responses (Warner et al., 
2000). While normally the Th1 branch develops within few years, this process is disturbed 
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in children who develop allergy (Holt and Macaubas 1997, Prescott et al., 1998). Although 
respiratory allergy is a Th2-mediated process, immune deviation to a Th1 response does 
not necessarily ameliorate the disease. The same goes for the Th1-mediated process leading 
to experimental autoimmune encephalomyelitis, which can, in a slightly different form, 
also be induced by Th2-cells (Lafaille et al., 1997). In a murine model of eosinophilic 
airway inflammation Th1 cells fail to counterbalance the effects of Th2 cells (Hansen et 
al., 1999, Li et al., 1998), and they may actually cooperate with Th2 cells (Randolph et al., 
1999). The inflammatory reaction initiated by Th1 cells plays a crucial role in this process. 
This supports the importance of the Th2-default in the lungs (Constant et al., 2000).  
Overall, the final character of the immune response is determined by various factors 
such as the APC, cytokines produced by the APC and other cells, nature and dose of the 
antigen, age, genetic background, route of administration and number of administrations.  
 
Increasing prevalence of respiratory allergy 
 
The prevalence of allergic airway diseases has increased during the last few decades in 
western and westernized societies (Schäfer and Ring, 1997, Lundbäck 1998, Beasley et al., 
2000). Since the genetic make up of a diverse population cannot change so rapidly, the 
cause(s) will most likely be found in our changing lifestyle and environment (Cookson et 
al., 1997, von Mutius et al., 1998, ISAAC 1998, Alm et al., 1999). While some argue that 
these factors should act in a certain “critical period” during childhood (first 1-2 years after 
birth) to permanently retain the Th2-biased response after birth (Prescott et al., 1999), 
studies from East/West Germany show that children older than 3 years are still influenced 
(von Mutius et al., 1998).  
 
Factors in Western lifestyle 
 
Different factors (Hopkin 1997) associated with western lifestyle, such as smaller family 
size (Matricardi et al., 1998), vaccinations and childhood infections (Cookson 1997, 
Brehler and Luger 1999, Kramer et al., 1998), intestinal microflora (Björksten et al., 1999), 
Western diet (Black and Sharpe 1997) and lifestyle-associated environmental changes such 
as in- and outdoor air pollution (Frew and Salvi, 1997, Steerenberg et al., 1999b) have been 
proposed to explain the increasing prevalence (Fig. 3). The first three all support the idea 
that diminished exposure to infection, especially at a young age, might promote atopy. The 
Th1 environment created during infections like tuberculosis and measles may modify the 
developing immune system by inhibiting Th2 reactions, whereas the absence of such 
infections may give Th2 mechanisms space to act (Shirakawa et al., 1997). In apparent 
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contrast seems to be the fact that Th1 cells cooperate with Th2 cells as mentioned before 
(Hansen et al., 1999, Randolph et al., 1999), and reports on measles and other infections 
increasing the risk for allergy (Paunio et al., 2000, Bodner et al., 1998). It is evident that 
different types of infections have distinct effects on the development of allergy. Matricardi 
et al. (2000) demonstrated that respiratory allergy was less frequent in people heavily 
exposed to orofecal and foodborne microbes, while this was not the case for highly 
infectious airborne viruses such as mumps and measles. Whereas some helminthic 
infections may inhibit atopic immune disorder, other members of this heterogeneous group 
do not (Mao et al. 2000).  
The fact that our contemporary diet contains increased amounts of ω−6 
polyunsaturated fatty acids (PUFAs) and less ω−3 PUFAs may cause Th2-mediated 
allergy. Ω−6 PUFAs such as linoleic acid are precursors of arachidonic acid, which can be 
converted to prostaglandin (PG) E2. Ω−3 PUFAs as present in oily fish inhibit this 
formation (Black and Sharpe, 1997). PGE2 on its turn reduces IFNγ  production by T 
lymphocytes and thus stimulates Th2 responses (Black and Sharpe, 1997, Kalinski et al., 
1999).  
A plausible but unproven case can be made for increasing levels of allergens like 
house dust mite in modern heated, well isolated houses (Leung et al., 1998, Garrett et al., 
1998). For several allergens, differences in allergy-prevalence could not be explained by 
differences in exposure (Jogi et al., 1998).  
 
Air pollution 
 
Indoor (von Mutius et al., 1996, Maier et al., 1997) and outdoor (Wjst et al., 1993, Lipsett 
et al., 1997, Duhme et al., 1996, Rusznak et al., 1994, Popp et al., 1989, Ulvestad et al., 
2000) air pollution appear to play an immunomodulatory role in the lungs. It is important 
to distinguish that air pollutants may cause sensitization, thereby increasing the prevalence 
of allergic disease, and/or exacerbate already existing allergy, hence increase its severity 
(Wardlaw 1992). Although the increase in severity is undoubtedly clear (Korrick et al., 
1998, Lipsett et al., 1997, Jacobs et al., 1997, Pope and Dockery 1992, Duhme et al., 
1996), the role of air pollution in sensitization is controversial (van Vliet et al., 1997, 
Ishizaki et al., 1987, von Mutius et al., 1998, ISAAC 1998).  
The fact that humans are exposed to a mixture of pollutants makes discrimination 
between the roles of the different components virtually impossible (Lipsett et al., 1997). 
However different pollutants appear to have distinct effects, therefore a distinction has to 
be made between different types of air pollution. 
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Figure 3: Factors in Western lifestyle that possibly influence the prevalence of respiratory allergy. 
  
 
Pollutants like (ultra) fine particles and oxidant gases such as nitrogen dioxide (NO2) and 
ozone (O3) appear to influence the functioning of the immune system, thereby possibly 
playing a role in airway allergy (Devalia et al., 1996, Behrendt et al., 1997). This is in 
contrast to pollutants such as sulfur dioxide (SO2) and larger dust particles, which appear to 
affect mostly the upper airways, causing bronchitis-like disease.  
This distinction was determined from the fact that in the severely polluted (SO2, 
larger dust particles) former East Germany the prevalence of respiratory allergy is lower 
than in former West Germany (high levels of ultrafine particles and NO2) (von Mutius et 
al., 1992). The fact that after the unification the prevalence is increasing in the former East 
indicates that some factors in Western lifestyle play a role (von Mutius et al., 1998). Also 
within the same country and even the same region differences in prevalence can be found, 
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for example Swedish children with an antroposophic lifestyle (Alm et al., 1999) or children 
who spend their first years of life in a rural area show a lower prevalence of atopy than in 
comparable urban populations (Nilsson et al., 1999).  
Probably a combination of several of the above mentioned factors will determine the 
development of allergy, causing an increased risk of developing an IgE-mediated allergy 
for a person in a Westernized society who is exposed to a “Western” diet, “Western” air 
pollution, and a “Western” infection pattern.  
 
Particulate air pollutants  
 
Particulate air pollution is known to play an important role in the exacerbation of existing 
airway disease (Jacobs et al., 1997, Pope and Dockery 1992, Lipsett et al., 1997) and the 
induction of immunological alterations in humans (Hadnagy et al., 1996). Road transport is 
a major source of the smallest class of particles and gaseous pollutants. The presence of 
heavy car traffic, producing large amounts of diesel exhaust particles (DEP), coincides 
with (new cases of) allergic diseases of the airways (Ishizaki et al., 1987, Aarts et al., 
1999). Epidemiological evidence suggests that an increase in liquid petroleum derived 
pollutants, a/o. fine particles, O3, and NOx is associated with exacerbation of allergic 
airway disease (Devalia et al., 1996, Maynard and Waller 1996, Lipsett et al., 1997). 
 
Particulate matter 
 
Particulate matter has gained a lot of attention over the past 10 years, and is recognized as 
an important causative agent of acute and probably also long-term pulmonary effects 
(Dockery and Pope 1994). Yet, the exact role of PM is not clear (Wardlaw 1992), and 
because PM is a heterogeneous agent, it is not sure which component of PM is responsible 
for the effects. PM is usually characterized according to its size, PM10 representing 
particles up to 10 µm. The coarse fraction with diameters between 2.5 and 10 µm mainly 
consists of inorganic minerals such as wind blown dust. Silicates are mainly present in this 
coarse fraction (Ormstad et al., 1998, Churg and Brauer, 1997). Crystalline silica particles 
(SIP) are known for their adjuvant activity (Mancino et al., 1983) as well as their 
fibrogenic potential, while amorphous SIP are nonfibrogenic and the inflammatory 
response they induce after one dose is transient (Yuen et al., 1996). Little is known about 
the immunomodulatory potential of SIP in relation to respiratory allergy. 
 The fine (0.1-2.5 µm) and ultrafine (<0.1 µm) fractions predominantly consist of 
carbonaceous particles like DEP that are composed of carbonaceous particle cores to which 
polycyclic aromatic hydrocarbons are attached. Carbon black particles (CBP) lack these 
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substances, but they are possibly not as inert (Løvik et al., 1997, Nilsen et al., 1997) as 
they were once thought to be (Crosbie 1986). DEP, however, are known from both 
epidemiological as well as experimental studies in humans and mice (Saxon and Diaz-
Sanchez 2000) to have effects on lung function and respiratory allergy.  
 
Diesel exhaust particles 
 
DEP make up an important part of PM and are most likely responsible for the increase in 
respiratory symptoms observed in persons exposed to high levels of PM in the vicinity of 
freeways (van Vliet et al., 1997). From a Japanese study it was concluded that the presence 
of DEP plays a crucial role in the increasing prevalence of respiratory allergy to a common 
allergen (Ishizaki et al., 1987). In animal studies the immunomodulating activity of DEP 
has been shown in several models. In mice the adjuvant activity has been shown after 
immunization with DEP and ovalbumin (OVA) via various routes. After intraperitoneal 
injection of DEP and OVA, the primary IgE antibody responses are higher than after 
injection of OVA alone (Muranaka et al., 1986). Also exposure to a combination of antigen 
and DEP via the inhalatory route was shown to result in higher local and systemic levels of 
cytokines (IL-4, IL-5, IL-10, GM-CSF), higher IgE and IgG titers in blood and aggravated 
airway inflammation (eosinophils, neutrophils, lymphocytes) in mice (Takano et al., 1997, 
Fujimaki et al., 1994 and 1997). Similar results were obtained after intranasal exposure 
(Takafuji et al., 1987, Nilsen et al., 1997) and in a rat model (Steerenberg et al., 1999a). 
In humans Diaz-Sanchez et al. (1997a) showed that subjects who are allergic to 
ragweed display enhanced specific IgE production and skewed Th2-cytokine patterns after 
combined intranasal exposure to allergen and DEP. This confirms the finding in 
epidemiological studies that allergic persons show worsening of respiratory symptoms 
during spells of severe air pollution. In healthy subjects acute short-term DEP exposure 
caused a pulmonary and systemic inflammatory response. The fact that by means of 
standard lung function measurements (peak expiratory flow rate, forced expiratory volume, 
etc) this response cannot be observed may explain why this inflammatory response has not 
been noted in earlier studies (Salvi et al., 1999 and 2000). In 1999 Diaz-Sanchez et al. also 
showed that the induction of allergy to a new antigen (keyhole limpet hemocyanin [KLH]) 
was facilitated by coexposure to DEP. This finding supports the few epidemiological 
studies that report enhanced risk on sensitization for subjects who are exposed to 
(particulate) pollution.  
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Interactions between particulate air pollution and the immune system 
 
Mechanisms of interaction 
 
Mechanisms by which particles enhance the immune response to common allergens could 
act at different levels. Particles and allergens could already interact in the outside air. 
Particles in the aqueous phase can interact with pollen in vitro, causing allergens to be 
concentrated on respirable size particles (Knox et al., 1997), which function as allergen 
carriers (Ormstad et al., 1998). The organic substances adsorbed on particles could play a 
role in preactivation of pollen, which under appropriate conditions could release its, 
possibly altered, allergens (Behrendt et al., 1992). Also the presence of endotoxin in the air 
or on particles could stimulate IgE-mediated immune responses (Wan et al., 2000).   
After inhalation, the particle-allergen complex may deposit in a different site as 
compared to a protein alone. Allergen may be slowly released locally in the lung, 
resembling “classical” adjuvant function (Janeway and Travers 1994). Particles could also 
change the microenvironment within the lung and act as adjuvant by causing local airway 
irritation and inflammation, as has been shown for DEP (Siegel et al., 1997, Gilmour 1995) 
and residual oil fly ash (ROFA) (Lambert et al., 1999). Locally the particles are taken up 
by macrophages (Kobzik 1995, Palecanda et al., 1999) in which the production of 
cytokines like TNFα and IL-1 and mediators such as nitrogen oxide (NO) can be induced 
(Becker et al., 1996). Epithelial cells also take up particles, and produce proinflammatory 
mediators like IL-6 and IL-8 (Steerenberg et al., 1998, Bayram et al., 1998). Cytokine 
release by epithelial cells of asthmatic patients is increased as compared to non-asthmatic 
subjects, indicating that individuals with airway disease are more vulnerable to the adverse 
effects of air pollution (Devalia et al., 1999). Together possible damage of the epithelial 
barrier and a decrease in ciliary activity may cause impaired clearance of antigen (Devalia 
et al., 1997), increasing the amount of antigen available for cells of the immune system.  
Another possibility may be that the presence of particles downregulates the normal 
suppressor activity of macrophages on DC antigen presentation (Thepen et al., 1992, Holt 
et al., 1993). Macrophages are able to transport particles to the draining lymph nodes of the 
lung (Harmsen et al., 1985, Lehnert et al., 1986), but it is unknown if immunomodulation 
can also be performed locally in the draining lymph nodes. Although cytokine production 
is observed in the lymph nodes, it is less likely that antigen presentation by DC will be 
influenced in the PBLN since during migration DC become unresponsive to stimuli from 
the environment.  
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Crucial particle characteristics  
 
Which characteristic of a particle is crucial in adjuvant activity remains unclear. The 
adsorbed substances as present on DEP appear to play an important role, at least in in vitro 
systems (Takenaka et al., 1995, Bayram et al., 1998, Yang et al., 1997, Ohtoshi et al., 
1998, Tsien et al., 1997), but the (hard core of) the particle itself also contributes to the 
adjuvant activity. This was shown in the primary popliteal lymph node assay (PLNA) by 
Løvik et al. (1997) who demonstrated that CBP, representing the non-extractable particle 
core of DEP, injected subcutaneously (sc) with OVA caused an increase in PLN weight, 
cell numbers, cell proliferation and IgE-levels. Yet, CBP were slightly less potent than 
DEP. In addition to that, also clean, synthetic particles like polystyrene particles are able to 
adjuvate the immune response via different routes of administration (Granum et al., 
2000b).  
Size is probably an important characteristic because it plays a crucial role in 
determining whether and where particles are deposited after inhalation. While particles 
larger than 10 µm are deposited in the upper airways and are subsequently removed by the 
mucus-escalator and swallowed, particles of 2.5 µm reach conducting airways and the 
alveolar region and stay present in the alveoli for a long time (Churg and Brauer 1997, 
Ferin et al., 1992). In addition to that, number (Granum et al., 2000b), surface reactivity 
(Fubini 1997) and charge (Oortgiesen et al., 2000) appear to be important determinants. An 
order of importance for the afore mentioned characteristics seems impossible to give.  
 
Mouse models on respiratory allergy and pollution  
 
Animal models are necessary for research on the immune system and allergy, because they 
give crucial information in addition to in vitro, human and epidemiological studies. 
Whereas in vitro assays are necessary to investigate a mechanistical aspect of the immune 
response, the interactions that take place in the complete and complex immune system 
cannot be reproduced in vitro. Also, as a consequence of ethical considerations, studies on 
human volunteers can only give a certain amount of information because sampling from 
different organs and body fluids is limited and also because a risk of sensitization always 
exists. Also epidemiological studies cannot replace in vivo studies completely. Firstly 
because the effect of one particular pollutant is hard to deduce from the mixture of 
pollutants that humans are exposed to, secondly because they do not give information on 
mechanism.  
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Therefore animal models have been developed. Most models are mouse models 
(Wills-Karp 2000), which is a logical choice of animal since it is a small animal, of which 
the immune system is similar to the human system and a lot of monoclonal antibodies are 
available (Karol 1994). Also many inbred and knockout strains are available (Wills-Karp 
2000). However, administration of an antigen via the relevant inhalatory or intranasal route 
easily induces tolerance (suppression of IgE responses) in mice. To achieve sensitization, 
antigen can be administered by means of injection and/or use of adjuvants (Kung et al., 
1994). Injection models such as the PLNA do not require special equipment, and both the 
assay itself as well as the read out of the immune response is relatively easy to perform. 
But although the PLNA is a suitable screening assay, the injection in the paw makes 
research beyond some basic immunomodulating mechanisms irrelevant for real life 
situations. Other models combine injections with inhalatory exposures (Hessel et al., 
1995), but even though those models effectively mimic respiratory allergy and/or asthma, 
they do not fully take the natural route of exposure into account. Because sensitization is 
achieved in an artificial way, only the effects of pollutants on sensitized animals can be 
assessed, while the effects of pollutants on the sensitization process remain undetermined.  
Models which only use inhalatory or intranasal exposure (Renz et al., 1992) are rare 
and often use long protocols, and in addition the pollutant is given during the whole period, 
irrespective of the phase of the immune response (Fujimaki et al., 1997, Maejima et al., 
1997, Nilsen et al., 1997, Takafuji et al., 1987). Only recently a simple model was 
developed in the rat in which exposure to the pollutant ROFA took place exclusively 1 day 
before sensitization, and the adjuvant effect was described extensively (Lambert et al., 
1999).  
 
Scope of this thesis 
 
The aim of this thesis was to develop a model to assess the immunomodulating capacity of 
particulate air pollution and to unravel underlying mechanisms. Our hypothesis was that 
exposure of naïve subjects to particulate air pollution during sensitization to an antigen 
leads to an increased risk of allergic sensitization.   
Our first question was: do different components of particulate air pollution possess 
any immunomodulating capacity? Therefore we determined the adjuvant activity of 
different types of particles in a subcutaneous injection model in mice. In this model the 
influence of the particles on the primary and secondary immune response was investigated 
(Chapter 2). Our second question was: do these particles modulate functions of the alveolar 
macrophage, one of the main cell types they come in contact with after inhalation? 
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Therefore we assessed the effects of the particles on a mouse alveolar macrophage cell line 
in vitro (Chapter 3). To find out whether the particles adjuvated the immune response, and 
especially allergic sensitization, after exposure via the relevant route in vivo, an intranasal 
exposure model was developed in mice (Chapter 4). To determine whether this adjuvant 
effect acted exclusively during the sensitization phase, we assessed the influence of the 
presence of particles during the different phases of the immune response in the intranasal 
exposure model (Chapter 5). In Chapter 6 we determined whether coadministration of 
particles and antigen was necessary for adjuvant activity by separating antigen and particle 
doses in the intranasal model. To evaluate different methods of antigen exposure, an 
inhalatory exposure model was developed in addition to the intranasal model (Chapter 7). 
Results as obtained in these studies are summarized and discussed in Chapter 8.  
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CHAPTER 2 
 
DIESEL EXHAUST, CARBON BLACK, AND SILICA 
PARTICLES DISPLAY DISTINCT TH1/TH2 MODULATING 
ACTIVITY  
 
Maaike van Zijverden, Anita van der Pijl, Marianne Bol, Frederiek van Pinxteren, Colin de 
Haar, André Penninks, Henk van Loveren, Raymond Pieters 
 
ABSTRACT                
 
Certain particulate air pollutants may play an important role in the increasing prevalence of 
respiratory allergy by stimulating T helper 2 cell (Th2)-mediated immune responses to common 
antigens. The study described here examined different particles, diesel exhaust particles (DEP), 
carbon black particles (CBP) and silica particles (SIP), for their immunomodulating capacity in both 
primary and secondary immune responses in female BALB/C mice. The primary response was 
studied after subcutaneous injection of one milligram (mg) of particle together with 10 microgram 
(µg) of reporter antigen TNP-OVA (2,4,6-trinitrophenyl coupled to ovalbumin) into the hindpaw. 
Interferon γ (IFNγ) and interleukin 4 (IL-4) production was assessed in the popliteal lymph node 
(PLN) at Day 2 and Day 5 after injection by flowcytometry and ELISA. The number of IL-4 
containing CD4+ T cells increased between Day 2 and Day 5 in DEP- and CBP-exposed mice, in 
contrast to SIP-treated animals. IL-4 production by cultured PLN cells was also significantly 
increased for DEP- and CBP-treated animals. The secondary response was studied in different 
organs after an intranasal challenge with TNP-OVA (50 µg) which was given 4 weeks after the 
initial subcutaneous injection. Five days after challenge the number of antibody forming cells (AFC) 
was assessed in peribronchial lymph nodes (PBLN), spleen, bone marrow and PLN, and antibody 
levels were determined in blood samples obtained weekly. It appeared that all particles acted as 
adjuvant, but the different particles stimulated distinct types of immune responses to TNP-OVA. 
DEP-treated animals show high IgG1 and IgE levels in serum and high IgG1 and IgE forming AFC 
numbers in PBLN, bone marrow and spleen. CBP-treated animals show even higher IgG1 and IgE 
levels and AFC numbers, and in addition display IgG2a production. SIP-injected animals display 
predominantly IgG2a responses. It is concluded that DEP are able to skew the immune response 
toward the T helper 2 (Th2) side, whereas SIP stimulate a Th1 response and CBP have a mixed 
activity, stimulating both Th1 and Th2 responses in this model.
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INTRODUCTION 
 
The prevalence of allergic airway diseases has increased during the past few decades in 
Western and Westernized societies (Schäfer and Ring, 1997, Lundbäck 1998, ISAAC 
1998). Since the genetic makeup of a diverse population cannot change so rapidly, the 
cause(s) will most likely be found in our changing lifestyle and environment. Different 
factors (Hopkin 1997) associated with Western lifestyle, such as smaller family size 
(Matricardi et al., 1998), childhood infections (Cookson 1997), and Western diet (Black 
and Sharpe 1997) and lifestyle-associated environmental changes such as air pollution 
(Frew and Salvi, 1997) have been proposed to explain the increasing prevalence.  
The role of air pollution, however, is not completely clear. First, air pollution has not 
been proven to increase the risk of sensitization of naïve subjects, although it clearly plays 
a role in the exacerbation of existing disease (Jacobs et al., 1997, Pope and Dockery 1992, 
Lipsett et al., 1997, Duhme et al., 1996). Second, a distinction must be made between 
different types of air pollution. Pollutants such as (ultra) fine particles and oxidant gases 
such as NO2 and O3 appear to influence the functioning of the immune system, thereby 
possibly playing a role in airway allergy (Devalia et al., 1996, Behrendt et al., 1997). This 
is in contrast to pollutants such as SO2 and larger dust particles, which appear to affect 
mostly the upper airways, causing bronchitis-like disease. This distinction has become 
clear from the fact that in the more-polluted former East Germany the prevalence of 
respiratory allergy is lower than in former West Germany (Mutius et al., 1992). Combined 
with the increasing prevalence in the former East after the unification, this indicates that 
some factors in Western lifestyle play a role (Mutius et al., 1998). One of those factors may 
be “Western pollution”.  
Fine particles, also called particulate matter (PM) in relation to airway diseases, 
have gained much attention over the past 10 years and are recognized as an important 
causative agent of acute and probably also long-term pulmonary effects (Dockery and Pope 
1994). Yet, the exact role of PM is not clear (Wardlaw 1992), and because PM is a 
heterogenic agent, it is not evident which component of PM is responsible for the effects. 
DEP make up an important part of PM (Bérubé et al., 1997), and are most likely 
responsible for the increase in respiratory symptoms observed in persons exposed to high 
levels of PM in the vicinity of freeways (van Vliet et al., 1997). A Japanese study 
concluded that the presence of DEP plays a crucial role in the increasing prevalence of 
respiratory allergy to a common allergen (Ishizaki et al., 1987).  
In accordance with this, DEP have been found to adjuvate in particular Th2-like 
immune responses in humans and mice. Intranasal exposure to allergen in combination 
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with DEP stimulates a Th2 type cytokine pattern and enhances specific IgE production in 
humans allergic to ragweed (Diaz-Sanchez et al., 1997a). In mice the adjuvant activity of 
DEP has been shown after immunization via various routes with DEP and ovalbumin. 
After intraperitoneal injection of DEP and OVA the primary IgE antibody responses were 
higher than after injection of OVA alone (Muranaka et al., 1986). Also exposure to a 
combination of antigen and DEP via the inhalatory route was shown to result in higher 
local and systemic levels of cytokines (IL-4, IL-5, IL-10, GM-CSF), higher IgE and IgG 
titers in blood, and aggravated airway inflammation in mice (Takano et al., 1997, Fujimaki 
et al., 1994, Fujimaki et al., 1996). Similar results were obtained after intranasal exposure 
of mice (Takafuji et al., 1987, Nilsen et al., 1997) and in a rat model (Steerenberg et al, 
1999a).  
PM is usually characterized according to its size, PM10 representing particles up to 
10 µm. Size is crucial in determining whether and where particles are deposited in the lung; 
(ultra) fine particles (<2.5 µm) seem to be able to reach the alveoli and stay present for a 
long time (Churg et al., 1997,  Ferin et al., 1992). However, size may not be the (only) 
critical characteristic, others like surface chemistry may be equally important (Murphy et al 
1998). At least in in vitro systems substances that are present on DEP can modulate the 
response (Takenaka et al. 1995, Bayram et al., 1998, Yang et al.1997, Ohtoshi et al., 1998,  
Tsien et al., 1997), in addition to the (hard core of the) particle that also contributes to the 
adjuvant activity. The latter was shown in the primary popliteal lymph node assay (PLNA) 
by Løvik et al. (1997), who demonstrated that carbon black particles (CBP), representing 
the nonextractable particle core of DEP, injected subcutaneously (sc) with OVA caused an 
increase in PLN weight, cell numbers, cell proliferation (inflammatory response) and IgE-
levels. Yet, they were slightly less potent than DEP. Carbonaceous particles like DEP and 
CBP are present in the ultrafine (<0.1 µm) and fine (0.1-2.5 µm) fractions of particulate 
matter. Silicates are also present in PM, but mainly in the coarse fraction, with diameters 
between 2.5 and 10 µm (Ormstad et al., 1998, Churg and Brauer 1997). Crystalline silica 
particles (SIP) are known for their adjuvant activity (Mancino et al., 1983) as well as their 
fibrogenic potential, while amorphous SIP are nonfibrogenic and the inflammatory 
response they induce after one dose is transient (Yuen et al., 1996). Little is known about 
the immunomodulatory potential of SIP in relation to respiratory allergy.  
In this study the carbonaceous particles DEP and CBP were compared to amorphous 
SIP. From the comparison between DEP and CBP an idea about the role of adsorbed 
substances can be formed. The capacity of these three particles, differing in size and origin, 
to modulate the obligatory costimulation and type of immune response was studied by 
measuring different types of costimulatory molecules, cytokines and antibodies. Cytokines 
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are among others produced by T helper cells (CD4+) which play a role in determining the 
direction of  the immune response. Th1 and Th2 subsets can be distinguished based on 
their cytokine patterns. Th1 cells produce IFNγ , which results in a cellular response and 
IgG2a production. Th2 cells produce IL-4, which stimulates a humoral response, 
characterized by IgG1 and IgE production. Cytokines are also produced by cytotoxic T 
cells (CD8+), effector cells of the cellular response. In the primary response, we 
determined IL-4 and IFNγ containing T cells and production, and the expression of CD80, 
CD86, and CD40 at 2 and 5 days after subcutaneous injection of particle together with the 
antigen TNP-OVA. The secondary response was studied after an intranasal challenge with 
antigen alone, which was given 28 days after the subcutaneous (sc) injection. The capacity 
of the different particles to stimulate antibody production in different organs during the 
secondary response was examined 5 days after challenge. In both models we compared the 
different particles with regard to their capacity to adjuvate the immune response to TNP-
OVA, while the emphasis was on determining Th1/Th2 characteristics of the response.  
 
MATERIALS AND METHODS 
 
Animals 
Female, specific pathogen-free BALB/c mice (6-8 weeks of age) were obtained from the 
Utrecht University breeding facility. Mice were housed under hygienic barrier conditions 
in filter-topped macrolon cages with bedding of wood chips, a temperature of 23±2oC, 50-
60% relative humidity and a 12-h light/dark cycle. They received standard lab chow and 
acidified tap water ad libitum. The experiments were approved by an ethical committee and 
conducted in accordance with the Guiding Principles in the Use of Animals in Toxicology.  
Chemicals and reagents 
SIP (SiO2) were obtained from Sigma Chemical Company (St. Louis, MO) and CBP from 
Brunschwich Chemie (Amsterdam, The Netherlands). DEP were a friendly gift from dr. P. 
Scheepers (Nijmegen University, The Netherlands). The antigen TNP-OVA was prepared 
as described by Albers et al. (1997). Immobilon-P membranes were obtained from 
Millipore (Etten-Leur, The Netherlands), and alkaline-phosphatase-conjugated goat 
αmouse IgG1, IgG2a and IgE antibodies from Southern Biotechnology Associates 
(Birmingham, AL). Antibodies for IgE and cytokine sandwich ELISA; αmouse IgE 
(02111D), αmouse IFNγ (18181D) and αmouse IL-4 (18191D) plus their biotinylated 
counterparts (188112D and 18042 D), and αmouse IFNγ (19301T) and IL-4 (19231V), 
were obtained from Pharmingen (Hamburg, Germany). ELISA plates (highbond 3590) 
were obtained from Costar (Cambridge, MA). All reagents for the TNP-specific ELISA 
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were all obtained from Sigma. Streptavidine coupled to horseradish peroxidase was 
obtained from CLB (Amsterdam, the Netherlands). Surface markers for flowcytometry 
(Pharmingen) were αCD3-FITC (01084D), αCD4-FITC (01064D), αCD8-FITC (01044D), 
αCD80-FITC (09604D), αCD86-FITC (09274D), αCD40-FITC (09664D), αCD4-PE 
(01075A) and αCD19-PE (09655B). For intracellular labeling αIFNγ-PE (18115A) and 
αIL-4-PE (18195A) were used.  
Treatment of the mice 
Particle suspensions (20 mg/ml) were prepared in saline containing 0.2mg/ml TNP-OVA 
and 10% normal mouse serum. The latter was added to facilitate suspension of the 
hydrophobic particles, while they stirred for 18 h (Løvik et al. 1997). A total volume of 50 
µl was sc injected into the right hind footpad of naive BALB/c mice. To determine the 
primary response, mice were terminated 2 or 5 days after injection and the right PLN was 
taken out. The secondary response was determined 5 days after an intranasal challenge, 
which took place 4 weeks after injection. This challenge was performed by pipetting 50 µl 
of saline containing TNP-OVA (1 mg/ml) on the nostrils under light ether anesthesia. 
Blood was collected weekly by orbita punction under ether anesthesia; sera were prepared 
and frozen individually. Five days after challenge mice were terminated and right PLN, 
bone marrow, spleen and PBLN were isolated. PLN, PBLN and spleen were minced to 
prepare single cell suspensions. Erythrocytes in spleen suspension were lysed using a 
0.83% (w/v) ammonia buffer and cells were washed 2 times in PBS/1% BSA.  
ELISPOT assay  
These assays were essentially performed as described previously (Schielen et al., 1995). 
Briefly, from each organ 0.5*106 cells in 500 µl PBS/1% BSA were incubated (4 h, 37oC) 
in wells containing TNP-BSA coated (overnight [o.n.] 4oC) Immobilon-P membranes as 
bottom. Thereafter, membranes were washed and incubated with optimal dilutions of 
isotype-specific alkaline phosphatase-conjugated αmouse Ig antibodies in PBS/T (o.n. 
4oC). After washing, spots were developed by incubation with 5-bromo-4-chloro-3-indolyl 
phosphate and nitroblue tetrazolium (BCIP/NBT). Specific AFCs per 106 cells were 
calculated from spot numbers counted with the aid of a stereo microscope.  
TNP-specific IgG1 and IgG2a ELISA 
Plates were coated (o.n. 4oC) with TNP-BSA (20 µg/ml) in 0.05 M carbonate buffer pH 
9.6, and blocked with PBS/1% BSA (1 h, room temperature [RT]). Serial dilutions of sera 
were incubated (1 h, RT) and plates were washed and incubated with an optimal dilution of 
alkaline phosphatase-conjugated anti-mouse IgG1 or IgG2a (1 h, RT), followed by p-
nitrophenyl phosphate (1 mg/ml in diethanolamine buffer, pH 9.8) for 30 min. Absorbance 
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was measured at 405 nm. Titers were calculated by means of the sample dilution at which 
extinctions were higher than background+2*SD.  
TNP-specific IgE ELISA  
Plates were coated (6 h, first hour at 37oC, last hours at RT) with αIgE, 2 µg/ml in 0.05 M 
carbonate buffer, pH 9.6. Serial dilutions of sera were incubated (o.n. 4oC) and plates were 
washed and incubated with an optimal dilution of alkaline phosphatase-conjugated TNP (1 
h, RT). See preceding section for last steps of the procedure.  
Flowcytometry  
For analysis of surface markers, single cell suspensions (5*106/ml) in RPMI/10% FCS 
were incubated with combinations of FITC and PE-conjugated αCD3, αCD4, αCD8, 
αCD19, αCD80, αCD86, and αCD40 at predetermined dilutions (30 min, RT). Cells were 
washed in PBS and stored for up to 24 h in PBS/0.1% paraformaldehyde prior to analysis. 
In vitro restimulation and intracellular staining were essentially performed as described by 
Openshaw et al. (1995). In short, freshly isolated single cell suspensions (5*106cells/ml) 
were stimulated with 50 ng/ml PMA and 500 ng/ml ionomycin in the presence of 10 µg/ml 
Brefeldin A for 4 h before an equal volume of PBS/4% paraformaldehyde was added. After 
fixing (20 min, RT), cells were washed in PBS and stored o.n. in PBS. Cells were washed, 
resuspended in PBS/1% BSA/0.5% saponin, and incubated for 10 min (RT). Next, PE-
conjugated αIFNγ, αIL-4, or isotype control was added at 5 µg/ml in PBS/1% BSA/0.5% 
saponin (30 min, RT). Cells were washed twice with PBS/1% BSA/0.5% saponin, once 
with PBS/1% BSA, and incubated for 10 min in this buffer to reseal cell membranes. 
Finally, surface staining was performed using FITC-conjugated αCD3, αCD4 and αCD8. 
Samples were analyzed on a FACScan flowcytometer (Becton Dickinson, San Jose, CA) 
with thresholds set on the isotype-control stainings that were included for every 
suspension.  
Cell culture  
A 100 µl sample from the cell suspensions (1*106/ml) was incubated with 50 µl stimulus 
(concanavaline A, 50 µl of 15 µg/ml) o.n. at 37oC, 5% CO2. After centrifugation (10 min at 
1000 rpm) supernatant was collected and stored at -20oC for analysis. After analysis, the 
results were corrected for the differences in T-cell percentages as assessed by FACS 
analysis. For example, although controls contain an average of 60% T cells, CBP-treated 
animals show an average of only 34%, resulting in a multiplication of CBP results with a 
correction factor of 60/34=1,8.  
Sandwich ELISA for IL-4 and IFNγ  
Plates were coated (o.n., 4oC) in 0.05 M carbonate buffer pH 9.6 with 1 µg/ml αmouse 
IFNγ or IL-4, and after washing were blocked with PBS/T/1% casein (4 h, RT). 
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Supernatants were then incubated o.n. at 4oC . Dilutions of mouse IFNγ or IL-4 were 
included on every plate for standard curve production. Plates were washed and incubated 
with 0.25 µg/ml biotine-conjugated αmouse IFNγ or IL-4  in PBS/T/1% casein (1 h, RT). 
After washing, streptavidine coupled to horseradish peroxidase (dilution 1:10,000) in 
PBS/T/1%casein was added (3/4 hr, RT). After washing, TMB (0.1 mg/ml) substrate was 
added, and the color reaction was stopped after 10 min with H2SO4. Absorbance was 
measured at 450 nm.  
Statistics 
Preceding statistical analysis, ELISPOT data (number of AFCs) were transformed to log10 
values to homogenize variance. Differences between group means were analyzed using 
one-way ANOVA with Scheffe post-hoc test for contrasts (p<0.05 or p<0.01). In the case 
of nonsufficient homogeneity of variances, a Kruskal-Wallis ranking test was performed 
(p<0.05).  
 
RESULTS 
  
Cell number, costimulation molecules, and cytokine and antibody production in PLN 
during the primary response 
At Day 2 and Day 5 after subcutaneous injection of particles together with TNP-OVA in 
the hind footpad of mice, various parameters were assessed to evaluate early events during 
the primary immune response. All particles induced clear changes in PLN cell number and 
cell types from Day 2 onward (Fig. 1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Cell numbers of PLN at Day 2 and 5 after injection and at Day 33 after injection and 
intranasal challenge. Depicted are average ±SD *p<0.01 vs. control group. **p<0.01 vs. control, 
DEP, CBP. #p<0.05 vs. SIP group. All determined by ANOVA followed by Scheffe’s post-hoc test. 
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At Day 5, cell numbers of the CBP and DEP-treated groups were increased significantly, 
while at Day 33 only the cell number of the SIP-treated group was elevated. The 
percentage of B cells was increased at Day 5 (Fig. 2A) and the percentage of T cells was 
decreased. Using the cell numbers given in Fig. 1 for calculations, it appeared that at Day 5 
a significant increase in absolute B cell numbers was observed in all particle-treated groups 
compared to controls (Fig. 2B). The DEP-injected group also showed a significantly higher 
increase compared to the SIP-injected group. Absolute T cell numbers did not change 
significantly in the particle-treated groups. The number of B cells, expressing 
costimulatory molecule CD86 (B7.2), was significantly increased in the DEP and CBP-
treated groups compared to the SIP-injected and the control group. A slightly, but not 
significantly, increased expression was observed for CD80 (B7.1) in all particle-injected 
groups. The DEP-injected group showed significantly increased CD40 expression, whereas 
this was less pronounced in the CBP and SIP-treated groups (Fig. 2B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Numbers of T cells, B cells and B cells expressing costimulatory molecules at Day 5 after 
injection of particles and TNP-OVA during the primary response as determined by flowcytometry. 
Cells were double stained for combinations of  CD3, CD4, CD8, CD19, CD80, CD86, and CD40. A: 
numbers on the y-axis are percentages. B: numbers on the y-axis represent absolute numbers per 
animal, which have to be multiplied by either 104 or 105 as is noted on the x-axis.. Depicted are 
average ±SD *p<0.05 vs. control group, determined by Kruskal-Wallis ranking test. **p<0.01 vs. 
control group, #p<0.01 vs. SIP group, determined by ANOVA followed by Scheffe’s post-hoc test.  
 
No significant changes in T helper cell cytokine pattern as determined by FACS analysis 
were observed at Day 2 (Fig. 3A), but all particle-treated groups contained a somewhat 
higher number of IFNγ-containing T helper cells than IL-4-containing cells. At Day 5, 
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however, the ratio of IL-4 to IFNγ  completely turned around for the DEP- and CBP-treated 
groups, from <1 at Day 2 to >1 at Day 5. This was caused by a significant increase in the 
absolute number of IL-4 containing CD4+ T cells in these groups. IFNγ-containing cells 
also increased in the DEP-treated group. The absolute number of IFNγ containing CD8+ T 
cells was significantly elevated in all particle-treated groups at Day 5 (Fig. 3B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Cytokine containing T cells in the PLN during the primary response at Day 2 and 5, as 
determined by intracellular staining for IL-4 and IFNγ, in combination with surface staining for CD3 
and CD4, and analysed by flowcytometry. Depicted are average ±SD. Figure 3A shows T helper cell 
data, *p<0.05 vs. control group, determined by ANOVA followed by Scheffe’s post-hoc test for IL4, 
or determined by Kruskal-Wallis ranking test. Figure 3B shows cytotoxic T cell data, *p<0.05 vs. 
control group, **p<0.01 vs control and p<0.05 vs. CBP and SIP, all determined by ANOVA 
followed by Scheffe’s post-hoc test.  
 
In addition to the number of cytokine-containing cells, actual cytokine production 
was assessed (Fig. 4). ELISA was performed on supernatants of overnight cultures of PLN 
cells, which were isolated 5 days after injection. A correction was made for the decrease in 
T cell percentage as observed in particle-treated groups, as indicated under the Materials 
and Methods. PLN cell cultures from CBP and DEP-treated groups produced significantly 
higher levels of IL-4 than controls, whereas IFNγ  production was significantly enhanced 
only in the CBP-treated group. Cytokine production in SIP-treated animals did not show 
significant changes (Fig. 4).  
At Day 7 after injection, ELISPOT on cultures of PLN cells was performed. Hardly 
any antibody-forming cells were observed in PLN cells, and small numbers of IgG1-AFCs 
were found only in the CBP-injected group (not shown).  
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Figure 4: Overnight cytokine production by PLN cells (removed at Day 5 after injection) as 
determined by ELISA, and corrected for T cell percentage. Depicted are average ±SD. Figure A: 
**p<0.01 vs. control, #p<0.05 vs. SIP, determined by ANOVA followed by Scheffe’s post-hoc test. 
Figure B: ** p<0.01 vs. all other groups, determined by ANOVA followed by Scheffe’s post-hoc 
test.  
 
 
Levels of TNP-specific IgG1, IgG2a and IgE antibody titers in serum during the 
secondary response  
Additional information about the immunomodulating activity of the different particles was 
obtained during the secondary response. Four weeks after the subcutaneous injection, an 
intranasal challenge with TNP-OVA alone was given, and at Day 33, 5 days after 
challenge, AFC numbers were determined in different organs. Immunoglobulin levels were 
assessed in sera obtained weekly. After injection, immunoglobulin levels could already be 
detected at Week 1 and increased steadily thereafter. After intranasal challenge at Week 4, 
a memory response was initiated, indicated by the rapidly increasing immunoglobulin 
levels (Fig. 5).  
Regarding the different isotypes, IgG1 levels in the DEP and the CBP-treated groups 
increased after injection at Day 0 and remained significantly elevated in comparison to 
control levels for 5 weeks. The IgG1 levels in the DEP and CBP-injected groups were 
significantly higher than those of the SIP-treated group, which remained at control levels. 
From Week 2 on, IgG2a levels of the SIP-treated group were significantly higher than the 
levels of control animals. IgG2a levels of both SIP and CBP-treated groups were 
significantly higher than those in the DEP-injected group, which were comparable to, or 
even significantly lower (in Week 3 and Week 4), than control levels. Specific IgE levels 
initially remained unchanged after injection, but were significantly enhanced in the CBP 
and the DEP-treated group after challenge (Week 5).  
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Figure 5: TNP-specific antibody titers in serum during the secondary response, challenge at week 4. 
Depicted are average ±SD. A: IgG1, B: IgG2a, C: IgE. *p<0.05 vs. control, for IgG1: #p<0.05 vs 
SIP, for IgG2a: #p<0.05 vs DEP, determined by ANOVA followed by Scheffe’s post-hoc test, or by 
Kruskal-Wallis ranking test for IgE.  
 
 
Number of TNP-specific antibody forming cells in the secondary response. 
At Day 33 the numbers of AFC was assessed in different organs. In all particle-injected  
groups, the number of IgG1-AFC was significantly enhanced in PBLN and spleen as 
compared to controls (Fig. 6). But IgG1-AFC numbers in the SIP-treated group were 
significantly less enhanced than those in the CBP-injected group. In bone marrow and PLN 
only the DEP and the CBP-injected groups, but not the SIP-injected group, had 
significantly higher IgG1-AFCs than the controls. The number of IgE-AFCs in PBLN and 
spleen were significantly increased in the CBP and DEP-injected groups compared to those 
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in the control and the SIP-treated group. In the PBLN, the numbers of IgG2a-AFCs were 
enhanced in the CBP and the SIP-treated group compared to the control group.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Number of TNP-specific antibody forming cells per 106 cells in PBLN, spleen, bone 
marrow and PLN, as determined by ELISPOT at Day 33 in the secondary response. Depicted are 
average ±SD. *p<0.05 vs. control, #p<0.05 vs. SIP, determined by ANOVA followed by Scheffe’s 
post-hoc test, or by Kruskal-Wallis ranking test  for PBLN IgE and IgG2a. 
 
DISCUSSION 
 
Particulate air pollution has been shown to play a role in the exacerbation of respiratory 
allergy. However, its influence on the induction of the immune response is unknown (Diaz-
Sanchez et al., 1997b). The present study intended to give more insight into the capacity of 
different particles to modulate the induction of an immune response. An overview of the 
results obtained in this study is given in Table 1. It readily appears that characteristics of a 
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production, are all increased in DEP- and CBP-treated animals and not in SIP-treated 
animals. In addition, CBP-treated animals also show increased IgG2a production. Although 
it is known that Th2-mediated responses are involved in respiratory allergy to common 
allergens, carbonaceous particles like DEP and also CBP could play a stimulatory role in 
this process.  
 
Table 1: Summary of data. Particle-treated groups were compared to the control group. 
 
 
Costimulatory
molecules
Cytokines Antibodies
Expression Production Excretion Excretion Present in serum
Bcell-
CD40
Bcell-
CD86
CD4
-IL-4
CD4-
IFNγ
CD8
IL-4
CD8
IFNγ
IL-4 IFNγ AFC
IgG1
AFC
IgE
AFC
IgG2
a
IgG1 IgE IgG2a
DEP + ++ + + - ++ + - + + - + + -
CBP +/- ++ + - - + ++ + + + + + + +
SIP +/- - - - - + - - - - + - - +
 
= no increase 
+/- = non-significant increase  
+ = significant increase p<0.05  
++ = significant increase p<0.01 
All determined by ANOVA followed by Scheffe’s post-hoc test, or by Kruskal-Wallis ranking test 
(see figures for details). 
 
 
The different characteristics of the immune responses stimulated by the particles are 
already illustrated in the primary response, during which differences are seen in expression 
of costimulatory molecules and cytokine production between the groups treated with 
different particles. At Day 5 after injection, a higher expression of the costimulatory 
markers CD40 and CD86 was observed in the groups treated with carbonaceous particles 
as compared to the SIP-treated group. CD80 expression was not enhanced, indicating a 
difference in expression kinetics or a more prominent role of CD86 in these Th2-mediated 
immune responses, as was also observed in an experimental allergic encephalomyelitis 
model (Kuchroo et al., 1995).  
During the primary response the IL-4/IFNγ ratio in T helper cells of both DEP and 
CBP-treated animals changed from <1 at Day 2 to >1 at Day 5. The effector cytotoxic T 
cells revealed an increased IFNγ production in all particle-treated groups. The higher 
number of IL-4-containing T helper cells is reflected by a higher level of IL-4 in culture 
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supernatant of DEP and CBP-treated animals. The increased number of IFNγ-containing 
cytotoxic T cells is reflected by a significantly increased level in supernatant of CBP 
animals, although the increase of the levels of DEP and SIP-treated animals was not 
significant. In our model  the IFNγ content of a cell possibly does not correlate completely 
with actual excretion. Together, these data on the primary response indicate a difference in 
kinetics of the adjuvant activity between SIP, CBP and DEP.  
Differences in immunomodulation were even more obvious in the secondary 
response after the intranasal challenge with TNP-OVA. In the SIP-treated group high 
IgG2a levels and AFC numbers were found. A Th1-mediated immune response was also 
observed after inhalation of silica (Davis et al., 1999). In contrast, in CBP and DEP-treated 
animals high IgE and IgG1 levels and AFC numbers were found, indicative of a Th2-
stimulating capacity of the carbonaceous particles. The adjuvant activity and Th2-skewing 
capacity of DEP have been shown in different animal models and in man. DEP and CBP 
clearly showed adjuvant activity in our model, but the character of the adjuvant activity 
differed slightly. CBP-treated animals showed IgG2a production, whereas IgG2a levels in 
DEP-treated animals seemed even somewhat suppressed compared to control levels. The 
immune response induced by the presence of DEP was, although somewhat less powerful, 
in the end more clearly of the Th2 type than the response after CBP injection. The attached 
substances that are present on DEP, consisting mostly of polyaromatic hydrocarbons 
(PAH-DEP), are often suggested as being responsible. In our model the attached 
substances of DEP could possibly be involved in this skewing toward the Th2 side, as has 
also been shown by others (Takenaka et al., 1995, Tsien et al., 1997).  
Nevertheless, attached substances are apparently not responsible for the entire 
adjuvant activity, since two particles lacking attached substances, CBP and SIP, also acted 
as adjuvant. Evidently the presence of any particle core is crucial. However, SIP, size 1-5 
µm, consisting of oxidized silica, induced a type of immune response different from CBP 
(0.3 µm), which have a carbonaceous core. Particle core characteristics like size and 
material probably play a crucial role in determining the type of immune response that is 
initialized.  
In this study, different types of particles were able to adjuvate the primary immune 
response, with effects that were also clearly measurable during the secondary response.  
Modulation of sensitization may also take place in humans who are coexposed to allergens 
and pollutants. Although so far only epidemiological evidence exists for the involvement 
of particulate pollutants in the exacerbation of respiratory allergy, our present results may 
imply the facilitated initiation of allergy by the presence of particles as well. In contrast to 
our model, in real life the lung is exposed to antigen and particles. Whether particles also 
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act as adjuvant in the initiation phase of an immune response after administration via the 
relevant route, and which factors are crucial then are the subjects of investigation.  
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CHAPTER 3 
 
MODULATORY EFFECTS OF PARTICULATE AIR 
POLLUTANTS ON ALVEOLAR MACROPHAGE 
FUNCTION IN VITRO  
 
Maaike van Zijverden, Wendy van Dalen, Raymond Pieters, Flemming Cassee, Jan 
Dormans, Henk van Loveren, Peter Steerenberg 
 
ABSTRACT  
 
Particulate air pollution is known to affect human health. Its role in the aggravation of existing 
respiratory allergy is evident, and particulate matter may also play a role in the increasing prevalence 
of the disease. When particulate air pollution is inhaled by man, especially the (ultra) fine (<2.5 µm) 
particles are deposited deeply into the lung, where they are phagocytized by alveolar macrophages. 
In addition to clearing foreign material, these cells are important immune regulators. In the present 
study we therefore determined effects on cell damage and functional effects of exposure to different 
types of particles in a murine alveolar macrophage cell line (CRL 2019). Silica (SIP), diesel exhaust 
particles (DEP) from two different sources (DEP1 and DEP3), and carbon black particles (CBP), all 
smaller than 5 µm, were tested at a concentration of 0.11 and 0.33 mg/ml.  
Our results demonstrate that this selection of particles had diverse effects on cell damage, 
phagocytosis and cytokine production. Cell damage ranged from extensive cell damage (indicated by 
LDH release) as induced by CBP, moderate damage by DEP1 and SIP, to no damage by DEP3. All 
particles caused a decrease in phagocytosis, from moderate decreases induced by SIP and DEP1 to 
large decreases induced by CBP and DEP3. TNFα production was concentration-dependent for all 
particles and DEP1 and CBP stimulated the highest absolute levels. Effects on IL-1β and IL-6 were 
measurable only after LPS-priming of the macrophages, production was not dependent on particle 
concentration. No correlation appeared to exist between inducing cell damage, blocking 
phagocytosis and stimulating production of cytokines. In addition, we tested the effect of ozone pre-
exposure of DEP. We observed that after exposure of DEP3 to ozone, ozone-pretreated DEP3 
displayed significantly higher TNFα production and complete phagocytosis inhibition at lower 
particle concentrations compared to non-exposed DEP3, whereas LDH release was not affected. The 
increased production of TNFα and the impairment of phagocytosis in vitro are in line with a role for 
alveolar macrophages in the mechanism of sensitization to common allergens in subjects exposed to 
PM.  
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INTRODUCTION  
 
The prevalence of asthma and respiratory allergy has been increasing at a high rate in 
Western industrialized countries (Lundbäck 1998, Schäfer and Ring 1997). This trend has 
been shown to coincide with the increase in fossil fuel combustion and emission of 
(ultrafine) particulate matter (PM) (Peterson and Saxon 1996). Diesel exhaust particles 
(DEP) make up an important part of ambient PM. In animal studies the immunomodulating 
activity of DEP has been shown to result in cytokine production, enhanced IgE and IgG 
levels, and increased airway inflammation (Takano et al., 1997, Fujimaki et al., 1994 and 
1997, Takafuji et al., 1987, Nilsen et al., 1997, Steerenberg et al., 1999a). In humans, 
exposure to DEP has been shown to cause aggravation of symptoms in subjects already 
suffering from respiratory allergy (van Vliet et al., 1997). In healthy subjects, DEP cause 
an inflammatory response (Salvi et al., 1999 and 2000) and facilitate mucosal sensitization 
to a new antigen (Diaz-Sanchez et al. 1999). Taken together, it is hypothesized that PM, 
and especially its major constituent DEP, facilitates the development of respiratory allergy.  
The ultrafine fraction (PM<0.1µm) mainly consists of carbonaceous particles 
originating from combustion processes (e.g. DEP) in developed countries, whereas in the 
coarse (2.5-10µm) fraction inorganic minerals such as silica, and larger carbon aggregates 
are found (Ormstad et al., 1997). Larger particles are deposited in the conducting airways, 
from which they can be cleared by mucociliary clearance. In contrast, particles of 2.5 µm 
and smaller are effectively deposited in the alveolar region of the lung (Churg and Brauer 
1997, Ferin et al., 1992). Alveolar macrophages can take up particles by a receptor-
mediated mechanism (Kobzik 1995, Palecanda et al., 1999), and this phagocytosis capacity 
has been shown to decrease during exposure to particles (Becker and Soukup, 1998).  
In addition to effects of particles on innate macrophage functions like phagocytosis, 
the production and secretion of regulatory molecules such as cytokines and chemokines 
involved in acquired immunity may be affected by the presence of PM (van Rooijen and 
Sanders 1997). Resident alveolar macrophages are crucial in downregulation of antigen 
presenting cell functions of pulmonary dendritic cells (Poulter and Burke 1996). Depletion 
of macrophages leads to an increase of (IgE-mediated) immune responses to inhaled 
allergen (Thepen et al., 1992, de Haan et al., 1996, Leenaars et al., 1997), suggesting that 
disturbance of macrophage function may play a role in asthma and respiratory allergy. 
Macrophages spontaneously secrete low levels of IL-1β and somewhat higher levels of 
TNFα, IL-6 and IL-8. This production is increased after exposure to particles like urban air 
particles (Dong et al., 1996, Becker et al., 1996, Ning et al., 2000) and DEP in vitro (Yang 
Chapter 3 
 
 
37 
 
et al., 1997). The oxidant stress caused by the generation of ROS and NO in response to 
particle exposure is (partly) responsible for the cytokine production (Hiura et al., 1999, 
Barrett et al., 1999).  
Taking into account the diverse and important functions of the alveolar macrophage, 
changed macrophage functions as can be induced by particles may play a role in enhanced 
allergic sensitization. Increased levels of (pro)inflammatory cytokines may lead to 
inflammation. TNFα produced by alveolar macrophages acts as the main trigger for the 
upregulation of several cytokines and adhesion molecules by means of nuclear factor 
(NF)κB activation in the lung, finally leading to inflammation (Lentsch et al., 1999). 
Moreover, in a rat model TNFα was shown to play a crucial role in adjuvant activity of 
residual oil fly ash (ROFA) particles on the immune response to a protein antigen (Lambert 
et al., 2000a). A decline in phagocytosis capacity may cause coadministered antigen to 
escape uptake and degradation by alveolar macrophages. This may cause larger quantities 
of antigen to contact immune cells such as DC, a process that is known to enhance 
sensitization and inflammation (MacLean et al., 1996). The cytokine-rich environment 
together with enhanced antigen presentation could hypothetically lead to enhanced risk of 
allergic sensitization.  
In the present study we tested the effect of particles on both phagocytosis and 
cytokine production of an alveolar macrophage cell line of BALB/c mouse origin. Cells 
were incubated with different types of PM, either or not after priming with 
lipopolysaccharide (LPS), which has been shown to cause an enhanced cytokine response 
to particles in alveolar macrophages (Imrich et al., 1999, Ning et al., 2000). In the present 
study we used amorphous silica (SIP) representing the coarse fraction of PM, and DEP, 
representing the (ultra-)fine fraction. In addition, (ultra-)fine carbon black particles (CBP) 
were used that lack the attached chemicals as found on DEP. DEP from different sources 
were used (DEP1 and DEP3). Moreover, we pre-exposed DEP3 to ozone for 1, 24 or 48h, 
and tested the effect of ozone treatment of DEP in relation to macrophage function. After 
overnight incubation of cells and particles, culture supernatant was removed on which IL-
1β, IL-6, TNFα and LDH assays were performed, whereas total LDH content and 
phagocytosis capacity was quantified (Burleson et al., 1987) in the remaining 
macrophages.  
 
MATERIALS AND METHODS  
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CRL2019 
The murine alveolar macrophage cell line CRL 2019 was obtained from ATCC  
(Manassas, VA). Cells were cultured and maintained in 75 cm2 culture flasks (Nuclon, 
Nunc, Roskilde, Denmark) in complete RPMI 1640 (Gibco BRL, Breda, the Netherlands) 
supplemented with 10% fetal calf serum (FCS), 2% penicilline-streptomycine (SVM, 
Bilthoven, the Netherlands), 2% sodium bicarbonate BRL, 1% sodium pyruvate and 1.25% 
Glucose (Gibco BRL). The macrophages were removed from the culture flasks by 
trypsinization (3 min). Trypsine solution was diluted 10 times with phosphate buffered 
saline (PBS), and sodium hydrogen carbonate colution (0.75 g/l), 1% penicilline-
streptomycine and 0.05% EDTA (all derived from SVM). CRL 2019 macrophages were 
cultured until the 20th passage. 
Particle collection and preparation of the suspensions 
 Silica particles (SIP) were approximately 1–5 µm (S-5631, Sigma Chemical Company, St. 
Louis, MO). Carbon Black Particles (CBP, 65 – 110 nm) were obtained from Brunschwich 
Chemie (06-0025, Amsterdam, the Netherlands). Diesel Exhaust Particles (DEP) type 1 
(65-160 nm) were generated by 1980 Model 5.7 L Oldsmobile V-8 engines containing D-2 
diesel control fuel. DEP1 were collected via the exhaust pipe and were diluted 1:10 with 
filtered air (Mauderly et al., 1987). DEP3 (35-55 nm) were a friendly gift from F. Cassee 
(RIVM, The Netherlands). They were collected from a diesel motor Cummins type 6 BT 5-
9 with a capacity of 113 kW. All carbonaceous particle suspensions (CBP, DEP1 and 
DEP3) contained a mixture of single particles as well as larger aggregates (1-10µm).  
 Ozone was generated by irradiation of oxygen with ultraviolet light (3 O2 Æ 2 O3). 
The generated ozone was led through a column filled with 25 mg DEP3. The concentration 
of the ozone treatment was +/- 10 ppm in 2.7 l/min compressed air. In our experiments we 
used DEP3 exposed to 0, 1, 24 and 48 hours of ozone. 
DEP1, DEP3 and CBP were suspended in plane RPMI 1640 medium (without 
serum) and sonicated for 6×30 seconds. SIP were suspended by shaking in complete RPMI 
1640 medium. All particles were tested for endotoxin content by means of a Limulus 
amebocyte lysate (LAL) test (Limusate, Sigma), none reached detection level (0.025 
ng/ml).   
Scanning electron microscopy of particle suspensions  
The ultrasonicated suspensions were dehydrated by means of a graded ethanol series, 
followed by two 5 min treatments in 100% hexamethyldisiazane (HMDS, no. 804324, 
Merck, Darmstadt, Germany). After the final HMDS treatment samples were air dried on a 
glass slide. Subsequently samples were coated with a thin layer of gold using a sputter 
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coating unit (Polaron, Watford, UK) and size was determined in a scanning electron 
microscope (PSEM 525, Philips, Eindhoven, the Netherlands). 
Exposure of the cells 
Cells (0.5*106 cells per well) were transferred to 6-wells flat bottom plates (Costar, New 
York, NY). Next day, 2 ml of fresh complete medium was added with or without (100 
ng/ml) lipopolysaccharide (LPS, Brunschwig). After 3 hours cells were washed 3 times 
with plane RPMI 1640 medium to remove excess LPS. The different particle suspensions 
(CBP, DEP1, SIP and DEP3 +/- 0, 1, 24 and 48 hours ozone pre-exposure) were 
administered at a concentration of 0 mg/ml (negative control), 0.11 mg/ml or 0.33 mg/ml 
for overnight (o.n.) incubation. After collection of the supernatants, cells were washed 2 
times with plane RPMI 1640 medium to remove excess particles. For measurement of 
intracellular amounts of LDH, IL-1β, IL-6 and TNFα, 0.5% Triton X-100 (Merck) was 
administered for 1 hour to destroy cell membranes.  
Phagocytosis 
Fluorescent polymer microspheres (diameter 2 µm, Duke Scientific, Palo Alto, CA) were 
added for 3 hours to assess phagocytosis at a temperature of 37°C or 0°C (negative 
control). After washing 2 times with plane RPMI 1640 medium, adhered cells were 
removed by brief trypsinization, and after centrigation (800 RPM, 5 min), 100 µl of each 
sample was used to prepare a cytospin preparation. After fixation (5 min methanol) and 
staining (5 min Giemsa and 20 min May-Grünwald (Merck)), phagocytosis was measured 
by counting the number of microspheres inside 100 cells using a fluorescent microscope. 
The macrophages were divided into 2 groups: cells that phagocytized less than 20 
microspheres, and cells that phagocytized over 20 microspheres (positive cells).  
Cytokine assay 
Intracellular and extracellular cytokines (IL-1β, IL-6 and TNFα) were measured by ELISA. 
In the general procedure, plates were coated with rabbit-anti-mouse antibody (o.n. 4°C). 
After washing 6 times with PBS/0.1% Tween 20 and blocking (2 h) at room temperature 
(R.T.) with PBS/1% bovine serum albumine (BSA), plates were washed and incubated 
with the samples (1.5 h, RT). After washing, biotinylated antibody was administered  (1 h, 
RT). After washing, streptavidin-HRP-conjugate was administered (1 h, RT), followed by 
tetramethylbenzidine substrate (10 min RT, in the dark). The coloring reaction was stopped 
by the addition of sulfuric acid. The plates were read at 450 nm. The cytosets, CMC0814 
(IL-1β), CMC0064 (IL-6) and CMC3014 (TNFα), were obtained from Biosource 
(Ettenleur, the Netherlands).  The minimal detectable concentration was 2 pg/ml for all 
cytokines. All cytokines were expressed as pg per unit LDH, resulting in arbitrary units, to 
compensate for the slightly variable amount of cells present in each well.  
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Lactodehydrogenase (LDH) measurement 
LDH levels in supernatants and in suspension after lysis of the cells were measured with a 
spectrophotometer (Hitachi 912, Rosche, Almere, the Netherlands). To determine damage 
of the cells, the amount of the extracellular LDH was divided by the total values of the 
intracellular and extracellular LDH, and was expressed as percentage.  
Statistical analysis  
Data were expressed as the mean +/- SD. Statistical analysis was performed using a two-
tail Student’s t-test.  
 
RESULTS  
 
LDH levels 
Total LDH represents the number of cells present in a well. After exposure to 0.11 and 0.33 
mg/ml of respectively SIP, CBP, DEP1 and DEP3, cells preactivated with LPS showed a 
dose-dependent decrease in total amount of LDH of 7% and 11%, 22% and 32%, 16% and 
66%, and 7% and 6% respectively (not shown). Cells that were not preactivated by LPS 
treatment showed lower total amounts of LDH (not shown), probably caused by a lower 
level of activation and/or proliferation.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: LDH release after exposure to SIP, CBP, DEP1 and DEP3 at 0, 0.11 and 0.33 mg/ml. 
Depicted are average ± standard deviation of duplicate or triplicate measurements. * p<0.05, ** 
p<0.01, *** p <0.001, all versus 0 mg/ml, as determined by two-tail Student’s t-test. 
 
Release of LDH from cells represents cell damage, indicating toxicity of the 
particles. We noticed an increase in LDH release after administration of SIP, CBP, DEP1 
and DEP3 to preactivated cells. As shown in Fig. 1, without exposure to particles cells 
0%
10%
20%
30%
40%
50%
60%
70%
SIP CBP DEP1 DEP3
0 m g/m l
0.11m g/m l
0.33 m g/m l
+21%
**
+5%
+16%
+53%
***
+3%
+30%
*
Chapter 3 
 
 
41 
 
have a spontaneous release of approximately 12±5%. Administration of SIP (0.11 and 0.33 
mg/ml) led to an increase of LDH release to 18% and 29% respectively. After exposure to 
CBP or DEP1 (0.11 and 0.33 mg/ml), the LDH release increased to 30% and 62% and 10% 
and 37% respectively (Fig.1, and an overview of results of preactivated cells is given in 
Table 1). Administration of DEP3 did not influence LDH release. In non-preactivated cells 
increase of LDH release was roughly the same after CBP exposure, whereas SIP and DEP1 
stimulated approximately half of the release as compared to preactivated cells. DEP3 did 
not influence the LDH release (an overview of results of non-preactivated cells is given in 
Table 2). 
 
Table 1: LDH release, phagocytosis and increase of cytokine production in LPS-preactivated 
alveolar macrophages after exposure to SIP, CBP, DEP1 and DEP3.  
Table 2: LDH release, phagocytosis and increase of cytokine production in non-preactivated 
alveolar macrophages after exposure to SIP, CBP, DEP1 and DEP3.  
 
Table 1:
Increase of
LDH release
Inhibition of
phagocytosis
TNFα IL-6 IL-1β
SIP 0.11mg/ml
0.33mg/ml
5%
16%
21%
40%
28
15
-7
0
3
68
CBP 0.11mg/ml
0.33mg/ml
21%
53%
74%
100%
53
77
7
15
63
96
DEP1 0.11mg/ml
0.33mg/ml
3%
30%
35%
62%
29
149
26
85
76
46
DEP3 0.11mg/ml
0.33mg/ml
0%
0%
62%
92%
5
28
26
20
-
-
Table 2:
Increase of
LDH release
Inhibition of
phagocytosis
TNFα IL-6 IL-1β
SIP 0.11mg/ml
0.33mg/ml
2%
9%
44%
61%
14
47
-
-
-
-
CBP 0.11mg/ml
0.33mg/ml
6%
54%
59%
94%
2
7
-
-
-
-
DEP1 0.11mg/ml
0.33mg/ml
2%
16%
37%
68%
1
7
-
-
-
-
DEP3 0.11mg/ml
0.33mg/ml
0%
1%
20%
100%
3
6
-
-
-
-
LDH release (%): particle-treated sample – control sample.  
Phagocytosis (%): decrease of cells containing > 20 fluorescent microspheres.  
TNFα, IL-6, IL-1β: Absolute increase per unit LDH.  - = No production 
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Phagocytosis 
As shown in Fig. 2, the percentage of preactivated cells phagocytizing over 20 fluorescent 
microspheres was 27±3%. After exposure to SIP (0.11 and 0.33 mg/ml), the percentage of 
preactivated cells phagocytizing over 20 fluorescent microspheres was reduced to 20% and 
15% respectively (Fig. 2). After exposure to CBP (0.11 and 0.33 mg/ml) the percentage of 
cells phagocytizing over 20 microspheres decreased from 31% to 8% and 0% respectively. 
Administration of DEP1 reduced phagocytosis from 26% to 17% and 10% at 
concentrations of 0.11 mg/ml and 0.33 mg/ml, whereas preactivated cells exposed to DEP3  
(0.11 mg/ml and 0.33 mg/ml) showed a decline of cells phagocytizing over 20 
microspheres from 26% to 10% and 2%, respectively (Fig. 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Phagocytosis of fluorescent probes after particle exposure. The percentage of 
macrophages containing >20 probes after exposure to SIP, CBP, DEP1 and DEP3 at 0, 0.11 and 0.33 
mg/ml. Depicted are average ± standard deviation of 6 measurements.  
 
Phagocytosis was almost completely inhibited when cells were incubated with 
microspheres at 0°C (not shown). Non-preactivated cells showed a slightly lower 
percentage of cells phagocytzing over 20 microspheres 18±5% (not shown) compared to 
LPS primed cells when no particles were administered. Also in non-preacivated cells 
phagocytosis was reduced after particle exposure (Table 2).   
TNFα production 
After exposure of preactivated cells to 0.11 and 0.33 mg/ml CBP, DEP1 and DEP3, TNFα 
production (expressed per unit LDH, measured in supernatant) showed a concentration-
dependent increase (Fig. 3). After CBP exposure, TNFα production increased 
approximately 6- and 9-fold for 0.11 and 0.33 mg/ml, whereas after DEP1 exposure it 
increased 2- and 8-fold (Fig. 3). 
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Preactivated cells exposed to 0.11 and 0.33 mg/ml SIP failed to show an increase of TNFα 
production expressed in unit LDH (Fig. 3, Table 1). A concentration-dependent increase 
was also observed in non-preactivated cells, although absolute levels (not shown) and 
absolute increases (Table 2) were lower for all particles except SIP.  
We also measured the TNFα production expressed per unit LDH intracellularly. The 
intracellular TNFα production increased during exposure to the different particles 
comparable to the increase of the extracellularly detected TNFα (not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: TNFα release per unit LDH after SIP, CBP, DEP1 and DEP3 at 0, 0.11 and 0.33 mg/ml. 
Depicted are average ± standard deviation of duplicate or triplicate measurements. * p<0.05, ** 
p<0.01, *** p <0.001, all versus 0 mg/ml, as determined by two-tail Student’s t-test.  
 
IL-6 production 
Only preactivated cells show IL-6 production. As shown in Table 1, exposure to CBP, 
DEP1 and DEP3  led to an increase compared to the control sample, whereas IL-6 
production was not influenced by exposure to SIP.  
IL-1β production 
Cells that were not preactivated by administration of LPS showed no production of IL-1β. 
Preactivated cells, however, produced IL-1β when exposed to 0.11 and 0.33 mg/ml SIP, 
CBP or DEP1. No IL-1β production was measured when cells were exposed to DEP3 
(Table 1).  
DEP1 versus DEP3 
Although DEP1 and DEP3 are both diesel exhaust particles and have approximately the 
same size as examined by scanning electron microscopy (not shown), CRL 2019 
macrophages showed some important differences in response (Table 1 and 2). After DEP1 
exposure both LDH release and TNFα production increased strongly compared to DEP3 
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exposure. Exposure to DEP3, however, led to a stronger reduction of the phagocytosis 
compared to DEP1. It is known that DEP in ambient air can be altered by other air 
pollutant components, such as ozone. Therefore we pretreated DEP3 with ozone during 1, 
24 and 48 hours as described in Materials & Methods. This treatment did not lead to 
morphological changes of the particles as examined by scanning electron microscopy (not 
shown).  
LDH levels (ozone-exposed DEP3)   
In both preactivated and non-preactivated cells, total amount of LDH (not shown) after 
exposure 1, 24 and 48 hours ozone-exposed DEP3 (DEP3 ozone 1 , DEP3 ozone 24 and DEP3 
ozone 48) was hardly influenced compared to the control sample. Also the release of LDH in 
preactivated cells (an overview of results of preactivated cells is given in Table 3) and non-
preactivated cells (Table 4) was unaltered by ozone exposed DEP3.  
Phagocytosis (ozone-exposed DEP3) 
Whereas preactivated cells showed a decrease from 26% to 10% and 2% when exposed to 
0.11 and 0.33 mg/ml untreated DEP3 respectively, exposure to DEP3 ozone 1, DEP3 ozone 24 
and DEP3 ozone 48 inhibited phagocytosis to 5% (0.11 mg/ml) and to 0% (0.33 mg/ml) as 
shown in Fig. 4. Numbers of non-preactivated cells phagocytizing over 20 fluorescent 
microspheres decreased when exposed to untreated DEP3. Inhibition increased from 20% 
to 100% for 0.11 and 0.33 mg/ml respectively (Table 4). For DEP3 ozone 1 this was 
respectively 55% and 100%, whereas phagocytosis was completely blocked when the cells 
were exposed to DEP3 ozone 24 and DEP3 ozone 48 (Table 4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: The percentage of macrophages containing >20 probes after exposure to DEP3, 
DEP3ozone1, DEP3ozone24 and DEP3ozone48 at 0, 0.11 and 0.33 mg/ml. Depicted are average ± standard 
deviation of 6 measurements. 
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Table 3: LDH release, phagocytosis and increase of cytokine production in LPS-preactivated 
alveolar macrophages after exposure to DEP3, DEP3ozone1, DEP3ozone24, and DEP3ozone48.  
Table 4: LDH release, phagocytosis and increase of cytokine production in non-preactivated 
alveolar macrophages after exposure to DEP3, DEP3ozone1, DEP3ozone24, and DEP3ozone48. 
 
 
 
Table 3:
Increase of
LDH release
Inhibition of
phagocytosis
TNFα IL-6
DEP3 0.11mg/ml
0.33mg/ml
0%
0%
62%
92%
5
28
26
20
DEP3
ozone 1
0.11mg/ml
0.33mg/ml
0%
8%
83%
100%
22
38
16
3
DEP3
ozone24
0.11mg/ml
0.33mg/ml
0%
8%
81%
100%
56
72
17
59
DEP3
ozone48
0.11mg/ml
0.33mg/ml
0%
6%
83%
100%
40
70
61
42
Table 4:
Increase of
LDH release
Inhibition of
phagocytosis
TNFα IL-6
DEP3 0.11mg/ml
0.33mg/ml
0%
1%
20%
100%
3
6
-
-
DEP3
ozone 1
0.11mg/ml
0.33mg/ml
0%
0%
55%
100%
2
3
-
-
DEP3
ozone24
0.11mg/ml
0.33mg/ml
0%
4%
100%
100%
7
23
-
-
DEP3
ozone48
0.11mg/ml
0.33mg/ml
0%
4%
100%
100%
20
49
-
-
 
LDH release (%): particle-treated sample – control sample.  
Phagocytosis (%): decrease of cells containing > 20 fluorescent microspheres.  
TNFα, IL-6, IL-1β: Absolute increase per unit LDH.  
-: No production 
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TNFα, IL-6 and IL-1β production (ozone-exposed DEP3) 
Exposure to 0.33 mg/ml DEP3 of preactivated cells led to a significant increase in TNFα 
production compared to its control (Fig. 5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: TNFα release per unit LDH after exposure to DEP3, DEP3ozone 1, DEP3ozone24 and 
DEP3ozone 48 at 0, 0.11 and 0.33 mg/ml. Depicted are average ± standard deviation of duplicate or 
triplicate measurements. * p<0.05, ** p<0.01, *** p <0.001, all versus 0 mg/ml, as determined by 
two-tail Student’s t-test.  
 
For DEP ozone 1 TNFα production increased significantly at both 0.11 and 0.33 mg/ml. 
Exposure to 0.11 and 0.33 mg/ml DEP3 ozone 24 and DEP3 ozone 48 significantly stimulated 
TNFα production (Fig. 7). In non-preactivated cells TNFα also increased concentration-
dependently and more pronouncedly after exposure to ozone-exposed DEP as compared to 
untreated DEP (Table 4).  
Preactivated cells showed a spontaneous production of IL-6. No increased 
production of IL-6 was observed after exposure to ozone- exposed DEP3 (Table 3). Non-
preactivated cells show no IL-6 production at all (Table 4). Preactivated and non-
preactivated cells exposed to the different ozone-exposed DEP3 particles did not produce 
IL-1β at any time (not shown).  
 
DISCUSSION 
 
Outdoor air consists of a complex mixture of particulate and gaseous pollutants. In the 
present study we examined the effects of several particulate air pollutants on cell damage, 
phagocytosis and production of proinflammatory mediators in a murine alveolar 
macrophage cell line. In addition, the effect of a “secondary” particle, ozone-exposed DEP, 
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was assessed. The present study shows that different types of particles have distinct effects 
on cell damage, phagocytosis and cytokine production by alveolar macrophages. Moreover, 
ozone-exposed DEP show more pronounced effects on phagocytosis and cytokine 
production compared to untreated DEP.  
 SIP, DEP1 and especially CBP caused cytotoxicity in the macrophages, indicated 
by the LDH release that dose-dependently increased upon particle exposure, as was also 
found by others (Kim et al., 1999). In contrast to DEP1, DEP3 did not cause any increase 
in LDH release, but DEP3 did have the most profound inhibitory effect on phagocytosis. 
Therefore it can be concluded that the increase in cell damage is not related to the decrease 
in phagocytosis. CBP also inhibited phagocytosis almost completely, whereas DEP1 and 
SIP had the least effect. Ultrafine particles have been shown to inhibit phagocytosis when 
they occupied 2.6% of macrophage volume (Oberdörster et al., 1994). Particles may 
downregulate the expression of macrophage receptors involved in phagocytosis (Becker 
and Soukup 1998). The fact that alveolar macrophages employ distinct receptor-mediated 
mechanisms for different particles, as was described for SIP versus DEP (Kobzik 1995, 
Palecanda et al., 1999), may play a role in the observed differences.  
IL-6 and IL-1β production were not clearly particle concentration-dependently 
stimulated, and production was only observed after LPS preactivation of the cells, which 
has also been shown by others to amplify the cytokine response of macrophages (Imrich et 
al., 1999). On the contrary, TNFα was spontaneously released and displayed a clear 
particle-concentration-response relationship. CBP stimulated the highest cytokine levels, 
followed by DEP1, DEP3 and SIP respectively. This order correlates with adjuvant 
potential in an in vivo model (van Zijverden et al., Chapter 4). Overall it appears that 
increased cytokine production does not correlate with increased LDH release and inhibition 
of phagocytosis. The fact that cytotoxicity is not related to phagocytosis, has also been 
shown by others (Hadnagy and Seemayer, 1994).  
The present study shows that DEP of different sources have distinct effects. An 
explanation may be found in differences in amount or composition of attached substances. 
Interaction of DEP with ozone is known to cause substantial changes in the composition of 
the attached polyaromatic hydrocarbons, increasing the number of chemically reactive 
groups (Madden et al., 2000). This observation is highly relevant since ozone is a 
ubiquitous and reactive pollutant in ambient air, showing harmful effects on human health 
both alone (Hiltermann et al., 1997) and in combination with PM (Korrick et al., 1998). 
Recently, ozone-exposed DEP were shown to increase LDH content and 
polymorphonuclear cell infiltrate in lung lavage fluid when compared to untreated DEP in 
rat after in vivo administration (Madden et al., 2000). The present study shows the effects 
Chapter 3 
 
 
48 
 
of ozone-exposed DEP3 on macrophage function, displaying a more powerful inhibition of 
phagocytosis already at lower particle concentration and stimulation of TNFα production 
compared to untreated DEP3.  
Our results suggest that TNFα production by alveolar macrophages may represent 
an important determinant of adjuvant activity of PM in vivo. The concurrent severe decline 
in phagocytosis is in line with the hypothesis that a cytokine-rich environment in 
combination with augmented antigen presentation leads to increased risk of allergic 
sensitization. In humans exposed to a mixture of pollutants in outdoor air, the interaction of 
airborne particles with other pollutants such as ozone may pose an additional risk of 
sensitization.  
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CHAPTER 4 
 
PARTICULATE AIRBORNE POLLUTANTS ADJUVATE 
ALLERGIC SENSITIZATION 
 
 
Maaike van Zijverden, Marianne Bol, Rob Bleumink, Anita van der Pijl, Joost Vos, Henk 
van Loveren, André Penninks, Raymond Pieters 
 
ABSTRACT  
 
Particulate air pollution negatively affects human health. Whereas it is known to increase symptoms 
of existing respiratory allergy, its effect on sensitization to common allergens is unknown. For 
hazard identification a good animal model is needed to assess the possible immunomodulating 
effects of particles on the sensitization process and the further course of the immune response. 
Whereas existing models frequently make use of artificial methods like injection and/or adjuvants to 
facilitate sensitization, we have developed a model in which sensitization takes place via the relevant 
route of exposure. Antigen (2,4,6-trinitrophenyl coupled to ovalbumin [TNP-OVA], total dose 
30 µg) and particles (total dose 200 µg) were administered intranasally to female BALB/c mice 
during Day 1,2,3, and at Day 10 a challenge with antigen alone (10 µg) was performed. The immune 
response was read out 5 days after this challenge. Immunoglobulin (Ig) levels were measured in 
serum, antibody-forming cells (AFC) were determined in the lymph nodes draining the lung 
(peribronchial lymph nodes [PBLN]), and cell types present in bronchial alveolar lavage (BAL) were 
differentiated. The effects of two types of diesel exhaust particles (DEP) from different sources 
(DEP1 and DEP2), carbon black (CBP) and amorphous silica particles (SIP) were tested. All 
particles except SIP were found to be able to adjuvate the immune response to TNP-OVA. DEP1 and 
CBP induced the highest Ig-levels in blood and AFC-numbers in PBLN, followed by DEP2, whereas 
the increases induced by SIP were not significant. CBP induced an increased number of eosinophils 
in BAL, whereas SIP stimulated neutrophils to infiltrate. The effect of an extra challenge at Day 17 
was tested in animals exposed to CBP. At Day 22 these animals showed significantly higher IgG1-
AFC and eosinophil numbers as well as IgG2a levels compared to Day 15. The fact that particles 
display persistent adjuvant activity when they are administered during sensitization points out that 
the risk of sensitization of naive subjects may be increased during coexposure to particles and 
allergen.  
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INTRODUCTION  
 
The prevalence of asthma and respiratory allergy has been increasing at a high rate in 
Western industrialized countries during the past few decades (Lundbäck 1998, Schäfer and 
Ring, 1997). Since these higher rates are exclusively observed in Westernized societies 
(ISAAC 1998, Jogi et al., 1998, Beasley et al., 2000) it is generally thought that they are 
associated with various aspects of Western lifestyle (Hopkin 1997, Popp et al., 1989). 
Studies in (former) West and East Germany in the early 1990s clearly display the higher 
prevalence in the West (von Mutius et al., 1992). However, recent studies after unification 
show an increasing rate also in the former East (von Mutius et al., 1998). These 
epidemiological facts of asthma have resulted in different theories of asthma onset. One 
theory associates outdoor air pollution with asthma (Rusznak et al., 1994). Epidemiological 
support is for example found in studies showing differences in the prevalence of childhood 
asthma between rural and urban centers in several countries (Goren et al., 1988, Goren and 
Hellmann 1988, Weinberg 2000, Beasly et al., 2000), and the fact that in recent years 
asthma is increasing in cities of developing countries (Weinberg 2000). Both observations 
may partly be associated with air pollution produced by road transport (Duhme et al., 1996, 
van Vliet et al., 1997). The fact that humans are exposed to a complex mixture of 
pollutants and innumerable other environmental factors makes it hard to extract the 
responsible factor from epidemiological studies. Diesel exhaust particles (DEP) are one of 
the main suspects, because they make up a large part of air pollution in Western cities. 
Moreover, in already sensitized subjects DEP are known to be able to both increase 
symptoms (Pope and Dockery 1992 ) and IgE production (Diaz-Sanchez et al., 1997a), and 
cause inflammation (Salvi et al., 1999 and 2000) and even adjuvate mucosal sensitization 
to a neoantigen in naïve subjects (Diaz-Sanchez et al., 1999).  
DEP and other carbonaceous particles smaller than 2.5 µm are part of the (ultra)fine 
fraction of so called particulate matter (PM). The coarse fraction (2.5-10 µm) of PM mainly 
consists of inorganic wind blown dusts such as silica and large carbon aggregates (Churg 
and Brauer 1997, Ormstad et al., 1997). Size is crucial in determining whether and where 
particles are deposited in the lung. Ultrafine and fine particles are able to penetrate deep 
into the lung and stay present for a long time (Churg and Brauer, 1997, Ferin et al., 1992). 
Other particle characteristics such as attached chemicals and surface area probably also 
play a role in the adjuvant activity.  
The mechanism by which particles modulate the immune response is incompletely 
known (Salvi and Holgate 1999), but inflammation probably plays a central role (Saxon 
and Diaz-Sanchez 2000). Information on these mechanisms is indispensable for estimating 
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human risks of particle exposure (McClellan 1997). Therefore a good model is needed in 
which the effect of particles on sensitization and on the further course of the immune 
response can be assessed. Present models displaying important effector phase 
characteristics like specific IgE and eosinophils almost all use injections and/or adjuvantia 
to sensitize (Kung et al., 1994, Yamada et al., 1994, Hessel et al., 1995). Hence they do not 
reflect real life exposure and its unique characteristics (Constant et al., 2000). In addition, 
models in which particle and antigen exposure are combined are often long and 
complicated (Takafuji et al., 1987), and particle dosing is not related to the phase of the 
immune response but rather takes place continuously (Fujimaki et al., 1997, Takano et al., 
1997, Maejima et al., 1997). A recent promising rat model by Lambert et al. (1999) is 
relatively short (2 weeks) and particle exposure is limited to one dose.  
In the model presented in this study we intranasally sensitized mice with TNP-OVA 
together with different particles during 3 consecutive days. The capacity of the particles to 
adjuvate an immune response to the antigen was compared after an antigen challenge at 
Day 10. We compared the immunomodulating capacity of two types of DEP from different 
sources (DEP1 and DEP2), CBP and amorphous silica particles (SIP). DEP and CBP 
represent particles from the (ultra)fine fraction, but whereas DEP are known for their 
immunomodulating capacity, CBP are possibly not as inert (Løvik et al., 1997, Nilsen et 
al., 1997) as they were once thought to be (Crosbie 1986). This was also shown in a 
previous study using subcutaneous injection (van Zijverden et al., 2000), in which the 
carbonaceous particles DEP and CBP were compared with amorphous SIP, of which the 
immunomodulatory capacity in relation to respiratory allergy is unknown. All types of 
particles were able to act as adjuvant in this injection model, but the alteration in immune 
response with respect to Th1/Th2 differentiation differed with the different particles.  
In the present intranasal model, the immune response was assessed at Day 15,  five 
days after challenge. In addition, the effect of an extra challenge at Day 17 was tested in 
animals exposed to carbon black particles (CBP), and the response was determined at Day 
22. In all animals antibody levels in blood and antibody forming cells (AFC) in 
peribronchial lymph nodes (PBLN) were assessed. Also cell infiltrates in the lung were 
characterized in bronchial alveolar lavage (BAL).  
 
MATERIALS AND METHODS 
 
Animals 
Female, specific pathogen-free BALB/c mice (6-8 weeks of age) were obtained from the 
Utrecht University breeding facility. Mice were housed under hygienic barrier conditions 
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in filter-topped macrolon cages with bedding of wood chips, a temperature of 23±2oC, 50-
60% relative humidity and a 12-h light/dark cycle. They received standard lab chow and 
acidified tap water ad libitum. The experiments were approved by an ethical committee and 
conducted in accordance with the Guiding Principles in the Use of Animals in Toxicology.  
Chemicals and reagents 
Silica (amorphous, microcrystalline SiO2 [SIP]) was obtained from Sigma Chemical 
Company (St. Louis, MO) and CBP from Brunschwich Chemie (Amsterdam, The 
Netherlands). DEP1 and DEP2 were generous gifts from respectively Dr. P. Steerenberg 
(RIVM, the Netherlands) and Dr. P. Scheepers (Nijmegen University, the Netherlands). 
The antigen TNP-OVA (2,4,6-trinitrophenyl coupled to ovalbumin) was prepared as 
described by Albers et al. (1997). Immobilon-P membranes were obtained from Millipore 
(Etten-Leur, The Netherlands), and alkaline-phosphatase (AP)-conjugated goat- anti-mouse 
IgG1 and IgG2a antibodies from Southern Biotechnology Associates (Birmingham, AL). 
Anti-mouse IgE (02111D) for IgE ELISA was obtained from Pharmingen (Hamburg, 
Germany). All reagents for ELISA were obtained from Sigma Chemical Company (St. 
Louis, MO), whereas the plates (highbond 3590) were obtained from Costar (Cambridge, 
MA).  
Treatment of the mice 
Particle suspensions (2.67 mg/ml) were prepared in saline containing 0.4 mg/ml TNP-OVA 
and 5% heat inactivated normal BALB/C mouse serum. The latter was added to facilitate 
suspension of the hydrophobic particles, while they stirred for 18 h (Løvik et al. 1997). 
Naïve female BALB/c mice (n=8) were intranasally instilled by pipetting a total volume of 
25 µl on the nostrils under light ether anesthesia. Sensitization took place at Days 1, 2 and 
3, adding up to a total TNP-OVA dose of 30 µg and a total particle dose of 200 µg. A 
challenge dose of 10 µg TNP-OVA was given at Day 10 (Table 1). Blood was collected by 
orbita punction under ether anesthesia 3 days before the experiment and 5 days after 
challenge (Day 15), just prior to dissection, at which also BAL was obtained and PBLN, 
spleen and bone marrow were taken out. In a separate experiment the effect of an extra 
challenge at Day 17 was tested in animals exposed to CBP (n=4). Blood was drawn 3 days 
before the start of the experiment, and at Day 15 and Day 22, at which the dissection took 
place (Table 1).  
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Table 1: Treatment groups in the intranasal model (n=4-6). Blood samples were taken at Day –2 and 
at the end of the experiment at either Day 15 or Day 22.  
 
group Sensitization (Day 
1,2,3) 
Challenge 
(Day 10) 
End of 
experiment 
(Day 15) 
Challenge 
(Day 17) 
End of 
experiment 
(Day 22) 
Control TNP-OVA TNP-OVA yes - - 
Particle 
treatment 
TNP-OVA+ particles 
(total dose 200 µg)  
TNP-OVA yes - - 
Control TNP-OVA TNP-OVA no TNP-OVA yes 
Particle 
treatment 
TNP-OVA+ particles 
(total dose 200 µg)  
TNP-OVA no TNP-OVA yes 
 
TNP-specific IgG1 and IgG2a ELISA 
Plates were coated (overnight [o.n.] 4oC) with TNP coupled to bovine serum albumin 
([BSA] TNP-BSA, 20 µg/ml) in 0.05 M carbonate buffer pH 9.6, and blocked with 
phosphate buffered saline containing 0.05% Tween and 1% BSA ([PBS/T/BSA], 1 h, RT). 
Serial dilutions of sera were incubated (1 h, room temperature [RT]) and plates were 
washed and incubated with an optimal dilution of AP-conjugated anti-mouse IgG1 or 
IgG2a (1 h, RT), followed by p-nitrophenyl phosphate (1 mg/ml in diethanolamine buffer, 
pH 9.8) for 30 min. Absorbance was measured at 405 nm. Titers were calculated by means 
of the sample dilution at which extinctions were higher than background+2*SD. 
Background levels at Day 0 were subtracted from Day 15 and Day 22 data to obtain 
increases in titer.  
TNP-specific IgE ELISA.  
Plates were coated (6 h, first hour at 37oC, last hours at RT) with αIgE, 2 µg/ml in 0.05 M 
carbonate buffer pH 9.6. After washing, serial dilutions of sera were incubated (o.n. 4oC) 
and plates were washed and incubated with an optimal dilution of a biotin-TNP-BSA 
complex (1h, RT). After incubation (45 min, RT) with poly-HRP-streptavidine (CLB, 
Amsterdam, The Netherlands), tetramethylbenzidine (1 mg/ml) was added (15 min, RT). 
The coloring reaction was stopped with H2SO4 and absorbance was measured at 450 nm. 
Titers were calculated by means of the sample dilution at which extinctions were higher 
than background+2*SD. Background levels at Day 0 were subtracted from Day 15 and Day 
22 data to obtain increases in titer.  
ELISPOT assay 
These assays were essentially performed as described previously (Schielen et al., 1995). 
Briefly, organs were minced to prepare single cell suspensions, and 0.5*106 cells in 500 µl 
PBS/1% BSA were incubated (4 h, 37oC) in wells containing TNP-BSA (20 µg/ml) coated 
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(o.n. 4oC) Immobilon-P membranes as bottom. Thereafter, membranes were washed and 
incubated with optimal dilutions of isotype-specific AP-conjugated anti-mouse Ig 
antibodies in PBS/T (o.n. 4oC). After washing, spots were developed by incubation with 5-
bromo-4-chloro-3-indolyl phosphate and nitroblue tetrazolium. Specific AFCs per 106 cells 
were calculated from spot numbers counted with the aid of a stereo microscope.  
Bronchial alveolar lavage and cell differentiation  
The lungs of the mice were lavaged 3 times with 1-ml aliquots of PBS (37oC). The 
bronchial alveolar lavage was kept on ice until it was centrifuged (1000 g, 5 min). The 
pellet was resuspended in 250 µl of cold PBS. For differential cell counts cytospin 
preparations were made and stained 7 min with May-Grünwald (Merck, Darmstad, 
Germany), and subsequently 20 min with Giemsa staining (Merck). After coding, the 
cytospin preparations were evaluated using oil immersion microscopy. Cells were 
identified and differentiated into macrophages, eosinophils, neutrophils and lymphocytes 
by standard morphology. Macrophages containing one of the carbonaceous particles 
(DEP1,2 and CBP) could be detected because of the black color of the particles, and were 
indicated by M+. Per cytospin preparation at least 200 cells were counted, and the 
percentages of the various cell types were calculated.  
Statistics 
Preceding statistical analysis, ELISPOT data (the number of AFCs) were transformed to 
log10 values to homogenize variance. Differences between group means were analyzed 
using one-way ANOVA with Bonferroni’s post-hoc test for contrasts (p<0.05 or p<0.01). 
In the case of nonsufficient homogeneity of variances, a Kruskal-Wallis ranking test was 
performed.  
 
RESULTS  
 
The different particles were administered on 3 consecutive days together with antigen 
during the sensitization phase, up to a total dose of 200 µg/animal. At Day 10 a challenge 
with antigen was given, and at Day 15 the immunomodulatory capacity of different 
particles was assessed. In an additional experiment, CBP-exposed mice were given an 
additional antigen-challenge at Day 17, and the immune response was determined at Day 
22.  
Levels of TNP-specific IgG1, IgG2a and IgE antibodies in serum 
Immunoglobulin levels were determined in sera obtained at Day 0 and at the end of the 
experiment at Day 15 or Day 22. Day 0-background levels were subtracted from levels 
found at the end of the experiment. At Day 15 all particle-treated groups except SIP 
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showed significant increases in IgG1 titers compared to TNP-OVA controls. Levels of 
DEP1-treated animals were also significantly enhanced  compared to those in SIP-treated 
animals (Fig. 1A). IgG2a was significantly enhanced in DEP1-treated animals compared to 
those in TNP-OVA controls and SIP (Fig. 1B). IgE was enhanced significantly in CBP and 
DEP1-treated animals compared to controls (Fig. 1C).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: The increase in TNP-specific antibody titers in serum between Day 0 and Day 15 after 
exposure to CBP, SIP, DEP1 and DEP2 during sensitization with TNP-OVA (A,B,C) and between 
Day 0, 15 and 22 after exposure to CBP during sensitization with TNP-OVA (D,E,F). Depicted are 
averages ± standard deviations [SD]. Figure 1A: IgG1 titers. Figure 1B: IgG2a titers. Figure 1C: IgE 
titers. * = p<0.05 versus TNP-OVA control, ** = p<0.01 vs TNP-OVA control, # = p <0.05 vs SIP, 
## p<0.01 vs SIP. Figure 1D: IgG1 titers. Figure 1E: IgG2a titers. Figure 1F: IgE titers. * = p<0.05, 
** p<0.01 vs all TNP-OVA control groups, ## = p<0.01 versus all TNP-OVA Day 15 data, # p<0.05 
vs CBP Day 15 data from the same group, as determined by ANOVA followed by Bonferroni’s post 
hoc test. 
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At Day 22 IgG1 levels in CBP-treated animals were even more pronouncedly enhanced 
(Fig. 1D), whereas IgG2a was significantly higher at Day 22 compared to Day 15 (Fig. 
1E). IgE was significantly enhanced at Day 22 compared to controls (Fig. 1F).  
 
Number of TNP-specific antibody forming cells in PBLN  
The number of Ig-producing cells was assessed in PBLN, spleen and bone marrow. In the 
latter two organs hardly any AFC were identified (not shown). In PBLN IgG1 but no 
IgG2a and IgE-AFC could be detected. This is in accordance with IgG1 being the isotype 
detected in highest levels in serum (not shown). At Day 15 IgG1-AFC were found in 
significantly increased numbers in CBP- and DEP1-treated animals as compared to SIP, 
whereas numbers in CBP-treated animals were also significantly higher than TNP-OVA 
control level (Fig. 2A). At Day 22 this increase was even more pronounced, and 
significantly higher than TNP-OVA controls and Day 15 numbers of CBP-treated animals 
(Fig. 2B). The AFC numbers at Day 15 of the CBP-treated group in Fig. 2B appeared 
higher than those in Fig. 2A. However, this difference was not statistically significant and 
is considered to be due to inter-experimental and intra-species variation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Number of TNP-specific IgG1-forming cells per 106 cells, at Day 15 after exposure to 
CBP, SIP, DEP1 and DEP2 (Figure 2A) and at Day 15 and 22 after exposure to CBP (Figure 2B) 
(averages ± SD).  
Figure 2A: The dashed line represents TNP-OVA control level. * = p<0.05 vs control, # = p<0.05 vs 
SIP, ## = p<0.01 vs SIP, as determined by ANOVA followed by Bonferroni’s post hoc test.  
Figure 2B: ** = p<0.01 vs TNP-OVA control Day 15, # = p<0.05 vs TNP-OVA control Day 22, ## 
= p<0.01 vs TNP-OVA control Day 22, as determined by ANOVA followed by Bonferroni’s post 
hoc test.  
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Cell differentiation of BAL cells  
BAL cells from a representative TNP-OVA control animal are shown in Figure 4A. More 
than 95% of the cells are macrophages. BAL cells from the CBP- or DEP1/2-exposed 
animals showed that approximately 50% of the macrophages present was colored black 
(M+) (Fig. 3A and 4B). Phagocytosis of the white SIP could not be scored accurately. In 
addition, the CBP-treated group showed a significant eosinophil-infiltrate. The infiltrate of 
SIP-treated animals mainly consisted of neutrophils. Non significant infiltrates were 
observed in DEP1 and DEP2-treated animals (Fig. 3A). At Day 22 the eosinophil infiltrate 
in CBP-treated animals was significantly enhanced as compared to TNP-OVA controls and 
Day 15 levels of CBP-treated mice (Fig. 3B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Percentages of various cell types in bronchial alveolar lavage at Day 15 after exposure to 
CBP, SIP, DEP1 and DEP2 (Figure 3A) and at Day 15 and 22 after exposure to CBP (Figure 3B) 
(averages ± SD). “M+” = macrophages containing carbonaceous particles (SIP was not visible),  
“M“ = macrophages not containing particles, “eo” = eosinophil, “neutr” = neutrophil, “lympho”= 
lymphocyte.  
Figure 3A: * = p<0.05 versus DEP2, ** = p<0.01 vs TNP-OVA control and SIP, as determined by 
Kruskal-Wallis ranking test, and ## = p<0.01 vs TNP-OVA control, SIP, DEP1 and DEP2, as 
determined by ANOVA followed by Bonferroni’s post hoc test.  
Figure 3B: * = p<0.05 vs TNP-OVA control Day 15 and control Day 22, ** = p<0.01 vs CBP Day 
15, TNP-OVA control Day 15 and TNP-OVA control Day 22, as determined by ANOVA followed 
by Bonferroni’s post hoc test.  
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Figure 4A: Brochial alveolar lavage cells from a representative control animal (cytospin preparation 
after May Grünwald Giemsa staining). Arrow indicates macrophage.  
Figure 4B: Brochial alveolar lavage cells from a representative CBP-exposed animal, (cytospin 
preparation after May Grünwald Giemsa staining). Arrow1 indicates macrophage, arrow2 indicates 
macrophage with particles, arrow3 indicates eosinophil. (N.B: Pictures will be professionally edited 
for the final manuscript) 
 
DISCUSSION 
 
Particulate air pollution causes exacerbation of symptoms in allergic and asthmatic subjects 
(Pope and Dockery, 1992, Lipsett et al., 1997). However, the mechanism behind the 
general immunomodulatory capacity of PM and especially its influence on the sensitization 
process are unknown.  
In the study described here we developed a model in which the influence of different 
components of PM on both the systemic as well as the local immune response could be 
determined. The coadministration of particles during sensitization clearly adjuvated the 
immune response to the antigen TNP-OVA in this model. This immunostimulatory 
capacity was irrespective of the type of antigen, because the model could also be performed 
with OVA (unpublished results). Administration of an extra antigen challenge at Day 17 to 
CBP-treated animals revealed the persistent character of the adjuvant activity. This was 
illustrated by the ongoing increase of IgG1 and the significantly enhanced IgG2a levels and 
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IgG1-AFC and eosinophil numbers measured at Day 22 compared to Day 15. This 
deterioration of the overall effects may be caused by the persistent adjuvant effect of the 
particles.  
Strikingly, all the different carbonaceous particles displayed adjuvant activity, 
whereas SIP were less effective. CBP and DEP1 were the strongest adjuvants, as can be 
concluded from high antibody levels and AFC numbers. Moreover, SIP-exposure induced 
a neutrophil infiltrate, as was also reported by others (Bissonnette and Rola-Pleszczynski 
1989, Yuen et al., 1996), whereas CBP-treatment caused an infiltrate of eosinophil. The 
particle size difference between SIP and the other particles probably results in a different 
particle distribution in the lungs (Churg and Brauer, 1997, Ferin et al., 1992), possibly 
causing the difference in adjuvant activity. The observed difference in adjuvant activity 
between the two types of equally sized DEP as observed in our model indicates that DEP 
derived from different sources may have distinct biological effects. This may be caused by 
a difference in amount or composition of attached substances (Takenaka et al., 1995, Tsien 
et al., 1997), but other particle surface characteristics such as charge may also play a role 
(Oortgiesen et al., 2000). However, from the fact that also CBP, which lacks attached 
substances, adjuvates the response, it may be concluded that the mere presence of a particle 
core is sufficient to adjuvate an immune response, which is in agreement with other studies 
(Løvik et al., 1997, van Zijverden et al., 2000).  
Intranasal coadministration of particles and antigen was effective in adjuvating the 
immune response in our model. This resembles the real life situation in which subjects 
breathe DEP complexed to allergen (Ormstad et al., 1998, Behrendt et al., 1992). The 
response of CBP-treated animals showed characteristics of an immediate allergic response, 
e.g. the presence of IgE and eosinophils (Coyle et al., 1996). This indicates that particles 
may play a role not only in the aggravation but also in the induction of respiratory allergy. 
The effect of exposure during distinct phases of the immune response is presently subject 
of investigation.  
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CHAPTER 5 
 
PARTICULATE AIRBORNE POLLUTANTS ADJUVATE 
BOTH PRIMARY AND SECONDARY ANTIGEN-SPECIFIC 
IMMUNE RESPONSES AFTER INTRANASAL 
ADMINISTRATION  
 
Maaike van Zijverden , Marianne Bol, Teun van Herwaarden, André Penninks, Henk van 
Loveren, Raymond Pieters 
 
ABSTRACT 
 
Particulate airborne pollution triggers symptoms in persons already suffering from respiratory 
allergy, but its effect on the sensitization process and consequently its possible role in the increasing 
incidence of respiratory allergy is unknown. The study described here examined different particles, 
diesel exhaust particles (DEP) from 2 different sources, carbon black particles (CBP), and 
amorphous silica particles (SIP), for their immunomodulating capacity after intranasal administration 
during different phases of the immune response to a protein antigen. The intranasal exposure 
regimen in female BALB/c mice consisted of a sensitization phase of 3 consecutive doses of 10 µg 
of reporter antigen TNP-OVA (2,4,6-trinitrophenyl coupled to ovalbumin) at Day 1, 2, and 3, 
followed by a challenge with TNP-OVA (10 µg) at Day 10. To study the effect of particles on the 
sensitization process, they were coadministered with TNP-OVA at Day 1, Day 2 and Day 3 (total 
particle dose: 200 µg). The influence of particle exposure during the challenge was assessed in mice 
that were coadministered particles (67 µg) only with the challenge of TNP-OVA, while a third group 
of mice was exposed during both phases. TNP-specific antibody forming cells (AFCs) in 
peribronchial lymph nodes (PBLN) and immunoglobulin (Ig) levels in blood were measured at Day 
15 by respectively ELISPOT and ELISA. Groups receiving particles during both sensitization and 
challenge showed the highest increases in serum IgG1, IgE and to a lesser extent IgG2a levels. Also 
an increase in IgG1-AFC number was observed in lymph nodes draining the lung. Moreover, 
particles were able to stimulate the immune response after administration exclusively during 
sensitization. This may imply that exposure to particulate air pollution is involved in the facilitated 
initiation of allergy and supports the notion that particles contribute to the increasing prevalence of 
respiratory allergy.  
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INTRODUCTION 
 
Exposure to pollutants has been shown to trigger clinical asthmatic symptoms in an 
individual who is already sensitized and hyperreactive (Pierson and Koenig, 1992, Devalia 
et al., 1996). For instance hospital admission of asthmatics increases during spells of 
severe air pollution (Lipsett et al., 1997, Korrick et al., 1998, Jacobs et al., 1997). 
Although air pollution clearly plays a role in the exacerbation of respiratory symptoms, the 
relationship between pollution and initial sensitization is still open to debate (Wardlaw 
1992). There are some studies showing a higher incidence of asthma and bronchial 
hyperresponsiveness in subjects living near busy roads (Ishizaki et al., 1987, van Vliet et 
al., 1997, Wjst et al., 1993). In animal studies pollutants like diesel exhaust particles (DEP) 
(Diaz-Sanchez 1997b, Nilsen et al., 1997, Steerenberg et al., 1999a, Takano et al., 1997, 
Takafuji et al., 1987, Fujimaki et al., 1994, Maejima et al., 1997, Muranaka et al., 1986), 
O3 (Biagini et al., 1986), SO2, NO2  (Siegel et al., 1997, Gilmour 1995) and residual oil fly 
ash (ROFA) (Lambert et al., 1999) were shown to adjuvate the immune response (Gilmour 
1995). Only few of these studies (Biagini, Siegel, Lambert) concern modulation 
exclusively of the primary immune response, exposing naïve animals to pollutants solely 
during the sensitization phase of the immune response.  
Especially the role of airborne particulate matter (PM) has gained a lot of attention 
during the last decade, and it is recognized as an important causative agent of acute and 
possibly also long-term pulmonary effects (Dockery and Pope 1994). PM is a heterogenic 
agent, one of its main components in westernized societies are DEP. DEP have been shown 
in both humans (Diaz-Sanchez et al., 1997a and 1999, Ishizaki et al., 1987) and animals 
(Takano et al., 1997, Takafuji et al., 1987, Fujimaki et al., 1994, Maejima et al., 1997, 
Muranaka et al., 1986) to stimulate immune responses to common allergens. In addition to 
carbonaceous components such as DEP and soot also silicates may be present in PM, of 
which the immunomodulatory potential in relation to respiratory allergy is unknown. PM is 
usually described according to its size; PM10 represent particles up to 10 µm. Size is a 
crucial characteristic in determining whether and where particles are deposited in the lung 
(Churg and Brauer 1997, Ferin et al., 1992). For respiratory allergy, however, the exact 
role of PM and its crucial characteristic or its responsible component is unknown.  
In a previous study (van Zijverden et al., Chapter 4) we developed an intranasal 
exposure model in mice in which we showed that different particles were able to act as 
adjuvant when coadministered during sensitization, leading to inflammatory cell infiltrates 
and IgE production. This was also shown in rat by Lambert et al. (1999), who showed that 
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exposure of rats to ROFA before sensitization with antigen adjuvates a Th2-like immune 
response.  
The purpose of this study was to determine the adjuvant capacity of different types 
of particles after intranasal administration during different phases of the immune response. 
In our model, the antigen TNP-OVA was administered intranasally at Days 1, 2 and 3, and 
a challenge took place at Day 10. Particles were coadministered during the sensitization 
and/or challenge phase of the immune response. This enabled us to study the possible 
correlation of adjuvant activity with the phase of particle exposure. Two types of DEP were 
used, which differed in origin (DEP1 from a V8 motor, DEP2 from a 4 kW light duty 
engine). DEP1, DEP2 and carbon black (CBP) were compared to amorphous silica 
particles (SIP). The capacity of the four particles to modulate the type of immune response 
was studied by measuring Day 15-antibodies in serum and antibody forming cells (AFC) in 
lymph nodes draining the lung (PBLN).  
 
MATERIALS AND METHODS 
 
Animals  
Female, specific pathogen-free BALB/c mice (6-8 weeks of age) were obtained from the 
Utrecht University breeding facility. Mice were housed under hygienic barrier conditions 
in filter-topped macrolon cages with bedding of wood chips, a temperature of 23±2oC, 50-
60% relative humidity and a 12-h light/dark cycle. They received standard lab chow and 
acidified tap water ad libitum. The experiments were approved by an ethical committee and 
conducted in accordance with the Guiding Principles in the Use of Animals in Toxicology.  
Chemicals and reagents  
Silica (amorphous, microcrystalline SiO2 [SIP]) was obtained from Sigma Chemical 
Company (St. Louis, MO) and CBP from Brunschwich Chemie (Amsterdam, The 
Netherlands). DEP1 was a friendly gift from Dr. P. Steerenberg (RIVM, the Netherlands) 
and was derived from a V8 motor (Mauderly et al., 1987). DEP2 was obtained from Dr. P. 
Scheepers (Nijmegen University, The Netherlands), and was derived from a 4 kW light 
duty engine. The antigen TNP-OVA was prepared as described by Albers et al. (1997). 
Immobilon-P membranes were obtained from Millipore (Etten-Leur, The Netherlands), and 
alkaline-phosphatase-conjugated goat-anti-mouse IgG1, IgG2a and IgE antibodies from 
Southern Biotechnology Associates (Birmingham, AL). Anti-mouse IgE (02111D) for IgE 
ELISA was obtained from Pharmingen (Hamburg, Germany). ELISA plates (highbond 
3590) were obtained from Costar, Cambridge, MA. All reagents for the TNP-specific 
ELISA were obtained from Sigma Chemical Company (St. Louis, MO).   
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Treatment of the mice  
Particle suspensions (2.67 mg/ml) were prepared in saline containing 0.4 mg/ml TNP-OVA 
and 5% heat inactivated normal BALB/C mouse serum. The latter was added to facilitate 
suspension of the hydrophobic particles, while they stirred for 18 h. Naïve female BALB/c 
mice were intranasally instilled by pipetting a total volume of 25 µl on the nostrils under 
light ether anesthesia. Sensitization took place at Day 1, 2 and 3, adding up to a total TNP-
OVA dose of 30 µg. A challenge dose consisting of 10 µg TNP-OVA was given at Day 10. 
Particles were administered during either sensitization, challenge, or both phases, and 
consisted of 67 µg of particle per dose (Table 1). Blood was collected by orbita punction 
under ether anesthesia at Day 0 and 5 days after challenge at Day 15. At dissection PBLN, 
spleen and bone marrow were taken out for ELISPOT.  
 
 
Table 1: Treatment groups, n=4 (group 4, 7, 10, 13), n=10 (group 2, 3, 5, 6, 8, 9, 11, 12), n=18 
(group 1). Blood samples were taken at Day 0 and at Day 15 when animals were sacrificed. TNP-
OVA=10µg/dose, particles=67µg/dose. 
 
 
group Sensitization (day 1, 2, 3) Challenge (day 10)
1
2
3
4
5
6
7
8
9
10
11
12
13
TNP-OVA
TNP-OVA + CBP
TNP-OVA + CBP
TNP-OVA
TNP-OVA + DEP1
TNP-OVA + DEP1
TNP-OVA
TNP-OVA + DEP2
TNP-OVA + DEP2
TNP-OVA
TNP-OVA + SIP
TNP-OVA + SIP
TNP-OVA
TNP-OVA
TNP-OVA
TNP-OVA + CBP
TNP-OVA + CBP
TNP-OVA
TNP-OVA + DEP1
TNP-OVA + DEP1
TNP-OVA
TNP-OVA + DEP2
TNP-OVA + DEP2
TNP-OVA
TNP-OVA + SIP
TNP-OVA + SIP
 
TNP-specific IgG1 and IgG2a ELISA 
Plates were coated (overnight [o.n.] 4oC) with TNP-BSA (20 µg/ml) in 0.05 M carbonate 
buffer pH 9.6, and blocked with PBS/T/1% BSA (1 h, room temperature [RT]). Serial 
dilutions of sera were incubated (1 h, RT) and plates were washed and incubated with an 
optimal dilution of alkaline phosphatase-conjugated anti-mouse IgG1 or IgG2a (1 h, RT), 
followed by p-nitrophenyl phosphate (1 mg/ml in diethanolamine buffer, pH 9.8) for 30 
min. Absorbance was measured at 405 nm. Titers were calculated by means of the sample 
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dilution at which extinctions were higher than background+2SD. Background levels at Day 
0 were subtracted from Day 15 levels to obtain the increase in IgG1/IgG2a.  
TNP-specific IgE ELISA  
Plates were coated (6 h, first hour at 37oC, last hours at RT) with αIgE, 2 µg/ml in 0.05 M 
carbonate buffer pH 9.6. After washing, serial dilutions of sera were incubated (o.n. 4oC) 
and plates were washed and incubated with an optimal dilution of a biotin-TNP-BSA 
complex (1h, RT). After incubation (45 min, RT) with poly-HRP-streptavidine (CLB, 
Amsterdam, The Netherlands), tetramethylbenzidine (1 mg/ml) was added (15 min, RT). 
The coloring reaction was stopped with H2SO4 and absorbance was measured at 450 nm. 
Titers were calculated by means of the sample dilution at which extinctions were higher 
than background+2*SD. Background levels at Day 0 were subtracted from Day 15 levels to 
obtain the increase in IgE.  
Calculation of Stimulation Indices 
The increase in titers of a particle-treated group divided by the increase in titers as 
observed in the control group gives the stimulation index (SI) of a certain immunoglobulin 
isotype. The average of the SIs as observed in all groups treated during one particular 
phase of the immune response (either during sensitization, sensitization and challenge, or 
challenge phase) represents the overall SI for particle administration during that phase.  
ELISPOT assay 
These assays were essentially performed as described previously (Schielen et al. 1995). 
Briefly, organs were minced to prepare single cell suspensions, and 0.5*106 cells in 500 µl 
PBS/1% BSA were incubated (4 h, 37oC) in wells containing TNP-BSA coated (o.n. 4oC) 
Immobilon-P membranes as bottom. Thereafter, membranes were washed and incubated 
with optimal dilutions of isotype-specific alkaline phosphatase-conjugated anti-mouse Ig 
antibodies in PBS/T (o.n. 4oC). After washing, spots were developed by incubation with 5-
bromo-4-chloro-3-indolyl phosphate and nitroblue tetrazolium (BCIP/NBT). Specific 
AFCs per 106 cells were calculated from spot numbers counted with the aid of a stereo 
microscope.  
Statistics  
Preceding statistical analysis, ELISPOT data (number of AFC) were transformed to log10 
values to homogenize variance. Differences between group means were analyzed using 
one-way ANOVA with Scheffe post-hoc test for contrasts (p<0.05 or p<0.01). In the case 
of nonsufficient homogeneity of variances, a Kruskal-Wallis ranking test was performed 
(p<0.05).  
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RESULTS  
 
Levels of TNP-specific IgG1, IgG2a and IgE antibodies in serum 
To assess the immunomodulating activity of the different particles, immunoglobulin levels 
were determined in sera obtained at Day 0 and at the end of the experiment (Day 15). For 
every animal the background at Day 0 was subtracted from that at Day 15, giving the levels 
shown in Figure 1. IgG1 displayed the highest increase in titers between Day 0 and Day 15 
in most groups, IgE the lowest.  
Modulation of the immune response by particles administered during sensitization  
When particles were administered exclusively during the 3 days of the sensitization phase 
of the immune response, both CBP and DEP1-treated animals showed significant increases 
in IgG1 and IgG2a between Day 0 and Day 15. IgE titers significantly increased in DEP1-
treated mice. IgG1 levels in DEP2 and SIP-treated animals also showed a tendency to 
increase, whereas in these groups IgE and IgG2a remained at control levels (Fig. 1). The 
stimulation indices (SI) of the treatment groups for the different immunoglobulin isotypes 
are given in Table 2. Significantly higher SIs for the different isotypes support the 
relatively strong adjuvating activity of DEP1 and CBP.  
Modulation of the immune response by particles administered during sensitization 
and challenge  
The immune response was most clearly adjuvated when particles were administered in both 
sensitization and challenge phase. IgG1 was significantly enhanced in all particle-treated 
groups, but again most clearly in CBP and DEP1-exposed animals, which also showed 
significantly enhanced IgG2a levels. IgE was significantly enhanced in CBP and DEP1 
treated animals (Fig. 1). Again high SIs (Table 2), reflect the strong adjuvating capacity of 
CBP and DEP1. DEP2 and SIP-treated animals also showed increased SIs for IgG1.  
Modulation of the immune response by particles administered during challenge   
Exposure to particles solely in the challenge phase adjuvated the immune response in the 
DEP1-treated group, showing significantly enhanced IgG1 and IgG2a levels, whereas also 
IgE showed a tendency to increase. However SIs in the challenge phase were significantly 
lower compared to SIs of animals treated with DEP1 during sensitization or during both 
phases (Table 2). IgG1 titers of CBP-treated animals also showed a tendency to increase 
(Fig. 1), but this SI was significantly lower compared to animals to which CBP was 
administered during the other phases. Neither for DEP2 nor SIP-treated animals significant 
differences were found between SIs of groups treated during different phases (Table 2).  
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Figure 1: The increase in TNP-specific antibody 2log titers between Day 0 and Day 15 as 
determined by ELISA. A) Particle administration during sensitization. B) Particle administration 
during sensitization and challenge. C) Particle administration during challenge. Depicted is average 
+/- standard deviation.  
IgG1: * = p<0.01 vs control, ** = p<0.01 vs control, as determined by ANOVA followed by 
Scheffe’s post hoc test. Kruskal-Wallis ranking test was performed for  "particles in sensitization-
phase"  
IgG2a: * = p<0.01 vs control, ** = p<0.01 vs control, # = p<0.05 vs SIP, "= p<0.01 vs CBP as 
determined by ANOVA followed by Scheffe’s post hoc test. Kruskal-Wallis ranking test was 
performed for "particles in sensitization and challenge phase"  
IgE: * = p<0.05 vs control, ** = p<0.01 vs control as determined by ANOVA followed by Scheffe’s 
post hoc test. 
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Table 2: Treatment groups and their Stimulation Indices for the different immunoglobulin isotypes, 
based on increases in serum Ig-titers between Day 0 and Day 15 as determined by ELISA.  
 
 
 Group SI IgG1 SI IgG2a SI IgE
CBP sensitization
DEP1 sensitization
DEP2 sensitization
SIP sensitization
3.9±0.9 1, A
4.5±0.4 2, B
2.7±0.7
2.6±0.8
2.1±0.3 3
2.8±0.4 4
0.9±0.9
1.3±0.8
3.8±3.2
5.0±2.26
0.0±0.0
0.8±1.4
CBP sens + challenge
DEP1 sens + challenge
DEP2 sens + challenge
SIP sens + challenge
4.6±1.1 A
4.6±1.2 B
3.3±0.5
3.0±1.2
4.4±0.9 5, A
2.8±0.5
1.6±0.3
0.6±0.5
7.0±3.37, A
5.0±5.4
0.6±1.3
0.0±0.0
CBP challenge
DEP1 challenge
DEP2 challenge
SIP challenge
1.8±0.4
3.1±0.3
2.2±0.6
1.5±1.1
0.8±0.8
2.8±0.3
1.3±1.3
0.9±0.9
0.8±1.4
2.8±.6
0.6±1.3
0.0±0.0
As determined by ANOVA followed by Scheffe’s post hoc test, or in case of non-sufficient 
homogeneity of variances, a Kruskal-Wallis ranking test was performed. Depicted are averages ± 
standard deviation:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Number of cells and TNP-specific antibody forming cells in PBLN at Day 15 
Significant increases in PBLN cell number were induced when particles were administered 
during sensitization (Fig. 2A). Cell numbers also increased significantly in CBP and in 
DEP1-treated animals when particles were administered during both phases, whereas in the 
latter group they also increased significantly when particles were only administered during 
challenge (Fig. 2A).  
Differences between particles within 
each phase of exposure:  
1= >SIP sensitization (p<0.01) 
2= >DEP2 sensitization and SIP 
sensitization (p<0.01) 
3= >DEP2 sensitization (p<0.05) 
4= >DEP2 sensitization and SIP 
sensitization (p<0.01) 
5= >DEP2 sens+challenge and SIP 
sens+challenge (p<0.01) 
6= >DEP2 sensitization (p<0.05) 
7= >DEP2 sens+challenge and SIP 
sens+challenge (p<0.05) 
 
Differences between phases within 
each particle-treatment: 
A= >CBP challenge (p<0.05)  
B= >DEP1 challenge (p<0.01) 
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The number of specific AFC was assessed in PBLN, spleen and bone marrow. In 
the latter two organs hardly any AFC were identified (not shown). In PBLN only IgG1-
AFC could be found, which is in line with IgG1 being the isotype detected in highest levels 
in serum. In groups receiving particles only during the sensitization phase, CBP and DEP1-
treated animals showed significantly enhanced IgG1-AFC numbers, both were significantly 
higher than all other groups (Fig. 2B). Particle administration during both phases of the 
immune response caused significantly increased AFC-numbers in DEP1-treated animals, 
while CBP-treated animals also showed a tendency to increase. The single dose during the 
challenge phase caused no significant increase.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2A: Cell number of PBLN at Day 15. The dotted line represents control level. Average +/- 
standard deviation are depicted. *p<0.05 vs. control, #p<0.05 vs. SIP, ##p<0.01 vs. SIP, as 
determined by ANOVA followed by Scheffe’s post hoc test.  
Figure 2B: Number of TNP-specific antibody forming cells per 0.5*10e6 cells as determined in 
PBLN by ELISPOT at Day 15. The dotted line represents control level 
Average +/- standard deviation are depicted. *p<0.05 vs. control, , #p<0.05 vs. SIP, ##p<0.01 vs. 
SIP, as determined by ANOVA followed by Scheffe’s post hoc test.  
 
 
DISCUSSION  
 
The exposure of already sensitized subjects to particulate pollutants is known to aggravate 
respiratory symptoms (Lipsett et al., 1997). In the present study, different types of particles 
are shown to adjuvate the immune response when administered during different phases of 
the immune response. To summarize and discuss the results, average SIs ((SI IgG1+SI 
IgG2a+SI IgE)/3) are calculated for every phase (Table 3). In combination with data as 
presented in Fig. 1 and Fig. 2, it becomes clear that adjuvant activity was best expressed 
when particles were administered during both sensitization and challenge phase (average SI 
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3.1). Particles also clearly adjuvated the immune response when they were administered 
only during sensitization (average SI 2.5), whereas the single challenge dose was the least 
effective (average SI 1.6, Table 3). Overall DEP1 and CBP adjuvated the immune response 
best, as can be concluded from the significantly highest antibody increases (Fig. 1), and 
IgG1-AFC numbers (Fig. 3), and is also indicated by the high average SIs (Table 3).  
 
Table 3: Average Stimulation Indices 
 
Particle SI sensitization SI sensitization+
challenge
SI
challenge
CBP
DEP1
DEP2
SIP
3.3
4.1
1.2
1.6
5.3
4.1
1.8
1.2
1.1
2.9
1.4
0.8
average 2.5 3.1 1.6
Animals were exposed to different particles during distinct phases of the immune response. Shown 
are the average stimulation indices ((SI IgG1+SI IgG2a+SI IgE)/3) and the average stimulation 
indices for the different phases, based on increases in serum Ig-titers between Day 0 and Day 15 as 
determined by ELISA (Fig. 1) and the stimulation indices (Table 2). 
 
 
In this model the adjuvant effect of particles administered exclusively in the 
challenge phase was not as striking as after exposure in the sensitization phase or in both 
phases. This may be caused by the fact that the particle doses administered during the 3 
day-sensitization phase adds up to 200 µg, whereas the challenge phase comprises only one 
day and consequently one third of the sensitization dose. Still, this suffices to adjuvate the 
response in case of DEP1. In addition, the time between the challenge dose and the end of 
the experiment, although long enough to allow a secondary immune response to develop, 
may be too short for the adjuvant activity to be fully expressed. Moreover, this model is 
aimed at inducing a suboptimal immune response during sensitization in order to facilitate 
detecting small adjuvant effects, and therefore does not represent the situation in allergic 
subjects.  
DEP1 appears to have a stronger adjuvant activity than DEP2. This difference in 
adjuvant activity may be explained by a difference in particle characteristics such as 
amount of attached substances. However, in our model CBP and DEP1 were both strongly  
immunostimulatory, indicating that the mere presence of a particle core is enough to 
adjuvate an immune response. The possible differences between DEP from distinct sources 
is important to bear in mind when comparing studies from literature in which DEP is used. 
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A small difference in size for example may result in a different particle distribution in the 
lungs (Churg and Brauer 1997, Ferin et al., 1992).  
Regarding the different isotypes produced in our model, particles administered into 
the lung mostly stimulate immune responses with Th2 characteristics. Overall, the increase 
in the Th2-mediated isotype IgG1 is more prominent than the increase in the Th1-mediated 
isotype IgG2a (Fig. 1), and in addition the Th2-mediated isotype IgE is also produced in 
response to CBP and DEP1. This appears to be partly in contrast with results from the 
subcutaneous model (van Zijverden et al., 2000), in which the same particles stimulated 
both Th1 (SIP), Th2 (DEP) or mixed (CBP) reactions. This may reflect distinct default 
reactions in lung and skin; while in the skin a Th1 response arises to a particular antigen, in 
the lung the same antigen initiates a Th2 response (Constant et al., 2000). Although 
respiratory allergy to common protein antigens is a Th2-mediated disease, a Th1-mediated 
reaction is not necessarily less harmfull. On the contrary, Th1 cells may not only fail to 
counterbalance the effects of Th2 cells (Hansen et al., 1999), they actually may be 
indispensable and cooperate with Th2 cells in a murine model of eosinophilic airway 
inflammation (Randolph et al., 1999). The inflammatory reaction initiated by Th1 cells 
plays a crucial role in this process. The fact that DEP1 and CBP stimulate IgG2a 
production in addition to IgG1and IgE in our model indicates that both Th1 and Th2-
mediated reactions are taking place at the same time. This makes particles such as DEP1 
and CBP likely candidates to play a stimulatory role in the process of respiratory allergy.  
This study shows that intranasal administration of different types of particles in mice 
stimulates the immune response. The fact that particles also display adjuvant activity when 
they are administered exclusively during the sensitization phase may imply that exposure 
to particulate air pollution is able to cause facilitated initiation of allergy in humans. 
Although so far only epidemiological evidence exists for the involvement of particulate 
pollutants in the exacerbation of respiratory allergy, our present results may support a role 
for particles in the increasing incidence of allergy as well. The mechanism by which 
particles stimulate immunosensitization is presently subject of investigation.  
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CHAPTER 6 
 
COADMINISTRATION OF ANTIGEN AND PARTICLES 
OPTIMALLY ADJUVATES THE IMMUNE RESPONSE IN 
AN INTRANASAL ADMINISTRATION MODEL 
 
Maaike van Zijverden, Colin de Haar, Astrid van Beelen, Henk van Loveren, André 
Penninks, Raymond Pieters  
 
ABSTRACT 
 
Particulate matter is known to affect human health, yet the mechanism(s) by which it acts is largely 
unknown. One of the factors that may play a role in particle adjuvant activity is binding of allergen 
to particles. This may turn the particles into allergen carriers resulting in antigen deposition within 
the altered inflammatory microenvironment created by the particles. We compared the effectivity of 
simultaneous versus separate administration of antigen and particles during sensitization in an 
intranasal exposure model. Sensitization consisted of 3 doses (10 µg) of TNP-OVA at Days 1, 2 and 
3. Two hundred µg of carbon black particles (CBP) were administered either 1 day before 
sensitization (Day 0), 1 day after sensitization (Day 4), or during sensitization. The latter was 
performed either at Day 1 (200 µg) or at Day 1, 2 and 3 (67 µg/day). At Day 10 a challenge with 10 
µg of TNP-OVA was performed, and at Day 15 the immune response was assessed. The total 
number of cells as well as antibody forming cells (AFC) in lymph nodes draining the lung 
(peribronchial lymph nodes [PBLN]) were determined, and immunoglobulin levels in blood were 
assessed. Cell numbers of PBLN increased significantly in all particle-treated groups compared to 
controls. The number of TNP-specific IgG1-forming cells in the groups receiving particles during 
sensitization was significantly higher than control level. Only groups receiving particles during or 
before sensitization displayed significantly higher IgG1 levels than controls, in contrast to the group 
receiving particles after sensitization. TNP-specific IgE increased significantly compared to controls 
only in animals receiving 3*67µg doses during sensitization. IgG2a did not show significant 
differences, indicating that the response is predominantly Th2-mediated. These data indicate that 
coadministration of particles at all time points of antigen dosing constitutes as the most effective way 
to adjuvate an immune response in our model, as opposed to separate particle and antigen dosing. 
Also administration shortly before antigen administration was effective, suggesting that time-
dependent processes are involved in adjuvant activity of particles, supporting the important role of 
the altered inflammatory microenvironment created by the particles.
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INTRODUCTION  
 
Particulate matter (PM) is recognized as an important causative agent of acute and 
probably also long-term pulmonary health effects (Dockery and Pope 1994). One of these 
effects is the aggravation of symptoms of respiratory allergy, and possibly also facilitated 
sensitization to common allergens like pollen. Diesel exhaust particles (DEP), which make 
up an important part of PM, are likely to play an important role in these effects (van Vliet 
et al., 1997, Ishizaki et al., 1987). The immunomodulatory capacity of DEP has been 
shown in several animal models (Takano et al., 1997, Fujimaki et al., 1997, Takafuji et al., 
1987, Nilsen et al., 1997) and also in experimental human studies (Diaz-Sanchez et al., 
1997a and 1999).  
The exact mechanism by which particles enhance the immune response is unknown. 
Presumably, particles act at different levels (Salvi and Holgate 1999). Particles could 
interact with allergens in the outside air, turning respirable size particles into allergen 
carriers (Ormstad et al., 1998, Knox et al., 1987, Behrendt et al., 1992) that deposit 
concentrated amounts of possibly altered (Behrendt et al., 1997) allergen deeply into the 
lung. Once deposited, particles may alter macrophage (Yang et al., 1997) and epithelial cell 
(Steerenberg et al., 1998) function (Salvi et al., 1999), thereby changing the 
microenvironment of the lung and possibly leading to modified antigen presentation and 
allergy.  
So far, however, it is unknown whether both interaction and simultaneous deposition 
of the particle and allergen are necessary for adjuvant activity. A direct comparison within 
the same model between simultaneous and separate administration of antigen and particles 
has never been made. In the majority of the studies DEP and antigen are administered 
together, either via intratracheal or intranasal administration (Takano et al., 1997, Fujimaki 
et al., 1994, Takafuji et al., 1987, van Zijverden et al., Chapter 4). This appears to be an 
effective way to induce adjuvant activity in naïve mice, as measured by airway 
inflammation, cytokine production and IgG1 and IgE production. In sensitized human 
volunteers who were exposed to both ragweed and DEP simultaneously, increasing IgE and 
Th2 cytokines were observed (Diaz-Sanchez et al., 1997a). However, separate dosing of 
DEP and antigen was effective in causing mucosal sensitization in (naïve) human 
volunteers (Diaz-Sanchez et al., 1999) and elevated levels of IgE and IL-4 in mice 
(Fujimaki et al., 1997). In rats, residual oil fly ash (ROFA), administered 1 day before the 
first antigen administration, was shown to adjuvate sensitization to antigen (Lambert et al., 
1999). This indicates that coadministration of and physical attachment between particle and 
antigen is not obligatory for the adjuvant activity. 
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Hence, so far no definite conclusions can be drawn on the effectivity of 
coadministration versus separate dosing of antigen and particles, especially because no 
direct comparison between the different models used hitherto can be made. Therefore we 
used an intranasal exposure model in which antigen and particles could be administered 
either together with or separate from antigen during sensitization. Sensitization comprised 
intranasal administrations of 10 µg TNP-OVA at Days 1, 2 and 3. Two hundred µg of 
carbon black particles (CBP) were administered either 1 day before sensitization (Day 0), 1 
day after sensitization (Day 4), or during sensitization. The latter was performed either at 
Day 2 (200 µg) or at Day 1, 2 and 3 (67 µg/day). At Day 10 a challenge with 10 µg of 
TNP-OVA was performed, and at Day 15 the immune response was assessed. The number 
of cells and antibody forming cells (AFC) in lymph nodes draining the lung (peribronchial 
lymph nodes [PBLN]) was determined, and immunoglobulin levels in blood were assessed.  
 
MATERIALS AND METHODS 
 
Animals 
Female, specific pathogen-free BALB/c mice (6-8 weeks of age) were obtained from the 
Utrecht University breeding facility. Mice were housed under hygienic barrier conditions 
in filter-topped macrolon cages with bedding of wood chips, a temperature of 23±2oC, 50-
60% relative humidity and a 12-h light/dark cycle. They received standard lab chow and 
acidified tap water ad libitum. The experiments were approved by the ethical committee for 
animal use of the Utrecht University, and conducted in accordance with the Guiding 
Principles in the Use of Animals in Toxicology.  
Chemicals and reagents 
CBP was obtained from Brunschwich Chemie (Amsterdam, The Netherlands). The antigen 
TNP-OVA was prepared as described by Hudson and Hay (1989). TNP-BSA was coupled 
in an identical way. For TNP-specific IgE-ELISA, biotin was additionally coupled to TNP-
BSA. Immobilon-P membranes were obtained from Millipore (Etten-Leur, The 
Netherlands), alkaline-phosphatase (AP)-conjugated goat-anti-mouse IgG1, IgG2a and IgE 
antibodies from Southern Biotechnology Associates (Birmingham, AL, USA). Anti-mouse 
IgE (02111D) for IgE ELISA was obtained from Pharmingen (Hamburg, Germany). 
ELISA plates (highbond 3590) were obtained from Costar, Cambridge, MA. All reagents 
for the TNP-specific ELISA were obtained from Sigma Chemical Company (St. Louis, 
MO, USA).  
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Treatment of the mice 
Particle suspensions (2.67 mg/ml) were prepared in saline containing 5% heat inactivated 
normal BALB/C mouse serum and 0.4 mg/ml TNP-OVA in case of co-administration of 
antigen and particles. The mouse serum was added to facilitate suspending the hydrophobic 
particles, while stirring for 18 h. Naïve female BALB/c mice were intranasally instilled by 
pipetting a total volume of 25 µl on the nostrils under light ether anesthesia. Sensitization 
took place at Day 1, 2 and 3, adding up to a total TNP-OVA dose of 30 µg. A challenge 
dose consisting of 10 µg TNP-OVA was given at Day 10. Particles were administered 
either before, during, or after sensitization, and consisted of 3*67 µg of particles or 200 µg 
at once (Table 1). Control groups receiving only antigen, and only particles were added. 
Blood was collected by orbita punction under ether anesthesia at Day 0 and Day 15, 5 days 
after challenge and just prior to dissection, at which also bronchial alveolar lavage (BAL) 
was performed and PBLN were taken out.  
 
 
Table 1: experimental setup.  
 
G RO U P D ay 0 D ay 1 D ay 2 D ay 3 D ay 4 D ay 10
sensitization sensitization sensitization sensitization sensitization challenge
1: 3*67 group -
67µg CB P+
TN P-O V A
67µg CB P+
TN P-O V A
67µg  CBP+
TN P-O V A - TN P-O V A
2:
200dose group -
200  µg CB P+
TN P-O V A TN P-O V A TN P-O V A - TN P-O V A
3:
200before group 200  µg CB P TN P-O V A TN P-O V A TN P-O V A - TN P-O V A
4:
200after group TN P-O V A TN P-O V A TN P-O V A 200
 µg CB P TN P-O V A
5:
control I TN P-O V A TN P-O V A TN P-O V A - TN P-O V A
6:
control II saline TN P-O V A TN P-O V A TN P-O V A TN P-O V A
7:
control III
-
TN P-O V A TN P-O V A TN P-O V A saline TN P-O V A
8:
particle-control - 67  µg  CBP 67  µg  CBP 67  µg  CBP - saline
Treatment groups (n=6-8). During sensitization groups 1and 2 receive particles (CBP) and antigen 
(TNP-OVA) together, in either 3 doses of 67µg (1) or 1 dose of 200µg (2). CBP is administered 
before TNP-OVA sensitization in group 3, whereas in group 4 CBP is dosed after sensitization. All 
control groups receive only antigen TNP-OVA. In addition, control group II and III receive a dose of 
saline to control for the extra dose before (group3) and after (group 4) the antigen administrations. A 
particle-control group is added, which only receives particles and no antigen. 
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TNP-specific IgG1 and IgG2a ELISA  
Plates were coated (overnight [o.n.] 4oC) with TNP coupled to bovine serum albumin 
([BSA] TNP-BSA, 20 µg/ml) in 0.05 M carbonate buffer pH 9.6, and blocked with 
phosphate buffered saline (PBS) containing 0.05% Tween20 (Brunschwich) and 1% BSA 
([PBS/T/BSA]1 h, room temperature [RT]). Serial dilutions of sera were incubated (1 h, 
RT) and plates were washed and incubated with an optimal dilution of AP-conjugated anti-
mouse IgG1 or IgG2a (1 h, RT), followed by p-nitrophenylphosphate (1 mg/ml in 
diethanolamine buffer, pH 9.8) for 30 min. Absorbance was measured at 405 nm. Titers 
were calculated by means of the sample dilution at which extinctions were higher than 
background+2*SD. Background levels at Day 0 were subtracted from Day 15 levels to 
obtain the increase in IgG1/IgG2a.  
TNP-specific IgE ELISA  
Plates were coated (6 h, first hour at 37oC, last hours at RT) with αIgE, 2 µg/ml in 0.05 M 
carbonate buffer pH 9.6. After washing, serial dilutions of sera were incubated (o.n. 4oC) 
and plates were washed and incubated with an optimal dilution of a biotin-TNP-BSA 
complex (1h, RT). After incubation (45 min, RT) with poly-HRP-streptavidine (CLB, 
Amsterdam, The Netherlands), tetramethylbenzidine (1 mg/ml) was added (15 min, RT). 
The coloring reaction was stopped with H2SO4 and absorbance was measured at 450 nm. A 
standard curve of TNP-specific mouse IgE was included for calculating IgE amounts.  
ELISPOT assay  
These assays were essentially performed as described previously (Schielen et al., 1995). 
Shortly, PBLN were minced to prepare single cell suspensions, and 0.5*106 cells in 500 µl 
PBS/1% BSA were incubated (4 h, 37oC) in wells containing TNP-BSA (20 µg/ml) coated 
(o.n. 4oC) Immobilon-P membranes as bottom. Thereafter, membranes were washed and 
incubated with optimal dilutions of isotype-specific alkaline phosphatase-conjugated anti-
mouse Ig antibodies in PBS/T (o.n. 4oC). After washing, spots were developed by 
incubation with 5-bromo-4-chloro-3-indolyl phosphate and nitroblue tetrazolium 
(BCIP/NBT). Specific AFCs per 106 cells were calculated from spot numbers counted with 
the aid of a stereo microscope.  
Statistics  
Preceding statistical analysis, ELISPOT data (the number of AFCs) were transformed to 
log10 values to homogenize variance. Differences between group means were analyzed 
using one-way ANOVA with Scheffe post-hoc test for contrasts (p<0.05 or p<0.01). In 
case of non-sufficient homogeneity of variances, a Kruskal-Wallis ranking test was 
performed (p<0.05).  
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RESULTS  
 
Different time points of particle administration were compared: either during the 3 day 
antigen sensitization (antigen at Day 1,2 and 3, 200 µg particles at Day 1), before 
sensitization (Day 0), or afterwards (Day 4). In addition, particles were also administered 
during sensitization in three small doses (67 µg at Day 1,2,3) to compare the effect of the 
number of doses. All groups were challenged with antigen alone at Day 10, and the 
immune response was determined at Day 15. For all treatments, separate control groups 
were included in the experiment. However it appeared that all antigen controls, i.e. animals 
receiving antigen and no particles (Table 1, groups 5,6,7) showed the same results. This 
indicates that an extra dose of saline and its concurrent anesthesia at Day 0 or Day 4 did 
not modulate the immune response, and we have therefore decided to consider all antigen 
control animals as one group. The control animals receiving only particles and no antigen 
did not show any immune response at all.  
Number of cells and TNP-specific IgG1 antibody forming cells in PBLN at Day 15 
Cell numbers increased significantly in all particle-treated groups compared to antigen 
controls (Fig. 1A). Cell numbers of animals receiving only particles and no antigen showed 
a comparable increase (not shown). In addition, the cell number of the group receiving 3 
particle doses (67 µg) was significantly greater than the cell number of the group receiving 
one dose of particles (200 µg) during sensitization.  
The number of TNP-specific antibody forming cells in the 3*67dose and the 
200dose group was significantly higher than antigen control level. In addition, the 
3*67dose group was higher than the groups receiving 200 µg doses before and after 
sensitization, but only significantly higher than the 200before group.  
TNP-specific antibody titers in serum 
For IgG1 and IgG2a, background levels were determined in sera obtained at Day 0 and 
subtracted from levels found at the end of the experiment at Day 15. This difference 
between Day 15 and Day 0 is depicted. For IgG1, groups receiving 3 small doses 
(3*67dose group) or one dose during (200dose group) or before (200before group) 
sensitization all displayed significantly higher increases than antigen controls (Fig 2A). 
IgG2a did not show significant differences (Fig 2B). TNP-specific IgE increased 
significantly only in the 3*67dose group compared to antigen controls (Fig 2C).  
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Figure 1: A: Number of cells in peribronchial lymph nodes after particle dosing during sensitization 
(3*67dose and 200 dose groups), before sensitization (200before group) and after sensitization (200after 
group). ** p<0.01 vs control, # p<0.05 vs 200dose group.  
B: Number of TNP-specific IgG1-forming cells in PBLN after particle dosing during sensitization 
(3*67dose and 200 dose groups), before sensitization (200before group) and after sensitization (200after 
group). ** p<0.01 vs control, # p<0.05 vs 200before group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: A: The increase in titers of TNP-specific IgG1titers between Day 0 and Day 15 after particle 
dosing during sensitization (3*67dose and 200 dose groups), before sensitization (200before group) and 
after sensitization (200after group). ** p<0.01, * p<0.05 vs control.  
B: The increase in titers of TNP-specific IgG2a between Day 0 and Day 15 after particle dosing during 
sensitization (3*67dose and 200 dose groups), before sensitization (200before group) and after 
sensitization (200after group). C: TNP-specific IgE (ng/ml) at Day 0 and Day 15 after particle dosing 
during sensitization (3*67dose and 200 dose groups), before sensitization (200before group) and after 
sensitization (200after group). * p<0.05 vs control.  
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DISCUSSION 
 
We tested the hypothesis that particulate matter is involved in facilitation of sensitization to 
common allergens. Therefore we compared the effect of separate versus simultaneous 
administration of antigen and particle on sensitization in an intranasal exposure model. We 
found that co-administration of 3 small doses of particles during sensitization adjuvated the 
immune response best. One large dose during sensitization also adjuvated the IgG1 
response, but did not stimulate IgE production. In addition, a particle dose one day before 
the start of the antigen administrations adjuvated the IgG1 response, but no significant 
AFC numbers could be detected. Finally, a particle dose 1 day after the antigen 
administrations was not effective as adjuvant.  
It appears that the immune response can be modified by the relative times of particle 
and antigen exposure. Time dependency is demonstrated by the fact that alltogether, 
coadministration emerges as the most effective way to adjuvate an immune response in our 
model. Particles dosed in 3 doses simultaneously with antigen display the clearest adjuvant 
activity, even inducing IgE as opposed to one large co-administered dose. This indicates 
that a continuous particle exposure, possibly by stimulating an ongoing inflammatory 
response in close proximity of the co-administered antigen, favors adjuvant activity.  
The importance of the relative times of particle and antigen exposure is 
demonstrated by the fact that also administration of particles 1 day before antigen caused 
an enhanced immune response (as was also shown by Lambert et al., 1999), but IgG1 
levels and AFC numbers were not as high as in co-administered groups. In contrast, 
particle dosing 1 day after the antigen administrations did not adjuvate the immune 
response. In order to adjuvate the immune response, particles apparently have to be present 
in the lung at the same time or shortly before antigen is administered. During this time the 
particles are phagocytized by macrophages, which are known to produce proinflammatory 
mediators in response to particles (Yang et al., 1997). Moreover, particles induce a 
decrease in macrophage phagocytosis capacity (Becker and Soukup 1998, van Zijverden et 
al., Chapter 3), possibly decreasing antigen breakdown by macrophages thereby increasing 
the amount of antigen available for presentation by dendritic cells. Time dependency was 
also shown in an intraperitoneal injection model by Granum et al. (2000a), who 
demonstrated that adjuvant activity is lower with increasing time (from 1 to 3 days) 
between particle and antigen injection. In an inhalatory model a gaseous pollutant, NO2, 
was also shown to adjuvate the immune response to antigen that was administered 24 h 
later (Siegel et al., 1997), as opposed to antigen that was administered 7 days later.  
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Overall, adjuvant activity of particles appears to be a time-dependent process, 
suggesting that an inflammatory microenvironment as created by the particles is crucial for 
adjuvating sensitization by particles.  
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CHAPTER 7 
 
INTRANASALLY ADMINISTERED PARTICULATE 
AIRBORNE POLLUTANTS ADJUVATE THE IMMUNE 
RESPONSE IN AN INHALATORY ANTIGEN EXPOSURE 
MODEL  
 
Maaike van Zijverden, Anita van der Pijl, André Penninks, Raymond Pieters, Henk van 
Loveren 
 
ABSTRACT  
 
Particulate air pollution negatively affects human health. It is known to increase symptoms of 
existent respiratory allergy, but its effect on sensitization to common allergens is not clear. Therefore 
a good animal model is needed to assess the possible immunomodulating effects of particles on the 
immune response. Whereas existing models frequently make use of artificial methods like injection 
and/or adjuvants to facilitate sensitization, we modified an existing model (Hessel et al., 1995) to 
study effects of exposure to particles when antigen exposure took place via the relevant route. In 
BALB/c mice the original model, using 7 intraperitoneal (i.p.) injections on alternating days (1-13), 
was compared to the adapted model in which the i.p. injections were replaced by 7 ovalbumin 
(OVA) aerosols. Three weeks later all mice were exposed to 8 OVA aerosols on consecutive days. In 
addition, the effect of  weekly intranasal administrations of 100 µg of particles was assessed in the 
completely aerosol-treated animals. The effects of diesel exhaust (DEP1), carbon black (CBP) and 
silica particles (SIP) were tested. The immune response was read out 1 day after the last aerosol (Day 
42). Immunoglobulin (Ig) levels were measured in serum and antibody-forming cells (AFC) were 
determined in the lymph nodes draining the lung (peribronchial lymph nodes [PBLN]), spleen and 
bone marrow. Cells in bronchial alveolar lavage fluid (BAL) were differentiated. In comparison to 
the i.p. injected group, replacement of injections by aerosols led to a greater variability in response 
and lower average immunoglobulin levels in the aerosol exposed group. In all particle-treated 
groups, the number of animals that responded per group was increased, and they also showed higher 
IgG1 and IgG2a levels in serum. Specific IgE levels only increased in the CBP-treated group. No 
effect of treatment on BAL cell differentiation and AFC-numbers in PBLN was observed. 
Altogether, the immune response to OVA is differently adjuvated  by the presence of different 
particles. Whereas IgG1 and IgG2a production are stimulated by all types of particles, only CBP 
stimulated the production of IgE. This warrants the importance of more research into the mechanism 
of particle-induced immunomodulation.
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INTRODUCTION  
 
The prevalence of asthma and respiratory allergy has been increasing at a high rate in 
Western industrialized countries (Lundbäck 1998, Schäfer and Ring 1997). 
Epidemiological data have resulted in different theories of the increasing prevalence of 
asthma. One theory associates outdoor air pollution, and especially that produced by road 
transport, with asthma (Duhme et al., 1996, van Vliet et al., 1997, Rusznak et al., 1994). 
The fact however that humans are exposed to a complex mixture of pollutants makes it 
hard to extract the responsible factor from epidemiological studies. Diesel exhaust particles 
(DEP) are one of the main suspects. They make up a large part of air pollution in Western 
cities and are known to increase symptoms (Pope and Dockery 1992) and IgE production 
(Diaz-Sanchez et al., 1997a) in already sensitized subjects. Moreover they are able to cause 
inflammation (Salvi et al., 1999, 2000) and adjuvate mucosal sensitization (Diaz-Sanchez 
et al., 2000) in naïve subjects. So far the mechanism by which particles modulate the 
immune response is incompletely known (Salvi and Holgate 1999).  
To study the mechanisms underlying asthma and respiratory allergy, animal models 
are required. Models displaying important effector phase characteristics like specific IgE 
and eosinophils almost all use injections of allergenic materials and often adjuvantia for 
sensitization (Hessel et al., 1995, Kung et al., 1994, Yamada et al., 1994, van Zijverden et 
al., 2000). Despite the fact that these models effectively mimic respiratory allergy and/or 
asthma, they do not reflect real life exposure and its unique characteristics (Constant et al., 
2000), and are not suitable for studying the effect of air pollution on the sensitization 
process. This disadvantage has been overcome in other models in which the animals are 
exposed exclusively via the relevant route (Lambert et al., 1999, van Zijverden et al., 
Chapter 4). However, the administration of antigen and particles via intranasal or 
intratracheal instillation of suspensions  still differs greatly from real life inhalation 
exposure. Therefore we adapted an existing and well defined asthma model (Hessel et al., 
1995), in which all intraperitoneal (i.p.) injections during the sensitization phase were 
replaced by antigen aerosols. The adapted model consisted of 7 ovalbumin (OVA) aerosols 
on alternating days, which were 3 weeks later followed by 8 aerosols on consecutive days.  
The immunomodulating effect of weekly intranasal doses of 100 µg of different 
particulate pollutants was tested in this model. DEP and carbon black (CBP), both organic 
carbonaceous particles (<0.1µm) and part of the (ultra)fine fraction of particulate matter 
(PM), were tested. Ultrafine particles are able to penetrate deep into the lung and stay 
present for a long time (Churg et al., 1997, Ferin et al., 1992). CBP represents the carbon 
core of DEP but lacks the attached chemicals as present on DEP. Whereas DEP are known 
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for their immunomodulating capacity, CBP are possibly not as inert (Løvik et al., 1997, 
Nilsen et al., 1997, van Zijverden et al., 2000, Chapter 3,4) as they were once thought to be 
(Crosbie 1986). Also amorphous silica particles (SIP) were tested. The immunomodulatory 
capacity of SIP in relation to respiratory allergy is unknown. SIP (1-5 µm) predominantly 
belong to the coarse fraction of PM, which mainly consists of inorganic wind blown dusts 
and larger carbon aggregates (Ormstad et al., 1997). We compared the capacity of the 
different particles to adjuvate the immune response to OVA by measuring antibody levels 
in blood, antibody forming cells (AFC) in PBLN, spleen and bone marrow, and 
differentiating cells in brochial alveolar lavage (BAL).  
 
MATERIALS AND METHODS 
 
Animals 
Female, specific pathogen-free BALB/c mice (6-8 weeks of age) were obtained from the 
RIVM breeding facility. Mice were housed under hygienic barrier conditions in filter-
topped macrolon cages with bedding of wood chips, a temperature of 23±2oC, 50-60% 
relative humidity and a 12-h light/dark cycle. They received standard lab chow and 
acidified tap water ad libitum. The experiments were approved by an ethical committee and 
conducted in accordance with the Guiding Principles in the Use of Animals in Toxicology.  
Chemicals and reagents 
Silica (SiO2) was obtained from Sigma Chemical Company (St. Louis, MO) and CBP from 
Brunschwich Chemie (Amsterdam, The Netherlands). DEP1 was a friendly gift from Dr. P. 
Steerenberg (RIVM). The antigen ovalbumin (grade V) was obtained from Sigma. 
Immobilon-P membranes were obtained from Millipore (Etten-Leur, The Netherlands), 
alkaline-phosphatase (AP)-conjugated goat-anti-mouse IgG1 and IgG2a antibodies from 
Southern Biotechnology Associates (Birmingham, AL). All reagents for ELISA, except the 
OVA-specific IgE ELISA, were obtained from Sigma Chemical Company (St. Louis, MO), 
while the plates (highbond 3590) were obtained from Costar (Cambridge, MA). Plates for 
the OVA-specific IgE ELISA were obtained from Greiner Labortechnik (Frickenhausen, 
Germany), monoclonal rat anti-mouse was obtained from Zymed (clone LO-ME-2, 
Oxnard, CA). Blocking reagent and the reagent kit for labeling of OVA with digoxigenin 
(DIG antibody labelings kit) were obtained from Boehringer (Mannheim, Germany).  
Treatment of the mice 
Particle suspensions (4 mg/ml) were prepared in saline and 5% heat inactivated normal 
BALB/C mouse serum. Naïve female BALB/c mice were weekly intranasally instilled by 
pipetting a total volume of 25 µl on the nostrils under halothane anesthesia (weekly dose: 
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100 µg, first dose at Day 1). Sensitization with antigen (Table 1) took place at Day 
1,3,5,7,9,11 and 13 by exposing the mice (n=8-17) to an ovalbumin aerosol (2 mg/ml) for 5 
min, in groups of maximal 6 mice. The aerosol was generated with an ultrasonic nebulizer 
(Medix 8001, particle size 3-5 µm), connected to a plexiglass exposure chamber (5 l). The 
challenge phase consisted of 8 aerosols on consecutive days (Day 34-41). Blood was 
collected by orbita punction under halothane anesthesia at Day 0, 21 and 42, just prior to 
dissection at which also BAL was performed and PBLN, spleen and bone marrow were 
taken out. 
 
 
Table 1: Treatment groups in the inhalatory model (n=8-17). Blood samples were taken at Day 0, 
Day 21 and at the end of the experiment at Day 42. 
 
group Weekly doses Sensitization (day
1,3,5,7,9,11,13)
Boosters (day 34-41)
Positive control - i.p. OVA injections OVA aerosol
Negative control - Saline aerosols Saline aerosols
OVA-control Saline OVA aerosols OVA aerosols
Particle treatment 100 µg of particles in
saline (start: day 1)
OVA aerosols OVA aerosols
OVA -specific IgG1 and IgG2a ELISA 
Plates were coated (o.n. 4oC) with OVA (20 µg/ml) in 0.05 M carbonate buffer pH 9.6, and 
blocked with phosphate buffered saline (PBS) containing 0.05% Tween20 (Brunschwig) 
and 1% bovine serum albumin ([PBS/T/1%BSA], grade V, Sigma) during 1 h at room 
temperature (RT). Serial dilutions of sera were incubated (1 h, RT) and plates were washed 
and incubated with an optimal dilution of AP-conjugated anti-mouse IgG1 or IgG2a (1 h, 
RT), followed by p-nitrophenylphosphate (1 mg/ml in diethanolamine buffer, pH 9.8) for 
30 min. Absorbance was measured at 405 nm. Titers were calculated by means of the 
sample dilution at which extinctions were higher than background+2*SD. Background 
levels at Day 0 were subtracted from Day 21 or Day 42 levels to obtain the increase in 
IgG1/IgG2a.  
IgG1-responders were defined as displaying an increase of >3 titers between Day 21 
and Day 0, and >7 titers between Day 42 and Day 0. IgG2a-responders were defined as 
displaying an increase of >1 titer between Day 21 and Day 0, and >4 titers between Day 42 
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and Day 0. Averages of all animals together (responders and low-responders) were 
calculated.  
OVA-specific IgE ELISA 
Plates were coated (o.n. 4oC) with rat anti-mouse IgE (2 µg/ml) in 0.05 M carbonate buffer 
pH 9.6, and blocked with blocking reagent (Boehringer, 1h, 37oC). Serial dilutions of sera 
were incubated (1h, 37oC), and after washing an OVA-digoxigenin solution (0.01 µg/ml) in 
blocking reagent was added (1h, 37oC). Tetramethylbenzidine-substrate (0.1 mg/ml in 
sodiumacetate buffer pH 5.5) for 20 min, and after stopping the reaction with H2SO4 (2M), 
extinctions were measured at 450 nm. Titers were calculated by means of the sample 
dilution at which extinctions were higher than background+2*SD. The increase in titers 
between Day 42 and Day 0 was calculated. IgE-responders were defined as displaying an 
increase of >2 titers between Day 42 and Day 0. Averages of all animals together 
(responders and low-responders) were calculated.  
ELISPOT assay 
These assays were essentially performed as described previously (Schielen et al., 1995). 
Shortly, PBLN, spleen and bone marrow were minced to prepare single cell suspensions, 
and 0.5*106 cells in 500 µl PBS/1% BSA were incubated (4 h, 37oC) in wells containing 
OVA coated (20 µg/ml, o.n. 4oC) Immobilon-P membranes as bottom. Thereafter, 
membranes were washed and incubated with optimal dilutions of isotype-specific AP-
conjugated anti-mouse Ig antibodies in PBS/T (o.n. 4oC). After washing, spots were 
developed by incubation with 5-bromo-4-chloro-3-indolyl phosphate and nitroblue 
tetrazolium (BCIP/NBT). Specific AFCs per 10*6 cells were calculated from spot numbers 
counted with the aid of a stereo microscope.  
Bronchial alveolar lavage and cell differentiation   
The lungs of the mice were lavaged 3 times with 1-ml aliquots of PBS (37oC). The 
bronchial alveolar lavage was kept on ice until it was centrifuged (1000 g, 5 min). The 
pellet was resuspended in 250 µl of cold PBS. For differential cell counts cytospin 
preparations were made and stained 7 min with May-Grünwald (Merck, Darmstad, 
Germany), and subsequently 7 min with Giemsa staining (Merck). After coding, the 
cytospin preparations were evaluated using oil immersion microscopy. Per cytospin 
preparation at least 200 cells were counted and differentiated into macrophages, 
eosinophils, neutrophils and lymphocytes by standard morphology.  
Statistics 
Preceding statistical analysis, ELISPOT data (the number of AFCs) were transformed to 
log10 values to homogenize variance. Differences between group means were analyzed 
using one-way ANOVA with Scheffe post-hoc test for contrasts (p<0.05 or p<0.01). In 
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case of not sufficient homogeneity of variances, a Kruskal-Wallis ranking test was 
performed (p<0.05).  
 
RESULTS  
 
OVA- specific antibody levels in original i.p. model versus accustomed inhalatory 
model.  
Comparison of the i.p. sensitization model with our aerosol model shows that IgG1 levels 
in blood displayed a slower increase during aerosol exposure resulting in a lower level at 
Day 42 (Fig. 1A). Moreover, a greater variability in response was observed in the aerosol 
group for all isotypes, with the aerosol group containing  both “responders” (62%) and 
“low-responders” (38%). IgG2a levels also increased slower in the aerosol-treated animals 
compared to the i.p. model (Fig. 1B). IgE increased greatly in 88% of the animals after i.p. 
exposure (Fig. 1C). In the inhalatory exposure group, this was only observed in 37% of the 
animals (Fig. 1C). This suboptimal stimulation of the humoral immune response appeared 
suitable for detecting particle adjuvant activity, therefore we proceeded by administering 
100 µg of particles every week to aerosol-exposed animals (following section).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: OVA-specific antibody levels in the original i.p. model compared to the accustomed 
inhalatory model (n=8). Indicated is the percentage of responders. 
A: Increase in IgG1 titers at Day 21 and 42 in i.p. versus inhalatory exposed animals. Responders 
display an increase of >3 titers between Day 21 and Day 0, and >7 titers between Day 42 and Day 0.  
B: Increase in IgG2a titers at Day 21 and 42 in i.p. versus inhalatory exposed animals. Responders 
display an increase of >1 titer between Day 21 and Day 0, and >4 titers between Day 42 and Day 0.  
C: Increase in IgE titers at Day 42 in i.p. versus inhalatory exposed animals. Responders display an 
increase of >2 titers between Day 42 and Day 0.  
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OVA- specific antibody levels, AFC numbers and BAL cells in the inhalatory model 
after weekly particle exposure.  
Hundred µg of particle was administered intranasally weekly during 42 days (total of 6 
doses). Immunoglobulin levels were determined in sera obtained at Day 0, 21, and at the 
end of the experiment at Day 42. All particle-treated groups showed significant increases in 
IgG1 titers (Fig. 2A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: OVA-specific antibody levels in serum and OVA-specific IgG1-forming cells in PBLN in 
CBP, DEP1, SIP and OVA control-treated animals. n=(8-17). Indicated is the percentage of 
responders (A-C). 
A: IgG1 titers at Day 21 and 42 in CBP, DEP1, SIP and control-treated animals. Responders display 
an increase of >3 titers between Day 21 and Day 0, and >7 titers between Day 42 and Day 0. * 
p<0.05, ** p<0.01 vs control.  
B: IgG2a titers at Day 21 and 42 in CBP, DEP1, SIP and control-treated animals. Responders display 
an increase of >1 titer between Day 21 and Day 0, and >4 titers between Day 42 and Day 0. * p<0.05 
vs control.  
C: IgE titers at Day 42 in CBP, DEP1, SIP and control-treated animals. Responders display an 
increase of >2 titers between Day 42 and Day 0. * p<0.05 vs control. 
D: IgG1-forming cells in PBLN at Day 42.  
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At Day 21 these differences were most pronounced compared to the OVA-control group, 
which contained only 37% responders compared to 70-94% in the particle-treated groups 
(Fig. 2A). Also at Day 42 these differences were still significant, but less pronounced 
compared to Day 21 because the number of responders in the OVA-control group increased 
to 63%. IgG2a titers were not significantly increased compared to controls at Day 21, but 
were significantly enhanced at Day 42 for all particle-treated groups (Fig. 2B). IgE 
increased in 37% of the CBP-treated animals as compared to OVA-treated mice, whereas 
only 12% of the SIP-treated and none of the DEP-treated animals showed an enhanced IgE 
response (Fig. 2C).  
No antibody forming cells were detected in spleen and bone marrow (not shown). 
Statistically not significant increases in IgG1-AFC numbers were observed in PBLN (Fig. 
2D). No effects on composition of BAL fluid were found. 
 
DISCUSSION   
 
The present study intended to develop a model in which the immunomodulatory capacity 
of different components of PM could be tested after inhalatory antigen exposure. For this 
purpose, we modified an existing allergy model in the mouse (Hessel et al., 1995) by 
replacing all i.p. OVA injections by aerosol exposures. As expected, in this new, 
completely inhalatory model average antibody levels did not increase to levels as high as 
after i.p. exposure. Remarkably, the inhalatory exposed animals showed a large variation in 
antibody titers; either animals responded with a large antibody increase (responders), or 
they hardly showed any antibody levels (low-responders). Since no intermediate 
responding animals were observed, animals could be divided into responding and low-
responding animals. The inhalatory treatment appeared to be suitable for detecting adjuvant 
activity of particles. In the groups treated weekly with particles, it became clear that the 
different particles all displayed adjuvant activity on the humoral response. Not only did 
more animals per group respond, they also showed higher IgG1 and IgG2a levels compared 
to the OVA-controls. IgE increased in 37% of the CBP-treated animals.  
In an intranasal exposure model (van Zijverden et al., Chapter 4) we tested the same 
3 types of particles and their effects on the immune response to a protein antigen (TNP-
OVA). In this intranasal model, SIP displayed less pronounced adjuvant activity, IgG2a 
responses were in general less pronounced, and in addition to CBP also DEP stimulated 
IgE production. Moreover, inflammatory cells were found to infiltrate the lung, 
significantly elevated IgG1-AFC in PBLN were detected, and variations within each 
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treatment-group were not as pronounced as in the present inhalatory model. It is hard to 
directly compare the results from the intranasal and the inhalatory models since treatments 
differ greatly. However three factors can be appointed that possibly play a role in the 
observed differences. First, the role of the relative times of particle and antigen exposure 
has been shown in the intranasal model (van Zijverden et al., Chapter 6) by comparing 
simultaneous and separate administration of antigen and particles. We showed that 
administration of particles one day before antigen was less effective in inducing IgE and 
IgG1-AFC compared to coadministration, indicating that particle adjuvant activity involves 
time-dependent processes. Although others (Lambert et al., 1999) show that intranasal 
administration of residual oil fly ash particles 1 day before antigen is also effective in 
adjuvating the immune response, altogether adjuvant activity appears to be lower with 
increasing time between particle and antigen administration (Granum et al., 2000a). This 
was also shown for a gaseous pollutant (NO2) by Siegel et al., 1997.  
 Second, in addition to separate times of administration, in the present inhalatory 
model antigen and particles were administered via different methods of administration 
(respectively inhalatory and intranasal). This may further reduce the chance of antigen 
deposition in close proximity of the particles, thereby decreasing the impact of the particle-
induced inflammation on the immune response to the antigen. Third, the inhaled antigen 
dose is hard to control in whole body exposure and may not have been optimal in this 
model, indicated by the decreasing differences in IgG1 between controls and particle-
treated animals after Day 21. In addition, the amount of antigen entering the whole body-
exposed animal via the oral route, and the effect on possible tolerance induction, is 
unknown.  
In real life, subjects may be exposed to both complexes of antigen and pollutant 
(Behrendt et al., 1992, Ormstad et al., 1998) as well as antigen and pollution at distinct 
time points. For the latter situation, this model appears to reflect real life fairly well, by 
showing that the number of animals responding with a humoral immune response increases 
when animals receive particle administrations in addition to antigen exposure. However, 
for studies on the mechanism of particle adjuvant activity and hazard identification, a 
simple and reliable intranasal model (van Zijverden, Chapter 4-6) may be more suitable 
than a model employing whole body, inhalatory antigen exposure route.  
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Introduction  
 
The prevalence of respiratory allergy is increasing (Schäfer and Ring 1997, Lundbäck 
1998, Beasley et al., 2000). This increase appears to be correlated to Westernization and/or 
urbanization of countries. However it is unknown which factor in Western lifestyle is 
responsible. In general, factors concerning (patterns of) “infection” and “other factors in 
Western lifestyle” can be distinguished (Fig. 3 General Introduction). So far, vaccination 
against highly infectious airborne viruses has often been suggested to stimulate the 
development of allergy (Cookson 1997), but contradictory results have been found. Going 
through orofecal and foodborne infections appears to reduce the risk of allergy (Matricardi 
et al., 2000). Hence “infection” appears to be a heterogeneous gathering of infections 
belonging to different subgroups, which need to be distinguished since they display distinct 
effects on the development of allergy. A similar distinction appears to be necessary in the 
air pollution theory. Air pollution is a heterogeneous mixture of gaseous (NO2, SO2, O3) 
and particulate pollutants (particles from innumerable different sources). Although for a lot 
of compounds (NO2, O3, PM) a role in the aggravation of existing respiratory allergy is 
obvious, contradicting results are found in epidemiological studies on whether a high level 
of pollution also causes increased prevalence. The presence of mixtures complicates 
matters, making the effects of separate pollutants impossible to discern. Moreover, 
substances in the mixture may not all have different modes of action but rather show 
additive, antagonistic, or synergistic effects.  
For all theories, from infection to pollution, the most important gap in the 
knowledge concerns the mode of action. For particulate air pollution inflammation appears 
to be crucial for adjuvant activity. A number of factors, ranging from particle shape (e.g. 
fibrogenous SIP) to surface charge (Oortgiesen et al., 2000), appear to be involved in the 
capacity of particles to cause inflammation. Since the mechanisms of particle adjuvant 
activity are largely unknown, our aim was to develop an (animal) model in which 
immunomodulation could be determined, and mechanisms could be studied. In the 
following paragraphs the different in vivo and in vitro models used in this thesis to evaluate 
adjuvant activity of particles are summarized.  
 
Summary of results 
 
In Chapter 2 a modification of the reporter antigen PLNA ([RA-PLNA] Albers et al., 
1997) was introduced. This model is relatively simple to perform, control and read out. 
After injection of 1mg of particle and 10 µg of antigen in the hind paw, different aspects of 
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the immune response can easily be determined in the draining popliteal lymph node. Our 
results indicate that different components of particulate matter, DEP, CBP and SIP, are all 
able to act as adjuvant in the immune response to the reporter antigen TNP-OVA. 
However, the different particles stimulate different types of immune responses to the same 
antigen. At Day 2 and 5 after injection the increase in the Th2-related cytokine IL-4 is 
largest for CBP and DEP compared to SIP and control. Intranasal challenge with the 
reporter antigen after subcutaneous sensitization in the hind paw allows for assessment of 
the immune response in lungs, bone marrow and spleen, indicating that systemic 
immunosensitization has occurred. The isotype patterns (based on serum levels and AFC in 
PBLN, bone marrow, spleen and PLN) observed after the intranasal challenge approach are 
indicative of a type 2 response after DEP exposure, whereas SIP induce more a type 1 
response and CBP stimulate a mixed response to TNP-OVA.  
In Chapter 3 the in vitro effects of the various types of particles (DEP from various 
sources, SIP, CBP) on alveolar macrophages were assessed. All particles except DEP3 
cause cell damage and they all induce a decrease in phagocytic activity of the 
macrophages. TNFα production is enhanced in a dose-dependent way in response to 
particles. IL-1β and IL-6 are only measurable after LPS prestimulation. In this in vitro 
model, DEP from different sources do not stimulate the same response (as was also found 
in vivo in Chapter 4-6). DEP1 stimulate more LDH release and TNFα production, whereas 
DEP3 block phagocytosis more effectively. Because they are both of similar size, we 
addressed the question whether a difference in surface chemical composition may cause 
such changes. Pre-exposure of DEP3 to O3 for more than 1 hour causes an increase in 
TNFα production, indicating enhanced immunomodulating capacity, and complete 
blockage of phagocytosis. Overall, it can be concluded that the different particles clearly 
modulate crucial macrophage functions. There appears to be no correlation between the 
different processes of inducing cell damage, blocking phagocytosis, and the production of 
proinflammatory cytokines in response to particle exposure. In addition, ozone-exposure of 
DEP appears to be able to enhance immunomodulating capacity of DEP.  
A disadvantage of in vitro models is the fact that possibly important interactions 
between different cell types cannot be determined. The in vivo injection model, as 
presented in Chapter 1, also has a major drawback: it does not involve the real life route of 
exposure. To circumvent the disadvantages of in vitro and injection models, we developed 
a simple model using the relevant route of exposure. In Chapter 4 a model was presented 
in which the antigen and particle were administered via the intranasal route. In this model 
both sensitization (Day 1-3) as well as challenge (Day 10) take place intranasally. Particles 
are co-administered with the antigen during the 3-day sensitization. At Day 15 
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immunoglobulins in blood and AFC in draining lymph nodes of the lung (PBLN) are 
determined, and leukocyte distribution in BAL is assessed. In this model CBP adjuvate the 
response most clearly, followed by DEP1, DEP2 and finally SIP which hardly adjuvate at 
all. The order of magnitude of these responses, which appear to be mostly Th2-mediated, 
for the different particles roughly resembles that seen in Chapter 2 and 3. The effect of an 
extra challenge with TNP-OVA (Day 17) in animals which received CBP during 
sensitization, results in even more pronounced immunoglobulin production and lung 
infiltrates at Day 22 compared to Day 15, stressing the persistent character of the particle 
adjuvant activity. Macrophages containing particles are still present in BAL at Day 22. The 
fact that the carbonaceous particles (CBP, DEP) are able to adjuvate sensitization to an 
antigen indicates the increased risk of sensitization to allergen for naïve subjects who are 
exposed to particulate matter.  
In Chapter 5 we used the intranasal model to further determine the effect of particle 
exposure during different phases of the immune response. From this chapter it can be 
concluded that administration of particles with antigen during both sensitization and 
challenge is most effective in adjuvating the immune response, whereas administration 
exclusively during sensitization is almost equally effective, and instillation exclusively 
during challenge hardly adjuvates the immune response. Exposure to particulate air 
pollution during both sensitization and challenge results in optimal adjuvation of an 
immune response to a co-administered antigen.  
In Chapter 6 we determined whether co-administration of antigen and particles is 
actually crucial for adjuvant activity. It appears that simultaneous administration of three 
small doses (67 µg) and antigen is most effective in adjuvating the immune response. One 
large co-administered dose (200µg) is also capable of adjuvating the immune response, but 
no IgE production is induced. Moreover, also particles that are separately administered one 
day before the administration of antigen are able to act as adjuvant. However, particles 
administered one day after antigen administration do not adjuvate the immune response. 
Altogether, coadministration emerges as the most effective way to adjuvate an immune 
response in our model. It appears that the immune response can be modified by the relative 
times of particle and antigen exposure.  
In Chapter 7 we determined whether the immune response after inhalation of an 
antigen aerosol could be adjuvated by intranasal particle administrations. Although 
adjuvant activity is detectable in this model, it is not accompanied by lung infiltrate as in 
the intranasal model. This may firstly be caused partly by the fact that antigen and particles 
are not simultaneously administered. Secondly, different methods of exposure are used for 
particles and antigen (intranasal and inhalatory respectively), thereby possibly inducing 
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distinct deposition patterns. Since inflammation causing adjuvant activity is a time-
dependent process, this model may not provide optimal exposures.  
 
Different routes, different effects  
 
Different types of particles are obviously able to stimulate an immune response to antigen. 
However, they behave differently after administration via different routes. The responses in 
the intranasal model do not show the Th1/Th2 modulation as seen after injection (Chapter 
2), but rather involve variations in strength of the Th2 response. The inhalation model, in 
turn, shows mixed responses for all types of particles.  
At least two things may cause differences between the effects of injected particles 
and particles administered via the respiratory tract. Firstly, different responses may be a 
result of distinct deposition and retention patterns. Secondly, different cell types are present 
in skin versus lung, resulting in different biological responses. This is also illustrated by 
distinct default reactions in both organs, respectively Th1 in skin and Th2 in lung 
(Constant et al., 2000). In this thesis, route differences are for example demonstrated by 
SIP that adjuvate mainly IgG2a production in the injection model (Chapter 2), whereas 
after intranasal administration (Chapter 4-5), SIP induce predominantly IgG1. Injection 
causes SIP to stay present subcutaneously for a long time (unpublished observation), 
possibly stimulating an ongoing cellular inflammatory response resulting in a high level of 
IgG2a. The fact that injection causes this kind of effects, emphasizes the limitation of this 
artificial route of administration. Irrespectively however, injection of particles using the 
RA-PLNA can be regarded as a simple prescreening tool for hazard identification of 
different particles. Apart from this possible application of the RA-PLNA, it is evident that 
more mechanistical research requires animal models employing the respiratory tract as 
route of exposure.  
 
Usefulness and relevance of the intranasal model  
 
With respect to the applicability of our relevant route of exposure models, it is important to 
consider the dose of particles used and compare it with human exposures. However, a 
direct comparison is impossible to make, since intranasal instillation of particles in a fluid 
matrix leads to unknown differences in deposition compared to real life particle inhalation. 
In the intranasal model, a particle dose of 67 µg per day is administered to the mice. In 
humans a 1-day stay in Los Angeles has been estimated to lead to a total exposure of 100 
µg of particles (Saxon and Diaz-Sanchez 2000). This rough comparison shows that in our 
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model we are dealing with relatively high doses. Nevertheless, present studies (Chapter 4-
6) demonstrate the usefulness of our intranasal model in mechanistical studies. Moreover, 
as it is also relatively simple to perform, apparently more robust than the inhalatory model, 
and allows grading of different particle adjuvant activities, the intranasal model seems to 
be advantageous over the inhalatory model at this moment (Chapter 7).  
 
Relevance of in vitro studies 
 
In vitro studies can give additional information on the exact response of a single cell type 
to a certain particle. The order of the potency of particles to induce production of 
proinflammatory cytokines, especially TNFα (CBP>DEP1>DEP3>SIP), in alveolar 
macrophages (Chapter 3) coincides with the strength of their adjuvating capacity in our in 
vivo intranasal model (Chapter 4-6). This, together with the fact that TNFα has been 
appointed as crucial in a comparable intranasal model of particle exposure (Lambert et al., 
2000a), suggests that TNFα production by alveolar macrophages represents an important 
determinant of adjuvant activity in vivo. In addition to the TNFα-driven mechanism, the 
severe decline in phagocytic capacity of the macrophages as observed in vitro may be 
relevant for  the adjuvant capacity of particles in vivo. As a result of decreased phagocytic 
activity of alveolar macrophages, co- or subsequently administered antigen may escape 
uptake and/or degradation by these macrophages. As a result, a larger quantity of antigen 
may contact immune cells (such as interstitial DC). In addition, effects on the suppressive 
activity of the alveolar macrophage can not be excluded. In all, these in vitro studies 
suggest an important role for the alveolar macrophage, as it may contribute to a cytokine-
rich environment and enhanced antigen presentation by DC.  
  
Particles  
 
In addition to variations in adjuvant activity caused by different routes of exposure, 
differences between particles are also observed within the same model. Overall, CBP 
display the strongest adjuvant activity in the intranasal model, and SIP the weakest 
(Chapter 4-5). In vitro measurements of TNFα production in macrophages also indicate 
this order of strength (Chapter 3). DEP from different sources show distinct adjuvant 
activities. Also completely different types of particles, from ROFA (Lambert et al., 1999) 
to polystyrene particles (Granum et al., 2000a), are able to adjuvate an immune response. 
Cellular and molecular effects of particles are still incompletely understood, but may be 
very complex. Moreover, which particle characteristics are crucial in determining the 
immunomodulatory potential is unknown (Fubini et al., 1997).  
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Crucial particle characteristics  
 
The differential roles of possible crucial particle characteristics (a random list is given in 
Table 1) such as size, surface area, charge and attached substances, are hard to determine. 
This is firstly due to the fact that these crucial particle characteristics are not independent 
of one another. An experimental set-up to determine the effect of smaller size causes a 
simultaneous increase in total surface area and number of administered particles. 
Correcting for these changes by maintaining a constant number causes a subsequent 
decrease in total weight of the administered dose, etc.  
 
Crucial particle characteristics 
Core Attached substances 
Size 
Surface area 
Charge 
Shape 
Number 
Weight 
Absorption capacity 
Chemical composition 
Oxidizing potential 
Metals  
Endotoxin 
 
Table 1: Different particle characteristics that play a role in adjuvant activity 
 
Secondly, the importance of any particle characteristic for adjuvant activity is not constant 
over the entire process of respiratory sensitization. The different processes that play a role 
are depicted in Figure 1. From pre-exposure to exposure phase, and from retention on to 
effector phase, several mechanisms are at work, and many particle-cell interactions are 
involved. For these different phases, distinct particle characteristics can be appointed as 
crucial (Fig.1). The importance of every single particle characteristic can preferably be 
determined experimentally for the different phases, rather than for the complex 
immunosensitization process as a whole. For the pre-exposure phase, adsorption capacity is 
a crucial characteristic, determining the amount of substances that can become attached. In 
the exposure phase, weight as a conventional determinant of dose may preferentially be 
replaced by number, surface area or size (Granum et al., 2000b, Fubini et al., 1997). In 
determining site of deposition, size is a crucial characteristic. Particles smaller than 2.5µm 
are able to reach the conducting airways and the alveolar region (Anderson et al., 1988).  
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to the particles
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Deposition
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Translocation
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Retention  (= deposition – clearance)
Biological Changed phagocytosis
Response macrophage cytokines
B cells General cytotoxicity Epithelium cytokines
barrier
allergen
availability for
interstitial DC
“Changed Microenvironment”
Pre-exposure
Phase
Exposure
Phase
Deposition and
Retention
Phase
Effector
Phase
size
surface area
hydrophobicity
biodurability
size
surface area
number
adsorption capacity
adsorption capacity adsorption capacity
surface area
surface area
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Figure 1: “Changed Microenvironment” 
In time, distinct phases can be distinguished in the process leading to a changed microenvironment. 
In the pre-exposure phase, the adsorption capacity of a particle is crucial in determining whether or 
not the particle becomes a carrier (see text) of either chemicals or allergens. In the exposure phase, 
the dose is usually expressed as weight, but as weight is closely related to number, surface area and 
size, these are equally or even more important determinants of dose. In the deposition and retention 
phase, one of the main characteristics determining the pattern of deposition is size, whereas in 
addition surface area, hydrophobicity and biodurability are important in determining final retention. 
In the effector phase, many particle characteristics are involved in determining the reponse of 
different cell types. Of special interest are macrophages (see text), because they play a role in 
clearance of particles (and antigen) by means of phagocytosis, and in addition produce cytokines.  
Resuming, cytokines and cell damage together lead to inflammation. Inflammation on its turn leads, 
together with altered macrophage function and greater allergen availability, to a change in allergen 
responsiveness, ultimately possibly resulting in respiratory allergy.  
Italic = mechanism as described in text 
Underline = crucial particle characteristic 
 
 
They stay present for a long time and are therefore in general considered more toxic than 
larger particles (Churg and Brauer 1997, Ferin et al., 1992, Svartengren et al., 1987).  
Final retention (deposition minus amount cleared), on its turn, is determined by numerous 
particle characteristics such as size, surface area, number, mass and hydrophobicity 
(Oberdörster et al., 1994). Depending on the biological response process that is studied, 
one or a few particle characteristics can be regarded as most relevant. For (inhibition of) 
phagocytosis by macrophages for example, size and surface area (including attached 
substances) may be decisive (this thesis, Oberdörster et al., 1994), whereas in addition 
number may be a crucial particle characteristic for subsequent activation (Fubini et al., 
1997). B cells are known to be affected by attached chemicals as present on DEP (Tsien et 
al., 1997), indicating that for non-phagocytic cells especially surface characteristics 
causing general cytotoxicity may be important.  
 
Particles as carriers 
 
Adsorptive capacity is a particle characteristic that is crucial in the pre-exposure phase. 
Burning of fossil fuels produces both particles and chemicals, and depending on the type of 
particle the chemicals adsorb to the particles. Especially carbonaceous particles are known 
for their high adsorptive capacity, turning the particles into exquisite carriers. The capacity 
of particles to carry chemical substances is largely dependent on the surface characteristics 
of the particle, especially the material (e.g. silica versus carbon) and the micromorphology 
(smooth versus cavity-rich). The fact that particles lacking attached substances, such as 
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CBP, SIP (this thesis) and PSP (Granum et al., 2000b) are able to adjuvate the immune 
response shows that characteristics of the particle core are important. Løvik et al. (1997) 
show in the PLNA that CBP were only slightly less potent than DEP in inducing an 
inflammatory response and systemic IgE to ovalbumin. However, both attached chemicals 
and metals (Lambert et al., 2000b) are known to contribute significantly to the adjuvant 
capacity of particles. Diaz Sanchez et al. (1997b) shows that polyaromatic hydrocarbons 
(PAH) enhance ongoing IgE production, but not de novo synthesis. In addition to these 
quantitative effects, PAH also qualitatively alters the affinity of the IgE produced. 
Therefore attached chemicals seem to enhance the inflammatory potential of the particles, 
and modulate the nature of the adjuvant activity. Similar conclusions are drawn by 
Takenaka et al. (1995) and Tsien et al. (1997) from in vitro studies. Also the results 
presented in this thesis indicate that attached substances may play a role. The slight 
differences in character of the immune response induced by CBP and DEP (for example 
Chapter 2) and the differences between DEP from different sources (Chapter 3-5) may 
partly be caused by the modulating capacity of PAH. In Chapter 3 we show that DEP 
exposed to O3 cause an increased TNFα release by alveolar macrophages. Increased 
toxicity of ozone-exposed DEP is also observed in vivo, and ozonation reaction products 
present on DEP are held responsible, because ozone-exposed CBP do not show altered 
toxicity (Madden et al., 2000). Moreover, adsorbed chemicals influence surface 
characteristics such as charge, differences in which possibly modify cytokine responses of 
epithelium via the capsaicin receptor (Veronesi et al., 1999). In a pilot in vivo experiment 
we observed slight differences between the adjuvant activity of negatively charged 
polymeric particles versus neutral ones (unpublished observation). However, in our in vitro 
model we observed that this charge difference did not influence phagocytosis or cytokine 
production by macrophages (unpublished observation).  
A distinction can be made between carrying chemical substances and (protein) 
antigens. Whereas attached chemicals and metals add to the inflammatory capacity of the 
particle, carrying antigens may have quite different effects.  Binding of allergen to (ultra) 
fine particles like DEP in outside air (Ormstad et al., 1998) would concentrate the allergen 
on particles of respirable size (Knox et al., 1997). This may facilitate subsequent deep 
deposition into the lungs, where the mucus escalator is not readily able to remove them. 
The fact that in our in vivo experiments (Chapter 4-5), the smallest (<1 µm), carbonaceous 
particles adjuvate the immune response better than SIP (1-5 µm) seems in line with this 
idea. However, co-administration of antigen and particles is not a prerequisite for adjuvant 
activity (this thesis, Lambert et al., 1999, Granum et al., 2000a). Finally, chemicals present 
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on particles may be involved in the modification of attached allergen (Behrendt et al., 
1992, 1997), possibly making the allergen more immunogenic.  
 
Particula(r)(te) mechanisms of immunomodulation  
 
In the effector phase (Fig.1), particles interact with different types of cells. In the next 
paragraph, the effect of particles on macrophage function is addressed. Thereafter, an 
overall mechanism of particle adjuvant activity is proposed.  
 
Changed macrophage function  
 
The alveolar macrophage belongs to the first line of defense in the lung, phagocytizing and 
degrading foreign bodies after deposition. Phagocytosis is severely impaired in alveolar 
macrophages after particle exposure (Chapter 3). In vivo this impairment of phagocytosis 
has already been demonstrated in macrophages in which ultrafine particles occupied only 
2.6% of the cell volume (Oberdörster et al., 1994). This decreased phagocytosis possibly 
causes antigen to escape degradation, thereby prolonging antigen presence and availability 
for cells of the immune system to mount a response.  
In addition to their innate functions, macrophages also produce cytokines and other 
factors directly influencing adaptive immunity. For example T cells and DC are suppressed 
by macrophages (Holt 1993, Poulter 1994, Strickland 1996). In the PLN, macrophages 
have been shown to suppress the systemic immune response to a sc injected antigen, and 
deletion of these macrophages increases the number of AFC in the spleen (Delemarre et 
al., 1990). Also in the lung depletion of macrophages has been shown to increase IgE 
synthesis (Thepen et al., 1992). A decrease in suppressor activity has been suggested to be 
responsible for these effects. It is unknown whether exposure to particles affects suppressor 
activity, but the inflammatory microenvironment after entrance of particles may contribute 
to a breakdown of suppressive activity. The presence of GM-CSF for example has been 
shown to disrupt this suppression (Bilyk and Holt 1993, Holt 1996), and TNFα, a major 
proinflammatory cytokine produced by alveolar macrophages, has been shown to be 
crucial in the adjuvant activity of ROFA (Lambert et al., 1999). TNFα is known to act as a 
trigger for the upregulation of several cytokines and adhesion molecules by means of 
NFκB activation in the lung, leading to inflammation (Lentsch et al., 1999). These results 
suggest that the combination of a decrease in suppressor activity and an increase in 
production of proinflammatory cytokines by macrophages play an important role in particle 
adjuvant activity.  
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Changed microenvironment: proposed mechanism 
 
Crucial processes in each of the described phases (Fig.1) contribute to what we call a 
“changed microenvironment in the lung”.  In short, in the pre-exposure phase particles 
interact with allergens and chemicals, and depending on their adsorption capacity they 
become carriers. During the exposure phase, weight, number, and total surface area are 
possible determinants of dose. These characteristics are strongly linked to size, the main 
characteristic determining the deposition pattern after dosing by inhalation. Small-sized 
particles are able to penetrate the epithelium and enter the interstitium, which is 
hypothesized to be crucial for inflammation (Oberdörster et al., 1992). In addition, other 
characteristics such as charge and hydrophobicity may also influence deposition and 
translocation. Once deposited and retended, a biological response can take place. Particles 
carrying reactive chemicals as a consequence of their adsorption capacity, or particles 
having a reactive surface area by any other cause, can have cytotoxic effects on every cell 
present. Epithelium and macrophages make up the largest part of cells in the lungs, and are 
clearly affected. Both cell types produce cytokines in response to particle presence, and 
apart from macrophages, also epithelial cells take up particles (Steerenberg et al., 1998). 
Cytotoxicity may negatively affect the barrier formed by the epithelium, causing nerve 
endings to be revealed and more allergen to cross the epithelial lining and contact for 
example DC. The decreased phagocytosis and suppressor capacity, together with increased 
production of proinflammatory mediators, may contribute to increased antigen presentation 
by DC. Central factors in the changed microenvironment are inflammation (cytokines, cell 
damage, nerve endings, infiltrating cells), allergen availability and changed macrophage 
(see previous paragraph) and APC function, which together could theoretically lead to a 
change in allergen responsiveness and development of respiratory allergy.  
  
Future directions  
 
A large amount of research remains to be performed on particle (immuno) toxicity. Several 
areas of interest can be indicated by means of Figure 1. Firstly, more knowledge is needed 
on the pre-exposure phase. Particles can interact with other substances, ranging from 
allergens to other pollutants, and too little attention is given to the particle acting as 
carriers. Carrying allergens does not only occur in obvious circumstances such as during 
pollen season with a simultaneous smog period. Also indoors, where fine particle 
concentrations are comparable to outdoor air, particles have been shown to carry allergens 
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(Ormstad et al., 1998). The attached allergens have been shown to be of (sub) micronic 
size and display altered allergenicity (Emberlin 1995), which may be caused by interaction 
with other air pollutants. Also the interaction of the attached chemicals present on particles 
with other pollutants like O3 is still a largely unexplored area, despite the fact that 
experimental and epidemiological studies showing the simultaneous effects of components 
in a mixture give rise to concern (Hoek et al., 1997). In experimental studies the modes of 
action of different pollutants and emerging additive and synergistic effects on sensitization 
have to be determined. This would enable epidemiological exposure data of different 
pollutants to be added up in order to obtain a total personal dose.  
Secondly, a more appropriate way to assess particle exposure dose may not be by 
measuring the usual ”weight per m3”, but rather determine the number and size (Peters et 
al., 1997), the two main determinants of total surface area. The exact influence of size, 
number and surface area on final retention is incompletely known, but may experimentally 
be determined by means of in vivo experiments with artificial particles such as polystyrene 
particles. They can be produced possessing all kinds of specific chemical and physical 
characteristics. This approach may result in a complete understanding of dosing, deposition 
and translocation leading to a computer model on particle kinetics, which can be applied to 
predict retention for every kind of environmental particle.  
To determine whether a certain particle really poses a threat to human health, 
probably the most complex problem is determination of the biological response. This can 
be performed by a combination of in vitro and in vivo studies. For in vitro tests a critical 
endpoint parameter has to be defined which has been shown relevant for the in vivo 
situation. And therefore more knowledge is necessary on biological mechanisms of particle 
interaction with the different cell types in the lung. For example, do cytokines produced by 
epithelium actually contribute to the inflammatory response in the lung, or is break-down 
of its barrier function more crucial, preventing antigen to enter and causing sensory nerve 
ends to be exposed. Influence of particles on barrier function, but also the role of sensory 
nerves producing neuropeptides deserve more attention. In a comparable way different 
functions of the macrophage can be weighed. In addition to the production of regulatory 
substances, more attention should be given to the mechanism by which macrophages 
phagocytize particles. Implications of the fact that different mechanisms are  used for 
different particle types (Kobzik 1995) are unknown. Tests with artificial particles may 
indicate which particle characteristic is crucial in influencing the most important cell 
functions. Simultaneously, in vivo tests are to be performed, both to determine the 
relevance of the in vitro findings, and to give overall mechanistical information. Cytokine 
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intervention studies, macrophage depletion studies, and different knockout mice can give 
highly necessary information.  
Joined forces on elucidating pre-exposure interactions and dose measurement, 
supplemented with computer modeling for deposition, and knowledge on crucial particle 
characteristics for particle-cell-interactions, may ultimately lead to a situation in which 
determining the main characteristics of an unknown particle can be used for hazard 
identification.  
 
Concluding remarks  
 
The findings described in this thesis give further evidence for the hypothesis that the 
increased presence of DEP and similar airborne pollution may cause those with the 
appropriate genetic predisposition to become sensitized to allergens to which they may not 
otherwise have become sensitized. Coexposure to allergen, particulate air pollution and 
complexes of particles with (possibly altered) allergen contributes to this increased risk of 
sensitization. The intranasal model described in this thesis may substantially contribute to 
determination of sensitizing and adjuvating potential of unknown particulate pollutants, 
and the further elucidation of mechanisms of adjuvant activity. Moreover, in combination 
with chemical analysis of particles and epidemiological data, it may play an important role 
in hazard identification, dose-response determination, and ultimately risk assessment of 
PM. 
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Samenvatting  
 
Allergische aandoeningen van de luchtwegen zoals hooikoorts komen steeds vaker voor. 
Bij allergie wordt een immuunreactie (= een reactie van de afweer) die normaliter tegen 
ziekteverwekkende organismen optreedt, ingezet tegen een “onschuldig” eiwit: het 
allergeen. Bekende allergenen zijn pollen van gras en bomen, huidschilfers van kat en 
andere huisdieren en de uitwerpselen van huisstofmijt. De toename van allergie beperkt 
zich tot westerse landen en landen met een vergelijkbare levensstijl. Dit geeft aanleiding tot 
veel epidemiologisch onderzoek naar aan levensstijl gerelateerde factoren die de afgelopen 
tientallen jaren veranderd zijn en mogelijk een cruciale rol spelen in het ontstaan van 
allergie, alsook. Dit is erg lastig onderzoek, aangezien de mens vanaf de conceptie al 
blootstaat aan ontelbare omgevingsfactoren. Zo levert onderzoek in voormalig Oost 
Duitsland zowel voor als na de hereniging veel informatie over allergie in een samenleving 
die “verwestert” . Ook onderzoek in gemeenschappen die qua levensstijl op een aantal 
punten duidelijk verschillen van de omringende westerse samenleving (bv. 
antroposofische) levert veel kandidaatfactoren. Deze kunnen grofweg worden ingedeeld in 
de categorieën infecties, dieet en luchtvervuiling. De eerste categorie is gebaseerd op het 
idee dat een verminderde blootstelling aan infecties het ontstaan van allergie zou 
bevorderen. Epidemiologisch onderzoek toont aan dat oudste kinderen, in het bijzonder van 
kleine gezinnen, vaker allergisch zijn. Dit geldt ook voor kinderen die niet naar de crèche 
gaan of door een andere reden weinig in contact komen met leeftijdgenoten. Jongere 
gezinsleden en crèchegangers daarentegen staan vanaf zeer jonge leeftijd vaker bloot aan 
onschuldige kinderziektes, wat hen zou beschermen tegen allergie. Ook wordt er met een 
beschuldigende vinger gewezen naar vaccineren tegen kinderziektes, maar op dit vlak 
bestaan veel tegenstrijdige onderzoeksresultaten. Een recent Italiaans onderzoek toont aan 
dat het doormaken van onschuldige infecties gerelateerd aan voedsel en hand-mond gedrag 
gecorreleerd is aan een kleinere kans op allergie. Dit geldt daarentegen niet voor ernstige 
infecties waartegen ingeënt wordt, zoals mazelen en de bof.  
De tweede categorie factoren betreft ons eten. Onder andere de vetsamenstelling van 
ons “westerse” dieet is de laatste decennia erg veranderd, wat mogelijk onze afweer-
reacties (waaronder allergie) beïnvloedt. Ook de samenstelling van onze darmflora 
verandert mee. Zo hebben kinderen uit Estland een andere darmflora dan Zweedse 
kinderen, die in vergelijking vaker allergisch zijn. Naast infectie-patroon en dieet vormt 
luchtvervuiling de derde categorie. De “klassieke” luchtvervuiling in het voormalige 
Oostblok maar ook bijvoorbeeld in veel ontwikkelingslanden bestaat uit roet en 
zwaveldioxide. Dit in tegenstelling tot de vervuiling in westerse landen waarin gassen als 
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stikstofdioxide en zeer fijne deeltjes (met een grootte van enkele micrometers tot veel 
kleiner) voorkomen. Fijne deeltjes in de lucht zijn afkomstig van verschillende bronnen, 
zowel natuurlijke (vulkanen, aardkorst, zeezout) als antropogene (industrie, verkeer). Zeer 
veel onderzoek wordt bijvoorbeeld gedaan naar de extreem fijne deeltjes die door 
dieselmotoren worden uitgestoten, en die vooral in westerse steden een belangrijk deel 
vormen van de luchtvervuiling. Dit blijft een actueel probleem aangezien de nieuwere 
dieselmotoren wel minder gewicht aan deeltjes uitstoten, maar dat deze reductie alleen de 
grotere deeltjes betreft, terwijl de kleinste deeltjes de lucht in blijven vliegen.  
Deze fijne deeltjes en hun rol in het ontstaan van luchtwegallergie staan centraal in 
het onderzoek dat beschreven is in dit proefschrift. Terwijl van deeltjes al wel bekend is dat 
ze de symptomen van reeds bestaande allergie verergeren, staat nog niet vast dat deeltjes 
ook allergie veroorzaken in mensen die voorheen nog niet allergisch waren. Onze 
hypothese was dat in niet allergische mensen blootstelling aan deeltjes kan leiden tot het 
ontstaan van allergie tegen een willekeurig allergeen uit hun omgeving. Daarom was het 
doel van dit onderzoek een (dier- of cellijn-) model te ontwikkelen waarin de modulerende 
en/of stimulerende (=adjuvant) invloed van deeltjes op het ontstaan van allergie gemeten 
kan worden. Bovendien zou in dit model het achterliggende mechanisme onderzocht 
kunnen worden. In het hier beschreven onderzoek worden verschillende soorten 
dieseldeeltjes (DEP) vergeleken met koolstofdeeltjes (CBP) en silica deeltjes (SIP). Silica 
is een belangrijke component van de aardkorst en dus ook van opwaaiend stof en mijnstof. 
Dieseldeeltjes bestaan uit een koolstofkern waaraan allerhande chemicaliën geadsorbeerd 
zijn die tijdens de verbranding vrijkomen. Koolstofdeeltjes hebben eenzelfde soort kern 
maar bevatten geen aanhangende chemicaliën.  
In het eerste experimentele hoofdstuk (Chapter 2) is getest of de verschillende 
modeldeeltjes DEP, CBP en SIP de immuunreactie tegen een willekeurig allergeen kunnen 
beïnvloeden (de allergische respons is altijd gericht tegen een allergeen en niet tegen de 
deeltjes). Hiertoe zijn de deeltjes samen met een allergeen ingespoten in de poot van 
muizen. Het inspuiten van het allergeen zonder de deeltjes gaf geen meetbare 
immuunrespons, evenmin als de deeltjes op zichzelf. Wanneer ze echter samen werden 
toegediend was er wel een duidelijke immuunrespons te meten: de deeltjes fungeerden als 
adjuvant. De eigenschappen van die immuunrespons bleken enigszins afhankelijk van welk 
type deeltje er werd meegespoten. Behalve stimulatie was er dus ook sprake van 
differentiële modulatie.  
In Chapter 3 hebben we bekeken of de deeltjes het functioneren van de macrofaag, 
de belangrijkste “opruim” cel in onze longen, in vitro (= in de reageerbuis, tegengesteld 
aan in vivo = in een levend organisme) beïnvloeden. Het bleek dat macrofagen werden 
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beschadigd door de deeltjes en hun capaciteit om deeltjes op te nemen (en zo op te ruimen) 
verminderde. Bovendien produceerden ze tijdens blootstelling aan de deeltjes stoffen die 
een ontsteking bevorderen. De modulatie van deze essentiële macrofaagfuncties speelt 
mogelijk een rol in de ontwikkeling van allergie.  
De vorige twee hoofdstukken gaven aanleiding tot vermoedens over een mogelijke 
rol als adjuvant voor deeltjes in luchtwegallergie, maar uit de artificiële toediening 
(injectie) in Chapter 2 en de beperkte informatie uit in vitro metingen aan één enkel celtype 
(Chapter 3) konden geen harde conclusies getrokken worden. Daarvoor was een in vivo 
model nodig, waarin de toediening plaatsvindt via de luchtwegen, de manier waarop 
mensen ook in werkelijkheid blootgesteld worden. In Chapter 4 worden de resultaten 
beschreven van intranasale blootstelling (via de neus) van muizen aan allergeen en deeltjes. 
De deeltjes werden alleen de eerste paar dagen van de allergeenblootstelling meegegeven, 
om na te gaan of het ontstaan van (nieuwe gevallen van) allergie wordt beïnvloed. Ook 
voor dit model gold dat allergeen en deeltjes afzonderlijk geen meetbare respons opwekten, 
maar dat er na gecombineerde toediening wel een meetbare immuunrespons optrad. 
Bovendien bleek de adjuvant werking na 3 weken nog steeds aanwezig en dus persistent 
van karakter te zijn. De deeltjes bleken dus ook na toediening via de relevante route (de 
luchtwegen) de immuunrespons te adjuveren (stimuleren). In Chapter 5 dienden we de 
deeltjes behalve tijdens de eerste dagen ook later tijdens de reactie nog eens toe, en het 
bleek dat de adjuvant werking daar nog sterker door werd.  
In Chapter 6 wilden we testen of het essentieel was dat de deeltjes tegelijk met het 
allergeen werden gegeven, zoals we tot nu toe gedaan hadden, of dat de deeltjes ook wel 
wat eerder of later dan het allergeen toegediend konden worden om hun stimulerende werk 
te verrichten. Bovendien varieerden we het aantal deeltjesdoseringen, terwijl de uiteindelijk 
toegediende totale hoeveelheid deeltjes gelijk bleef. Het bleek dat het toedienen van kleine 
doses tegelijk met iedere allergeentoedoening het meest effectief was in het stimuleren van 
de immuunrespons. Vergeleken met deze kleine doseringen werkte één grote dosis iets 
minder goed. Als deze dosis reeds één dag voor het begin van de allergeentoedieningen 
werd gegeven, was de immuunstimulatie nog iets minder effectief. Een deeltjesdosering 
één dag na de allergeentoedieningen werkte helemaal niet.  
In Chapter 7 hebben we onderzocht of de deeltjes ook als adjuvant werken als het 
allergeen via een aerosol (= een wolk van allergeen) wordt toegediend. Aerosolinhalatie 
benadert de blootstelling in het dagelijks leven meer dan intranasale toediening. Het bleek 
dat de deeltjes ook in dit model als adjuvant werkten. Er kleefden echter een aantal 
bezwaren aan dit model, o.a. betreffende de lange duur van een experiment, dat het lastiger 
maakt om mee te werken dan het simpele en effectieve intranasale model.  
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Samenvattend kunnen we concluderen dat de verschillende typen deeltjes allemaal 
de immuunrespons in meerdere of mindere mate stimuleren. Er kan echter nog geen 
definitieve uitspraak gedaan worden over het mechanisme achter de adjuvant activiteit, 
omdat er zeer veel variabelen zijn. De deeltjes hebben zeer complexe chemische en 
fysische eigenschappen en bovendien spelen in de immuunrespons veel verschillende 
celtypen een rol.  
In de algemene discussie (Chapter 8) wordt een hypothese geformuleerd over het 
ontstaan van een “veranderd micromilieu in de long” als oorzaak van allergie inductie. In 
het kort komt het erop neer dat deeltjes de long binnen komen na buiten het lichaam al dan 
niet al chemicaliën en allergeen gebonden te hebben. Hoeveel deeltjes er precies 
binnenkomen, en hoe diep ze de luchtwegen binnendringen, is onder andere afhankelijk 
van de grootte. Een fraktie van de deeltjes wordt, al dan niet met hulp van macrofagen, uit 
de longen verwijderd door middel van transport met het longslijm, dat met deeltjes en al 
wordt afgevoerd en doorgeslikt. De kleine deeltjes dringen door de eerste cellaag van de 
long heen, veroorzaken ontsteking en kunnen tientallen jaren in de long aanwezig blijven. 
Behalve de eerste cellaag van de long raken ook de macrofagen beschadigd door de 
aanwezigheid van de deeltjes en gaan ook de macrofagen stoffen produceren die ontsteking 
bevorderen. Door de inertheid van de deeltjes is de macrofaag niet erg effectief in het 
opnemen en opruimen van de deeltjes. In combinatie met de beschadiging van de eerste 
cellaag zorgt dit ervoor dat zowel deeltjes als ook allergeen makkelijker en in grotere 
hoeveelheden door de beschermende barrière van de long heendringen. Het allergeen komt 
op deze manier beter in contact met immuuncellen die makkelijk te aktiveren zijn in 
personen met de juiste genetische aanleg. Gesteund door de ontsteking en beschadiging van 
het micromilieu van de long wordt er eerder en heviger gereageerd op het allergeen. Het 
ontstaan van een nieuwe allergie is een feit.  
Dit onderzoek ondersteunt de hypothese dat blootstelling aan DEP en vergelijkbare 
deeltjesvormige luchtvervuiling in personen met de juiste genetische achtergrond het 
ontstaan van allergie voor een willekeurig allergeen kan veroorzaken. Het intranasale 
model zoals beschreven in dit proefschrift zou kunnen bijdragen aan het ontrafelen van het 
achterliggende mechanisme. Bovendien zou het model in combinatie met chemische 
analyses van de deeltjes een belangrijke rol kunnen spelen bij de identificatie van de 
adjuverende potentie van onbekende deeltjesvormige luchtverontreiniging. Het vaststellen 
van een dosis-repons relatie en combinatie met gegevens uit de epidemiologie zou van 
betekenis kunnen zijn voor het inschatten van gezondheidsrisico’s van deeltjesvormige 
vervuiling voor de mens. 
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